document incorporate reference portion proxy statement registrant annual meeting stockholder hold incorporate reference iii annual report table content item business general bristolmyers squibb company refer bristolmyer squibb bms company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger company division subsidiary engage discovery development licensing manufacturing marketing distribution sale pharmaceutical health care relate product acquisition divestiture july company complete sale bufferin excedrin brand japan asia exclude china taiwan certain oceanic country lion corporation japan million cash result transaction company recognize pretax gain million million net tax quarter october company complete acquisition adnexus therapeutics inc adnexus developer new therapeutic class biologic call adnectins net purchase price million addition event certain future development regulatory milestone achieve company obligate term agreement pay stockholder adnexus additional million december company enter definitive agreement avista capital partner avista sale medical imaging business purchase price approximately million cash subject customary postclosing adjustment close transaction complete january result transaction company expect recognize pretax gain approximately million million million million loss net tax quarter subject postclosing adjustment bristolmyer squibb website company internet website address wwwbmscom company make available free charge website annual quarterly current report include amendment report soon reasonably practicable company electronically file material furnish material securities exchange commission sec information relate corporate governance bristolmyer squibb include company standard business conduct ethic code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern company executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available company website wwwbmscom investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly company website information relate stockholder service include company dividend reinvestment plan direct deposit dividend available company website wwwbmscom investorsstockholder service caption company incorporate reference certain information part proxy statement annual meeting stockholder sec allow company disclose important information refer manner refer information company proxy statement annual meeting stockholder annual report available company website wwwbmscom investorssec filing caption march table content business segment company reportable segmentspharmaceutical nutritional convatec previously component health care operating segment january company complete sale medical imaging business avista result medical imaging business previously include health care operating segment present company result discontinue operation pharmaceutical segment global pharmaceutical international consumer medicine business pharmaceutical segment account company sale company sale company sale pharmaceutical sale account total pharmaceutical sale respectively international pharmaceutical sale account total pharmaceutical sale respectively segment nutritional convatec comprise company health care group nutritional segment consist mead johnson nutritionals mead johnson primarily infant formula children nutritional business convatec segment consist ostomy wound skin care business health care group sale account company sale company sale company sale health care group sale account total health care group sale respectively international health care group sale account total health care group sale respectively additional information segment item financial statementsnote segment information pharmaceutical segment pharmaceutical segment compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession company manufacture product puerto rico foreign country pharmaceutical net sale account total pharmaceutical net sale respectively pharmaceutical net sale europe middle east africa account total pharmaceutical net sale respectively pharmaceutical net sale japan account total pharmaceutical net sale company key product include plavix clopidogrel bisulfate avaproavalide irbesartanirbesartanhydrochlorothiazide reyataz atazanavir sulfate abilify aripiprazole erbitux cetuximab sprycel dasatinib baraclude entecavir orencia abatacept sustiva franchise efavirenz ixempra ixabepilone composition matter patent plavix expire currently subject patent litigation apotex inc apotex corp apotex generic company significant jurisdiction previously disclose august apotex launch generic clopidogrel bisulfate product compete plavix generic launch significant adverse impact plavix sale company estimate range million million billion billion estimate total prescription demand clopidogrel bisulfate brand generic increase compare estimate total prescription demand brand plavix increase period company believe supply generic clopidogrel bisulfate sell distribution channel follow apotex atrisk launch august substantially deplete june district court southern district new york district court uphold composition matter patent plavix enjoin apotex engage activity infringe patent include market generic product patent expire apotex appeal district court decision apotex appeal date set march damage phase trial ongoing information pende plavix litigation generic launch apotex item financial statement note legal proceeding contingency table content product company pharmaceutical revenue come product follow therapeutic class cardiovascular virology include human immunodeficiency virus hiv infection oncology affective psychiatric disorder immunoscience pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity market exclusivity base patent right andor certain regulatory form exclusivity country patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product company business focus innovative pharmaceutical product company rely patent right form protection maintain market exclusivity product discussion patent right regulatory form exclusivity intellectual property product exclusivity discussion impact generic competition company business generic competition increase portion company innovative pharmaceutical product biological product biologic currently generic version biological product approve law law change future absence new legislation food drug administration fda take step allow generic version certain biologic competitor seek approval biological product file safety efficacy datum address challenge biologic manufacturing involve complex process costly traditional pharmaceutical operation chart show net sale key product pharmaceutical segment year basic exclusivity loss patent right datum exclusivity occur currently estimate occur european union japan company sell pharmaceutical product country datum provide countrybycountry basis individual country sale significant outside japan instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical trial datum obtain marketing approval prior expiration datum exclusivity company estimate market exclusivity period product casebycase basis purpose business planning length market exclusivity company product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation company provide estimate business planning purpose intend indication company patent fare particular patent litigation bring potential infringer assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate table content past currently past currently past currently estimate estimate estimate year year year basic basic japanese basic pharmaceutical product exclusivity loss exclusivity loss exclusivity loss dollar million cardiovascular plavix avaproavalide pravachol coumadin virology reyataz sustiva franchise total revenue baraclude oncology erbitux taxol paclitaxel sprycel ixempra affective psychiatric disorder abilify total revenue immunoscience orencia pharmaceuticals efferalgan note currently estimate year basic exclusivity loss include statutory extension exclusivity earn speculative instance laterexpire patent cover particular form composition drug method manufacturing method drug patent result favorable market position company product product exclusivity predict assure note product file biologic license application bla year exclusivity list year patent expiration currently regulatory pathway approval followon biologic product describe detail intellectual property product exclusivity indicate brand name product register trademark own company subsidiary specific trademark ownership information find company currently market product jurisdiction indicate reference include follow current member state austria belgium bulgaria cyprus czech republic denmark estonia finland france germany greece hungary ireland italy latvia lithuania luxembourg malta netherlands poland portugal romania slovakia slovenia spain sweden united kingdom basic patent application file current member state list product instance date basic exclusivity loss different member states instances early late date basic exclusivity loss list country basic patent obtain datum protection available basic exclusivity expire bms acquire product exclusivity period relate sustiva brand biologic product approve bla currently regulatory approval path generic biologics pende application patent application file estonia latvia lithuania malta slovakia slovenia companys right commercialize aripiprazole terminate company right commercialize aripiprazole terminate data exclusivity expire table content summary indication intellectual property position license arrangement thirdparty manufacturing arrangement product applicable japan cardiovascular plavix clopidogrel bisulfate platelet aggregation inhibitor approve protection fatal nonfatal heart attack stroke patient history heart attack stroke peripheral arterial disease acute coronary syndrome clopidogrel bisulfate codevelope jointly market sanofiaventis sanofi worldwide alliance operate framework geographic territory america australia company primary territory europe asia sanofis primary territory composition matter patent expire include statutory patent term extension currently subject patent litigation apotex generic company significant jurisdiction district court uphold validity enforceability composition matter patent apotex appeal decision oral argument apotex appeal date set march possible time reasonably assess outcome appeal apotex andor timing renew generic competition apotex potential additional generic competition generic pharmaceutical company apotex prevail appeal company expect renew generic competition promptly information litigation matter generic launch apotex item financial statementsnote legal proceeding contingency regulatory datum exclusivity expire july member country key composition matter patent expire majority member country company obtain bulk requirement clopidogrel bisulfate sanofi party company sanofi finish product facility information company arrangement sanofi strategic alliance item financial statementsnote alliance investment avaproavalide irbesartanirbesartanhydrochlorothiazide angiotensin receptor antagonist indicate treatment hypertension diabetic nephropathy irbesartan codevelope jointly market sanofi worldwide alliance operate framework geographic territory america australia company primary territory europe asia sanofis primary territory september company elect terminate copromotion product sanofi ireland sweden norway finland denmark basic composition matter patent expire include pediatric extension data exclusivity expire august avapro october avalide irbesartan manufacture company sanofi company manufacture bulk requirement irbesartan finish avaproavalide facility avalide company purchase bulk requirement hydrochlorothiazide party information company arrangement sanofi strategic alliance item financial statementsnote alliance investment pravachol pravastatin sodium hmg coa reductase inhibitor indicate adjunct diet exercise patient primary hypercholesterolemia lower risk heart attack people clinically evident coronary heart disease elevate cholesterol reduce risk heart attack stroke patient clinically evident coronary heart disease table content company license patent cover pravastatin market company pravachol sankyo company ltd sankyo japan key provision agreement expiring exclusivity expire marketbymarket basis exclusivity patent include pediatric extension expire april company enter distribution agreement watson pharmaceutical watson november authorize watson distribute generic pravastatin sodium tablet december lek lek slovenian generic company whollyowne novartis novartis file suit company watson district court eastern district texas marshall texas leks complaint allege company sale pravachol watson sale authorize generic pravachol infringe patent lek information litigation matter item financial statementsnote legal proceeding contingency composition matter patent expire country company obtain bulk requirement pravastatin sankyo finish product facility coumadin warfarin sodium oral anticoagulant predominantly patient atrial fibrillation deep venous thrombosispulmonary embolism market exclusivity expire basic patent protection regulatory datum protection expire company acquire coumadin company obtain bulk requirement warfarin party produce majority finish good facility virology reyataz atazanavir sulfate protease inhibitor treatment hiv reyataz launch july company develop atazanavir worldwide license novartis pay royalty base percentage net sale company entitle promote reyataz use combination norvir ritonavir nonexclusive license agreement abbott laboratories company date july amend pay royalty base percentage net sale market exclusivity reyataz expect expire major member country japan data exclusivity expire company manufacture bulk requirement atazanavir finish product facility sustiva franchise efavirenz active ingredient sustiva nonnucleoside reverse transcriptase inhibitor nnrti treatment hiv sustiva franchise include sustiva antiretroviral drug treatment hiv bulk efavirenz include combination therapy atripla sell joint venture gilead sciences inc gilead company gilead share responsibility commercialize atripla gilead record atripla revenue consolidate result joint venture operating result company record revenue bulk efavirenz component atripla sale product gilead joint venture thirdparty customer company revenue efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand europe company gilead share responsibility commercialize atripla certain european country gilead record revenue future net sale atripla country europe company record revenue percentage relative contribution represent sustiva december european commission grant marketing authorization atripla information company arrangement gilead strategic alliance item financial statementsnote alliance investment table content right market efavirenz canada france germany ireland italy spain license merck inc royalty base percentage net sale market exclusivity sustiva expect expire country company company market efavirenz japan company obtain bulk requirement efavirenz party produce finished good facility company provide bulk efavirenz gilead responsible produce atripla finish good baraclude entecavir potent selective inhibitor hepatitis virus approve fda march treatment chronic hepatitis infection baraclude discover develop internally approve market country outside include china japan company learn china company file clinical trial permission company receive approval company aware application clinical trial permission china approve uncertainty china exclusivity law possible company receive marketing authorization china health authority company composition matter patent expire application patent term extension approve extend patent expiration composition matter patent expire japan patent term extension approve japan extend patent expiration supplementary protection certificate request approve country extend exclusivity approve product company manufacture bulk requirement entecavir finish product facility oncology erbitux erbitux cetuximab igg monoclonal antibody design exclusively target block epidermal growth factor receptor egfr express surface certain cancer cell multiple tumor type normal cell erbitux biological product approve treatment combination irinotecan patient egfrexpresse metastatic colorectal cancer mcrc fail irinotecanbase regimen monotherapy patient intolerant irinotecan march fda approve erbitux use treatment squamous cell carcinoma head neck specifically erbitux approve use combination radiation therapy treatment locally regionally advanced squamous cell carcinoma head neck single agent treatment patient recurrent metastatic squamous cell carcinoma head neck prior platinumbase therapy fail october company receive fda approval supplemental biologic license application sbla filing update erbitux product labeling include overall survival datum single agent egfrexpresse mcrc patient failure irinotecanbase oxaliplatinbase regimen erbitux market north america company distribution copromotion agreement imclone system incorporate imclone company share copromotion right erbitux merck kgaa japan codevelopment cocommercialization agreement sign october company imclone merck kgaa merck japan erbitux market japan application submit japanese pharmaceutical medical devices agency pmda use erbitux treat patient advance colorectal cancer description company alliance imclone strategic alliance item financial statementsnote alliance investment table content july company imclone amend term agreement codevelopment copromotion erbitux north america amendment company jointly agree expand investment ongoing clinical development plan erbitux million dollar development cost threshold value sole responsibility company cost excess threshold share company accord predetermine ratio composition matter patent specifically claim erbitux erbitux approve fda health authority monotherapy use patent use erbitux combination antineoplastic agent approve fda combination use claim grant patent expire inventorship use patent challenge researcher yeda research development company ltd yeda september court grant yeda complete ownership patent imclone appeal court decision file declaratory judgment action allege yeda researcher remain sole inventor patent patent invalid pursuant settlement agreement execute announce december imclone sanofi yeda end worldwide litigation relate use patent sanofi yeda grant imclone worldwide license use patent settlement agreement change imclone worldwide royalty rate erbitux sale commercial agreement imclone company pay royalty imclone sale erbitux impact settlement agreement yeda right license use patent yeda license patent party result product competition erbitux occur early assess extent competitive impact occur quantify impact yeda grant amgen inc amgen license use patent amgen receive fda approval market egfrproduct compete erbitux information litigation item financial statementsnote legal proceeding contingency european equivalent use patent oppose information biologic patent intellectual property product exclusivity company obtain finished good requirement cetuximab use north america imclone imclone manufacture bulk requirement cetuximab facility finish perform party imclone description company supply agreement imclone manufacture quality assurance taxol paclitaxel paclitaxel treatment refractory ovarian cancer firstline treatment ovarian cancer combination cisplatin secondline treatment acquire immunodeficiency syndrome aidsrelate kaposis sarcoma treatment metastatic breast cancer failure combination chemotherapy adjuvant treatment nodepositive breast cancer treatment non small cell lung carcinoma cisplatin active ingredient taxol paclitaxel patent protection japan regulatory protection form datum exclusivity datum exclusivity expire initial approval generic version paclitaxel grant revoke fda reinstate datum exclusivity expire data exclusivity taxol paclitaxel japan expire patent claim approve dose administration schedule expire japan nullity action file japanese patent office invalidate patent company appeal decision invalidation decision affirm generic paclitaxel launch japan paclitaxel develop collaborative research development agreement government agreement company obtain right government taxol paclitaxel data company manufacture bulk requirement paclitaxel finish product facility table content sprycel dasatinib multitargete tyrosine kinase inhibitor approve fda june treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include imatinib treatment adult philadelphia chromosomepositive acute lymphoblastic leukemia resistance intolerance prior therapy dasatinib approve november sprycel discover develop internally basic composition matter patent protect dasatinib expire april patent term extension request grant extend patent term june country patent pende grant expire april exclude term extension patent application file cyprus estonia latvia lithuania malta netherland slovakia slovenia new chemical entity protection expire orphan drug exclusivity expire protect product generic application currently approve orphan indication company manufacture bulk requirement dasatinib finish product facility ixempra ixempra ixabepilone microtubule inhibitor belong class antineoplastic agent epothilone analogs october fda approve ixabepilone combination capecitabine treatment patient metastatic locally advanced breast cancer resistant treatment anthracycline taxane cancer taxane resistant anthracycline therapy contraindicate monotherapy treatment metastatic locally advanced breast cancer patient tumor resistant refractory anthracycline taxane capecitabine marketing authorization currently seek country basic composition matter patent protect ixabepilone expire patent term extension request grant extend patent term september corresponding patent grant country expire june exclude term extension patent application file malta new chemical entity protection expire ixabepilone develop company subject license agreement helmholtz zentrum fur infektionsforschung gmbh hzi relate epothilone technology agreement hzi entitle royalty net sale country product sell company manufacture bulk requirement ixabepilone facility include manufacture active ingredient drug product comprise pharmaceutical kit finish baxter oncology gmbh affective psychiatric disorder abilify aripiprazole atypical antipsychotic agent patient schizophrenia acute bipolar mania bipolar disorder aripiprazole copromote company otsuka pharmaceutical ltd otsuka company right commercialize aripiprazole terminate otsuka sole right commercialize aripiprazole germany spain company copromote otsuka affiliate france company currently act distributor product copromote otsuka affiliate european market company act exclusive distributor company exclusive licensee product rest world exclude japan certain country spain germany company records alliance revenue contractual share net sale record expense relate product alliance revenue record company net sale base party customer net sale copromotion country company recognize alliance revenue abilify ship risk reward ownership transfer thirdparty customer france italy company currently record net sale relate cost product sell country company exclusive right sell abilify company record net sale relate cost product sell information company arrangement otsuka strategic alliance item financial statementsnote alliance investment table content basic composition matter patent abilify expire include grant patent term extension otsuka file patent trademark office uspto request reexamination composition matter patent patent patent cover abilify june uspto issue parte reexamination certificate patent confirm patentability original claim approve additional new claim otsuka receive formal notice teva pharmaceuticals usa teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceuticals ltd sun apotex state file abbreviate new drug application anda fda dosage form aripiprazole company otsuka comarket abilify notice states anda contain piv certification direct patent cover aripiprazole expire october addition notice purport provide otsuka respective piv certification certification contain allegation enforceability patent andor validity andor infringement claim otsuka file patent infringement action base patent teva barr sandoz sun apotex district court new jersey synthon district court middle district north carolina otsuka sole right enforce patent composition matter patent force germany france italy netherlands romania sweden switzerland spain denmark original expiration date extend grant supplemental protection certificate country romania denmark datum exclusivity expire composition matter patent austria belgium finland greece ireland luxembourg portugal latvia hungary cyprus czech republic slovenia slovakia poland malta lithuania bulgaria estonia company obtain bulk requirement aripiprazole otsuka otsuka company finish product facility immunoscience orencia abatacept biological product fusion protein novel immunosuppressive activity target initially adult patient moderate severe rheumatoid arthritis inadequate response certain currently available treatment abatacept approve fda december commercially available february orencia discover develop internally company series patent cover abatacept method use late composition matter patent expire company submit request patent term extension composition matter patent expire possibly extend term patent majority countries company patent covering abatacept expire datum exclusivity expire january repligen corporation regent university michigan file complaint company district court eastern district texas marshall division allege company thenanticipate sale orencia infringe patent august zymogenetics inc file complaint company district court district delaware complaint allege company manufacture sale orencia infringe patent information litigation item financial statementsnote legal proceeding contingency company obtain bulk abatacept party manufacturing facility company finish product facility pharmaceuticals efferalgan efferalgan formulation acetaminophen introduce distribute effervescent tablet indicate treatment fever mild moderate pain adult child market primarily europe composition matter patent europe efferalgan table content addition product discuss company pharmaceutical segment include company whollyowne upsa consumer medicine business europe include efferalgan describe aspirine upsa dafalgan fervex europe overseas market strategic alliance arrangement company enter strategic alliance arrangement party company right develop manufacture market andor sell pharmaceutical product right own party company enter strategic alliance arrangement party party right develop manufacture market andor sell pharmaceutical product right own company alliance arrangement form include licensing arrangement codevelopment comarkete agreement copromotion arrangement joint venture alliance arrangement reduce risk incur research development expense lead revenuegenerate product gross margin alliance product generally low substantially gross margin company product partner profit alliance product share company alliance partner assurance new alliance form company actively pursue arrangement view alliance important complement discovery development activity companys significant current alliance arrangement company product sanofi plavix avaproavalide otsuka abilify imclone erbitux gilead atripla company significant alliance arrangement investigational compound development medarex inc medarex ipilimumab monoclonal antibody investigate anticancer treatment right own medarex astrazeneca plc astrazeneca saxagliptin oral compound discover company potential treatment diabete dppiv inhibitor dapagliflozin oral compound discover company potential treatment diabete sodiumglucose cotransporter sglt inhibitor pfizer inc pfizer apixaban anticoagulant discover company study prevention treatment broad range venous arterial thrombotic condition significant alliance arrangement discuss detail additionally company license arrangement novartis reyataz hzi ixempra novel microtubulestabilize agent treatment breast cancer general company strategic alliance arrangement periods coextensive period market exclusivity protection countryby country basis base company current expectation respect expiration market exclusivity company significant market license arrangement novartis reyataz expect expire japan hzi ixempra expect expire anniversary commercial sale japan discussion market exclusivity protection include chart show net sale key product year basic exclusivity loss occur expect occur japan product intellectual property product exclusivity company strategic alliance arrangement party right manufacture market andor sell pharmaceutical product contain customary early termination provision typically find agreement kind generally base party material breach bankruptcy voluntary involuntary product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination day notice generally available involuntary bankruptcy petition file dismiss material breach party occurred cure early termination product safety concern typically arise product determine create significant risk harm patient concern product efficacy level toxicity company strategic alliance arrangement typically contain provision provide party right terminate alliance short notice general party company strategic alliance arrangement continue exclusivity protection expiration termination alliance company retain right product party intellectual property loss right product market sell company pursuant strategic alliance arrangement party country territory material company result operation cash flow case plavix material financial condition liquidity customary pharmaceutical industry term company strategic alliance arrangement generally coextensive exclusivity period discuss vary countrybycountry basis discuss company strategic alliance otsuka expire november puerto rico prior expect expiration market exclusivity protection abilify include grant patent term extension table content current market product sanofi company agreement codevelopment cocommercialization avaproavalide angiotensin receptor antagonist indicate treatment hypertension diabetic nephropathy copromote certain country outside tradename aprovelcoaprovel comarkete certain country outside company tradename karveakarvezide plavix platelet aggregation inhibitor copromote certain country outside tradename plavix comarkete certain country outside company tradename iscover worldwide alliance operate framework geographic region cover certain european asian country define territory cover puerto rico canada australia certain latin american country define territory region cover puerto rico canada australia certain latin american country manage separate territory agreement puerto rico avaproavalide second agreement puerto rico plavix plus canada australia mexico brazil colombia argentina product territory territory partnership exist supply product country territory manage certain central expense market research development royalty country territory structure company local affiliate sanofi comarket separate brand affiliate operates independently sell compete brand copromote single brand territory comarketing country include germany spain italy irbesartan greece china clopidogrel bisulfate company sell iscover karveakarvezide sanofi sell plavix aprovelcoaprovel country china company retain right currently comarket iscover company sanofi copromote plavix aprovelcoaprovel france belgium netherlands switzerland portugal addition company sanofi copromote plavix austria italy ireland denmark finland norway sweden turkey taiwan korea singapore malaysia hong kong aprovelcoaprovel certain french export country sanofi act operating partner territory own majority financial control interest territory company ownership interest territory company account investment partnership entity territory equity method record share result equity net income affiliate consolidate statement earning company share net income partnership entity tax million million million territory company sanofi copromote plavix canada puerto rico avaproavalide canada territory countries australia mexico brazil colombia clopidogrel bisulfate argentina comarketing country company sanofi modify previous exclusive license company avaproavalide puerto rico form copromotion joint venture company contribute avaproavalide intellectual property sanofi agree pay company million million company account payment sale interest license defer amortize total million income expect useful life license approximately year date formation copromotion joint venture company act operating partner territory uspuerto rico avaproavalide territory own majority control interest territory company consolidate partnership result territory record sanofis share result minority interest expense net taxis million million million company record sale territory uspuerto rico avaproavalide territory territory comarkete country million million million september company opt copromotion right sanofi aprovelcoaprovel ireland sweden denmark finland norway company opt comarkete copromotion arrangement number country prior company receive royalty payment sanofi base percentage sanofis net sale optout country territory partnership govern series committee enumerate function power responsibilitie territory senior committee senior committee final decision make authority respect territory enumerate function power responsibility jurisdiction agreement sanofi expire later respect plavix respect avaproavalide americas australia europe asia expiration patent exclusivity right applicable territory alliance arrangement terminate company sanofi affected country territory depend circumstance event voluntary involuntary bankruptcy insolvency case involuntary bankruptcy continue day order decree approving continue unstayed effect day table content material breach obligation major alliance agreement remain uncured day follow notice breach commencement diligent prosecution cure occur day notice iii deadlock senior committee render continue commercialization product impossible give country territory case avaproavalide respect advertising promotion spending level sale force commitment increase combine cost good royalty exceed specify percentage net selling price product good faith determination terminate party commercialization product terminate reason patient safety case termination right agreement include provision termination relevant alliance respect applicable product applicable country territory case termination bankruptcy insolvency material breach product applicable territory termination procedure slightly different event company lose right product applicable relevant country territory case bankruptcy insolvency material breach company default party discussion company strategic alliance sanofi item financial statementsnote alliance investment otsuka company enter worldwide commercialization agreement otsuka codevelop copromote abilify treatment schizophrenia relate psychiatric disorder japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt company begin copromote product otsuka puerto rico november june company receive marketing approval european commission product currently copromote otsuka germany france spain germany spain product invoice thirdparty customer company behalf otsuka company record alliance revenue contractual share thirdparty net sale record expense relate product company recognize alliance revenue abilify ship risk reward ownership transfer thirdparty customer france italy company presently exclusive distributor product company record net sale relate cost product sell expense company exclusive right sell abilify country europe americas number countries asia country company record net sale relate cost product sell term agreement company purchase product otsuka perform finish manufacture sale company otsuka thirdparty customer agreement expire november entire agreement expire june country company exclusive right sell abilify agreement expire later anniversary commercial sale country expiration applicable patent country early termination available base party voluntary involuntary bankruptcy failure minimum payment failure commence commercial sale month receipt necessary approval material breach notice require early termination strategic alliance immediately notice case voluntary bankruptcy minimum payment otsuka iii commercial sale occur month receipt necessary approval day material breach occur cure commencement cure occur day notice material breach day case involuntary bankruptcy petition file dismiss addition termination available otsuka day notice event company challenge otsuka patent right marketbymarket basis company market product direct competition abilify termination expiration alliance company retain right abilify company record total revenue abilify million million million total milestone payment otsuka agreement million million expense acquire inprocess research development remain million capitalize intangible asset amortize cost product sell remain life agreement range year company amortize cost product sell million unamortized capitalize payment balance million million december respectively discussion company strategic alliance otsuka item financial statementsnote alliance investments imclone company purchase million share imclone share million represent approximately imclone share outstanding prior company commencement public tender offer imclone share imclone biopharmaceutical company focus develop targeted cancer treatment include growth factor blocker cancer vaccine antiangiogenesis therapeutic equity investment imclone strategic agreement company imclone include commercialization arrangement expire september codevelopment copromotion erbitux series payment originally total billion company table content pay imclone milestone payment million agreement imclone revise reduce total payment million billion accordance agreement company pay imclone million million million million quarter payment approval fda bla erbitux use combination irinotecan treatment patient egfr express mcrc refractory irinotecanbase chemotherapy use single agent treatment patient egfrexpresse mcrc intolerant irinotecanbase chemotherapy milestone payment fda approval erbitux use treatment squamous cell carcinoma head neck combination radiation monotherapy company codevelopment copromotion right canada japan extent product commercialize country agreement cover north america imclone receive distribution fee base flat rate net sale north america company purchase commercial requirement bulk erbitux imclone price equal imclone manufacturing cost plus july company imclone amend term agreement codevelopment copromotion erbitux north america amendment company jointly agree expand investment ongoing clinical development plan erbitux million dollar development cost threshold value sole responsibility company cost excess threshold share company accord predetermine ratio company share copromotion right erbitux merck kgaa japan codevelopment cocommercialization agreement sign october bms bmkk squibb son llc imclone merck kgaa merck japan erbitux market japan company imclone submit february application pmda use erbitux treat patient advance colorectal cancer company account million total approval milestone pay license acquisition amortize payment cost product sell remain term agreement end company amortize cost product sell million million million respectively unamortized portion approval payment record intangible asset net consolidated balance sheet million million december respectively company determine equity share imclone net income loss eliminate imclone result milestone revenue imclone recognize million preapproval milestone payment company company record net income million million respectively net loss million share imclone result operation company record share result equity net income affiliate consolidate statement earning company record net sale erbitux million million million company record investment market value holding imclone common stock million approximately million december respectively million approximately million december respectively company hold million share imclone stock represent approximately imclone share outstanding december share basis carry value imclone investment closing market price imclone share december respectively compare respectively december early termination available base material breach effective day notice material breach material breach cure commencement cure occur month notice company exist significant concern regulatory patient safety issue seriously impact longterm viability product termination expiration alliance company retain right erbitux mckesson corporation mckesson company wholesaler provide warehousing packing shipping service erbitux mckesson hold erbitux inventory consignment company revenue recognition policy company recognize revenue inventory ship mckesson enduser mckesson hold inventory erbitux account divestiture oncology therapeutic network company discontinue consignment arrangement mckesson mckesson long hold inventory account company sell erbitux intermediary wholesaler specialty oncology distributor ship erbitux directly enduser product customer intermediary begin quarter company begin expand distribution model include wholesaler distributor hold erbitux inventory company recognize revenue shipment consistent revenue recognition policy discussion company strategic alliance imclone item financial statementsnote alliance investment table content gilead company gilead enter joint venture develop commercialize fixeddose combination company sustiva gileads truvada emtricitabine tenofovir disoproxil fumarate july fda grant approval atripla complete highly active antiretroviral therapy treatment product hiv available fixeddose combination take daily fixeddose combination contain multiple medicine formulate help simplify hiv therapy patient provider guideline issue department health human service list combination emtricitabine tenofovir disoproxil fumarate efavirenz preferred nonnnrtibase treatment use appropriate patient take antihiv medicine september company amend agreement commercialize atripla canada atripla approve health canada october european commission december commercialization country norway iceland company gilead share responsibility commercialize atripla canada certain european country provide fund fieldbased sale representative support promotional effort atripla gilead record atripla revenue canada countries europe company record revenue bulk efavirenz component atripla sale product joint venture gilead thirdparty customer company revenue efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand company record efavirenz revenue million million relate atripla sale gilead consolidate result joint venture operating result company account participation joint venture equity method accounting record share joint venture result equity net income affiliate consolidate statement earning company record equity loss joint venture gilead million million million joint venture company gilead continue terminate mutual agreement party describe event material breach party nonbreache party terminate joint venture party agree desirable practicable withdraw combination product market commercialize time generic version sustiva appear market gilead right terminate joint venture acquire right combination product canada company continue year receive percentage net sale base contribution bulk efavirenz atripla retain right sustiva discussion company strategic alliance gilead item financial statementsnote alliance investments investigational compound development medarex company enter worldwide collaboration share purchase agreement medarex codevelop copromote ipilimumab fully human antibody currently phase iii development treatment metastatic melanoma agreement effective january company receive certain governmental clearance approval receipt consent public health service sublicense company medarexs right mdx vaccine develop combination ipilimumab fda grant fast track status ipilimumab combination mdx treatment patient late stage unresectable metastatic melanoma fail intolerant firstline therapy january term agreement company cash payment million medarex expense research development additional million equity investment medarex milestone payment expect successful achievement regulatory salesrelated stage company medarex share future development commercialization cost medarex receive million regulatory milestone meet million salesrelated milestone medarex option copromote receive profit company company receive exclusive license outside pay royalty medarexthe agreement medarex expire follow event occur company voluntarily terminate agreement entirety countrybycountry basis provide medarex month prior write notice company voluntarily terminate agreement productbyproduct basis second product glp toxicology study later countrybycountry basis provide medarex month prior write notice depend circumstance company terminate medarexs copromotion option right day write notice end second calendar year event medarex provide percent certain performance obligation consecutive calendar year termination right exercise respect indication medarex fail meet performance obligation termination company scenario medarex long right share profit loss product terminate indication instead company pay medarex royalty net sale product medarex terminate agreement respect product day write notice company provide percent certain performance obligation consecutive calendar year generally termination company assign right product medarex receive royalty intellectual property license company medarex medarex elect copromote product indication event receive royalty sale product indication material breach manufacturing party party shall limit termination party manufacturing right table content astrazeneca january company enter worldwide japan codevelopment cocommercialization agreement astrazeneca codevelopment cocommercialization saxagliptin dppiv inhibitor saxagliptin agreement codevelopment cocommercialization dapagliflozin sglt inhibitor sglt agreement compound study treatment diabete discover company term agreement company receive astrazeneca upfront payment million january defer recognize life agreement income company amortize income million unamortized portion upfront payment million december milestone payment expect receive company successful achievement development regulatory event salesrelated milestone saxagliptin agreement company receive million development regulatory milestone meet additional million salesbased milestone meet sglt agreement company receive million development regulatory milestone meet additional million salesbased milestone meet agreement company astrazeneca share future development commercialization cost majority development cost initial development plan pay astrazeneca additional development cost generally share equally company record research development expense saxagliptin dapagliflozin development cost net alliance partner share agreement company jointly develop clinical marketing strategy share commercialization expense profitslosse equally global basis exclude japan company manufacture product certain limited exception record net sale pfizer april company pfizer enter worldwide codevelopment cocommercialization agreement apixaban anticoagulant discover company study prevention treatment broad range venous arterial thrombotic condition accordance term agreement pfizer upfront payment million company defer recognize life agreement income december company pfizer agree include japan worldwide agreement pfizer upfront payment million december defer recognize life agreement income company amortize income million unamortized portion upfront payment million december pfizer fund development cost effective january go forward company fund company record research development expense apixaban development cost net alliance partner share company receive additional payment million pfizer base development regulatory milestone company jointly develop clinical marketing strategy apixaban share commercialization expense profitslosse equally global basis information alliance relate product development drug discovery research development health care group nutritional segment nutritional segment mead johnson manufacture market distribute sell infant formula nutritional product include entire line enfamil product enfamil lipil product infant formula contain nutrients docosahexaenoic acid dha arachidonic acid ara naturally find breast milk dha ara believe support infant brain eye development company obtain nutrients sole provider pursuant nonexclusive worldwide license supply agreement supply agreement force provide firm guarantee supply pricing subject change pursuant pricing formula license expire begin countrybycountry basis year company commence sale country company nutritional product generally sell wholesaler retailer promote primarily health care professional company promote nutritional product directly consumer worldwide advertising company manufacture product foreign country nutritional sale account company sale company sale company sale nutritional sale account total nutritional sale respectively international nutritional sale account total nutritional sale respectively approximately onehalf gross sale infant formula subject rebate issue woman infant child wic program sale subject wic rebate low margin nonwic program sale table content key nutritional product line sale follow dollar million infant formula enfamil toddlerchildren nutritional enfagrow convatec segment convatec segment manufacture distribute sell ostomy modern wound skin care product principal brand convatec include natura surfit esteem aquacel duoderm flexiseal product market worldwide primarily hospital medical profession medical supplier company mainly rely internal sale force sale distributor world company manufacture product dominican republic convatec sale account approximately company sale company sale company sale convatec sale account total convatec sale respectively international convatec sale account total convatec sale respectively convatec sale business key product follow dollar million convatec ostomy wound therapeutic productivity transformation initiative company undertake broad range action fourth quarter previously announce threeyear productivity transformation initiative pti reduce cost streamline operation rationalize global manufacturing initiative track achieve billion annual cost saving cost avoidance pretax basis central company strategy nimble flexible generation biopharmaceutical enterprise key productivity initiative include reduce general administrative operation simplify standardize outsource appropriate process service rationalize company mature brand portfolio consolidate global manufacturing network eliminate complexity enhance profitability simplify geographic footprint implement efficient gotomarket model specific productivity goal include reduce number brand company mature product portfolio percent reduce number manufacture facility percent end reduce total headcount approximately percent position eliminate substantial majority position eliminate company announce impend closure manufacturing facility include barceloneta puerto rico mayaguez puerto rico cost associate implementation pti estimate billion billion pretax basis million incur approximately million expect incur ultimate timing recording charge predict certainty affect occurrence trigger event expense recognition generally accept accounting principle gaap factor table content sources availability raw material general company purchase raw material medical device supply require production company product open market product company purchase raw material medical device supply single source certain circumstance specify company product registration require company obtain raw material supply particular source company attempt possible mitigate raw material supply risk company inventory management alternative source strategy discussion source manufacture quality assurance discussion particular product manufacture quality assurance meet expect product demand company operate manage manufacturing network include thirdparty contract manufacturer inventory relate thereto manner permit company improve efficiency maintain flexibility ability reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital outofpocket expenditure regulatory approval company maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact company manufacturing government regulation price constraint pharmaceutical manufacturing facility require significant ongoing capital investment maintenance compliance increase regulatory requirement addition company add product line realign focus year company expect modify exist manufacturing network meet complex processing standard require newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation company capacity manufacture biologic clinical trial commercial launch capacity manufacture large commercial volume limited biologic important company product portfolio company continue arrangement thirdparty manufacturer addition expect substantial investment increase internal capacity produce biologic commercial scale board director approve capital expenditure approximately million bulk biologic manufacturing facility february company complete land purchase acre site locate large scale multiproduct bulk biologic manufacturing facility deven massachusetts construction deven massachusetts facility begin early facility project operationally complete company expect submit site regulatory approval commercial production biologic compound anticipate begin company rely party manufacture supply active ingredient necessary manufacture certain product include plavix abilify erbitux sustiva franchise orencia pravachol coumadin taxol paclitaxel maintain stable supply product company take variety action design provide reasonable level ingredient hold thirdparty supplier company company manufacture operation interrupt additional protection case company take step maintain approve backup source available example company rely combine capacity deven massachusetts syracuse new york manati puerto rico facility capacity available thirdparty contract manufacturer manufacture orencia commercial quantity company investigational compound latestage development compound receive regulatory approval company thirdparty manufacturer company rely exist future product unable maintain stable supply product operate sufficient capacity meet order requirement comply government regulation manufacturing pharmaceutical meet heighten processing requirement biologic company business performance prospect negatively impact additionally company thirdparty supplier experience extend plant shutdown substantial unplanned increase demand suspension manufacture regulatory reason company experience interruption supply certain product product shortage production resume expand connection divestiture license arrangement distribution agreement certain company product certain circumstance company enter agreement company agree supply product party addition liability arise company failure supply product agreement arrangement require company invest facility production non strategic product result additional regulatory filing obligation cause interruption manufacturing product company success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part company operation include research development purchasing facility planning manufacturing distribution company maintain qualityassurance procedure relate quality integrity technical information production process table content control production process involve detailed specification ingredient equipment facility manufacturing method process packaging material label company perform test stage production process final product ensure product meet regulatory requirement company standard test involve chemical physical chemical analyse microbiological testing combination analyse quality control provide business unitsite quality assurance group monitor exist manufacturing procedure system company subsidiary thirdparty supplier intellectual property product exclusivity company own license number patent foreign country primarily cover product company develop brand name trademark product area company consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity country market exclusivity expire generic version product approve market substantial rapid decline product sale rate decline vary country therapeutic category discussion generic version product impact product sale generic competition product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory intellectual property right develop country provide certain nonpatent incentive development medicine example japan provide minimum period time approval new drug regulatory agency rely innovators data approve competitor generic copy regulatory intellectual property right available certain market incentives research new indication orphan drug medicine useful treat pediatric patient regulatory intellectual property right independent patent right company possess particularly important drug lack broad patent protection regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data exclusivity basis competitor safety efficacy datum drug drug identical market innovator company estimate likely market exclusivity period product casebycase basis possible predict length market exclusivity company product certainty complex interaction patent regulatory form exclusivity inherent uncertainty concern patent litigation assurance particular product enjoy market exclusivity period time company currently estimate exclusivity limited estimate discussion market exclusivity pharmaceutical segment addition patent regulatory form exclusivity company hold intellectual property form trademark product enfamil trademark effect market exclusivity product consider marketing value worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely specific aspect law govern market exclusivity pharmaceutical vary country country follow summarize key exclusivity rule market represent significant company sale united states company seek market innovative pharmaceutical file complete set safety efficacy datum fda type application file depend drug chemical small molecule biological product large molecule innovative pharmaceutical chemical company file new drug application nda medicine biological product bla file type application file affect regulatory exclusivity right table content competitor seek launch generic substitute chemical innovative drug file anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical know new chemical entity entitle year regulatory data protection anda file fda innovators patent challenge describe generic manufacturer file anda fourth year fiveyear datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation new indication basis new clinical trial receive year datum protection finally nda designate orphan drug drug gain indication treatment condition occur rarely receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use significant portion patent life lose time take obtain regulatory approval innovator extend patent compensate innovator lose patent term specifically innovator identify patent claim product approve method use depend number factor extend expiration date patent limit extension maximum term patent extend year second extension cause patent effect year date nda approval company earn month additional exclusivity drug specific clinical trial conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity sixmonth period extend form exclusivity patent regulatory list fda time study complete submit fda product finally approve currently generic version biological product approve law law change future absence new legislation fda take step allow generic version certain biologic competitor seek approval biological product file safety efficacy datum address challenge biologic manufacturing involve complex process costly traditional pharmaceutical operation innovative drug cover patent hold nda sponsor minimum period regulatory exclusivity provide law innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph certification innovator decide file patent infringement suit generic manufacturer ndaliste patent successfully challenge innovator chooses sue filer paragraph certification filer generic qualifie entitle day period market exclusivity generic manufacturer time time anda include paragraph certification file respect certain company product company evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right increase likelihood generic challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product discussion litigation relate patent challenge generic company item financial statementsnote legal proceeding contingenciesplavix litigation intellectual property litigation second statutory regulatory provision limit ability innovator company prevent generic drug approve launch patent litigation ongoing fda actively consider way expand use regulatory mechanism allow regulatory approval drug similar generic copy innovative drug basis extensive datum require nda result development possible predict length market exclusivity particular company product certainty base solely expiration relevant patent current form regulatory exclusivity information new legislation government regulation price constraint table content european union recent pharmaceutical legislation impact procedure authorization pharmaceutical product centralize mutual recognition procedure particular legislation contain new data protection provision product regardless approve centralized mutual recognition procedure subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority generic company commercialize product year elapse initial marketing authorization grant innovator possible oneyear extension available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment transitional provision new datum protection requirement provision apply new marketing authorization application submit new legislation product continue cover old law year period datum protection centralize procedure period year mutual recognition procedure depend member state regardless procedure obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law pricing reimbursement procedure month year obtain patent pharmaceutical product generally enforceable contrast patent list regulatory authority generic copy approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant patent extended compensate patent term lose regulatory review process extension grant countrybycountry basis general law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property market exclusivity european medicine evaluation agency emea issue guideline outline additional information provide biosimilar product know generic biologic order emea review application marketing approval japan japan medicines new chemical entity generally afford year previously year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity rest world country outside japan wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar canada switzerland develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply world trade organization wto commitment take step implement law meaningful way enforcement wto obligation long process assurance outcome assess likely future market exclusivity company innovative drug develop country company take account formal legal right political factor marketing distribution customer company promote product medical journal directly health care provider doctor nurse practitioner physician assistant pharmacist technologist hospital pharmacy benefit manager pbms manage care organization mcos government agency company market directly consumer directtoconsumer print radio television advertising addition company sponsor general advertising educate public innovative medical research discussion regulation promotion marketing pharmaceutical government regulation price constraint company sale marketing organization company explain approve use advantage product medical professional company work gain access health authority pbm mco formulary list recommend approve medicine product include medicare plan reimbursement list demonstrate table content quality treatment benefit product marketing prescription pharmaceutical limit approve use particular product company continue develop information product provide information response unsolicite inquiry doctor medical professional drug complete clinical trial require regulatory authority safe effective treat medical problem manufacturer choose undertake additional study include comparative clinical trial competitive product demonstrate additional advantage compound study costly year complete result uncertain balancing consideration make difficult decide undertake additional study successful study major impact approve marketing claim strategy company operation include pharmaceutical marketing sale organization organization market distinct group product support sale force typically base particular therapeutic area physician group sale force focus sell new product introduce promotion physician increasingly target specialist high value primary care physician company prescription pharmaceutical product sell principally wholesaler company sell directly distributor retailer hospital clinic government agency pharmacie sale pharmaceutical wholesaler mckesson cardinal health inc cardinal amerisourcebergen corporation amerisourcebergen account approximately respectively company total net sale sale mckesson cardinal amerisourcebergen account approximately respectively company total net sale sale mckesson cardinal amerisourcebergen account approximately respectively company total net sale sale wholesaler concentrated pharmaceutical segment company pharmaceutical business inventory management agreement ima arrangement substantially direct wholesaler distributor customer allow company monitor wholesaler inventory level require wholesaler maintain inventory level month demand ima twoyear term december subject certain termination provision company sell erbitux intermediary wholesaler specialty oncology distributor ship erbitux directly end user product customer intermediary company sell erbitux wholesaler distributor hold erbitux inventory company recognize revenue shipment consistent revenue recognition policy information sale marketing nutritional convatec product nutritional segment convatec segment competition market company compete generally broadbase highly competitive principal mean competition vary product category business group company pharmaceutical segment compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate cost effectiveness marketing effectiveness product label service research development new product process sale company product impact new study indicate competitor product great efficacy treat disease particular form disease company product company sale impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage companys product subject progressive price reduction decrease volume sale successfully compete business mcos pbms company demonstrate product offer medical benefit cost advantage compare form care new product company introduce compete product market product later develop competitor manufacturer generic pharmaceutical typically invest far research development research base pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product certain country outside patent protection weak nonexistent company compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation discussion generic launch clopidogrel bisulfate product compete plavix item financial statementsnote legal proceeding contingenciesplavix litigation table content company large small manufacture sell product similar market company nutritional convatec segment source competitive advantage include patent trademark product quality efficacy brand identity advertising promotion product innovation broad distribution capability customer satisfaction price significant expenditure advertising promotion marketing generally require achieve consumer trade acceptance product company believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment assurance company research development effort result commercially successful product product process outmoded time time result product process develop competitor manage care organization growth mco major factor competitive makeup health care marketplace half population participate version manage care size patient population cover mcos marketing prescription drug pbms serve organization important company business mco include medical insurance company medical plan administrator healthmaintenance organization medicare formulary alliance hospital physicians physician organization organization consolidate few large entity enhance purchasing strength importance company major objective mco contain possible reduce health care expenditure typically use formulary volume purchase longterm contract negotiate discount pharmaceutical provider mcos pbms typically develop formulary reduce cost medication formulary base price therapeutic benefit available product generally low cost generic medicine favor breadth product cover formulary vary considerably mco formulary include alternative competitive product treatment particular medical problem mcos use variety mean encourage patient use product list formulary exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price company generally universally successful major product include mco formulary generic competition big competitive challenge company face less extent internationally generic pharmaceutical manufacturer expiration loss market exclusivity product company lose major portion sale product short period time fda approval process exempt generic costly timeconsuming clinical trial demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product generic competitor operate company large research development expense cost convey medical information product medical community information market exclusivity intellectual property product exclusivity rate sale decline product expiration exclusivity vary country general decline market rapid develop country decline develop country tend rapid develop country rate sale decline expiration exclusivity historically influence product characteristic example drug large patient population prescribe primary care physician tend experience rapid decline drug specialized area medicine oncology drug complex manufacture sterile injectable product usually experience slow decline simple manufacture note mco focus primarily immediate cost drug favor generic brandname drug government encourage use generic alternative brandname drugs health care program law generally allow case require pharmacist substitute generic drug rate government procedure therapeutically equivalent brandname drug substitution prescribe physician expressly forbid law policy provide add incentive generic manufacturer seek marketing approval automatic substitution remove need generic manufacturer incur sale marketing cost innovator incur table content research development company invest heavily research development believe critical longterm competitiveness bristolmyer squibb pharmaceutical research development major facility princeton hopewell new brunswick new jersey wallingford connecticut pharmaceutical research development carry facility belgium canada india management continue emphasize leadership innovation productivity quality strategy success bristolmyers squibb pharmaceutical research development company spend million million million companysponsore research development activity companysponsore pharmaceutical research development spending include certain payment thirdparty collaboration contract end company employ approximately people research development company include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel company concentrate pharmaceutical research development effort follow disease area significant unmet medical need affective psychiatric disorder alzheimersdementia atherosclerosisthrombosis diabete hepatitis hivaid obesity oncology rheumatoid arthritis relate disease solid organ transplant company continue analyze selectively pursue promising lead area addition discover develop new molecular entity company look way expand value exist product new use formulation provide additional benefit patient supplement company internal effort company collaborate independent research organization include educational institution researchbase pharmaceutical biotechnology company contract performance research facility company drug discovery program include alliance collaborative agreement agreement bring new product pipeline help company remain cut edge technology search novel medicine drug development company engage service physician hospital medical school research organization worldwide conduct clinical trial establish safety effectiveness new product drug development time consume expensive risky development human health product industry practice government regulation foreign country provide determination effectiveness safety new molecular entity preclinical test control clinical evaluation new drug marketed record datum preclinical clinical experience include nda bla fda require approval development certain product subject government regulation cover safety efficacy foreign country assurance compound develop result program obtain regulatory approval necessary market particular disease indication average chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine process discovery regulatory approval typically take year long drug candidate fail stage process latestage product candidate fail receive regulatory approval company believe investment research internally collaboration reward number new pharmaceutical compound indication stage development list investigational compound company later stage development compound phase iii clinical trial investigational compound ultimately company market product depend result preclinical clinical study competitive landscape potential product market manufacturing process necessary produce potential product commercial scale factor note assurance company seek regulatory approval compound approval sought obtain stage development company determine intellectual property issue patent protection available investigational compound patent coverage highlight include potential patent term extension apixaban apixaban oral factor inhibitor develop internally recently enter phase iii clinical trial prevention thromboembolic disorder april company enter worldwide agreement pfizer codevelopment cocommercialization apixaban company owns issue patent covering composition matter method use apixaban expire september extend february patent term adjustment saxagliptin saxagliptin oral compound potential treatment diabete discover internally currently phase iii clinical trial january company enter saxagliptin agreement astrazeneca codevelopment cocommercialization saxagliptin patent application cover composition matter issue expire table content ipilimumab ipilimumab codevelope medarex currently phase iii clinical trial monoclonal antibody investigate anticancer treatment novel class agent intend potentiate element immunologic response company own composition matter patent expire right method use patent own medarex expire company right medarex composition matter patent expires extend patent term adjustment pende medarex patent application cover composition matter method use ipilimumab belatacept belatacept biological product develop internally phase iii clinical trial fusion protein novel immunosuppressive activity target prevention solid organ transplant rejection company composition matter patent expire dapagliflozin dapagliflozin oral compound potential treatment diabete discover internally currently phase iii clinical trial january company enter sglt agreement astrazeneca codevelopment cocommercialization dapagliflozin patent application cover composition matter issue expire november company pierre fabre medicament announce termination license agreement development vinflunine chemotherapy agent investigation treatment advance metastatic bladder cancer tumor type company enter agreement respect investigational compound order share cost risk development case facilitate commercialization agreement form include codevelopment comarketing copromotion andor joint venture arrangement company competitor devote substantial fund resource research development addition consolidation occur pharmaceutical industry create company substantial research development resource extent company competitor successful research result erosion sale product unanticipate product obsolescence government regulation price constraint pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act fdc act federal statute regulation state statute regulation law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion company product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition company operation subject complex federal state local foreign environmental occupational safety law regulation company anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment particular importance fda jurisdiction virtually company business impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance company pharmaceutical product fda regulate company nutritional convatec product case fda requirement increase time money necessary develop new product bring market company pharmaceutical product medical device product sell convatec business subject premarket approval requirement new drug approve subject fdc act relate regulation biological drug subject fdc act public health service act phs act relate regulation biological drug license phs act medical device subject fdc act include medical device amendment companys nutritional product regulate fda primarily infant formula act amendmentsthe fda mandate drug manufacture package label conformity current good manufacturing practice cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production record keep quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject manufacturer possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy product occur follow approval table content federal government extensive enforcement power activitie pharmaceutical medical device manufacturer include authority withdraw product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market company materially adversely affect business financial condition result operation cash flow federal government similar power respect manufacturing operation nutritional business marketing authorization company product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject prescription drug marketing act pdma fdc act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample diversion discussion recent settlement certain investigation drug pricing sale marketing activity item financial statementsnote legal proceeding contingency fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda new authority require company conduct postmarkete safety study drug impose certain drug labeling change relate safety mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical trial prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state health care law protect integrity government health care program office inspector general department health human service oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal anti kickback statute criminalize offer value induce recommendation order purchase product service reimburse government health care program oig issue series guidances segment health care industry include compliance program guidance pharmaceutical manufacturer oig guidance include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice company subscribe phrma code implement compliance program address requirement set forth oig guidance company compliance health care law failure comply health care law subject company administrative legal proceeding include action state federal government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect company business financial condition result operation cash flow company subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service company license drug enforcement agency procure produce control substance company subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy company activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing company product regulatory requirement vary country country way company obtain marketing authorization pharmaceutical product route centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product second route obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state set forth pricing reimbursement product continue subject member state law table content fda approval approval emea obtain product approval product comparable regulatory authority country outside case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country market outside company operate environment governmentmandate costcontainment program government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut method cost control european country provide market price new medicine germany pricing freedom limited operation profit control plan germany operation reference price system company face significant delay mainly france spain italy belgium market access new product year elapse new medicine available national market additionally member states regularly impose new additional cost containment measure pharmaceutical recent year italy example impose mandatory price decrease existence price differential europe different national pricing reimbursement law lead significant parallel trade flow recent year congress state legislature consider number proposal enact law effect major change health care system nationally state level drive budget concern medicaid access reimbursement restriction implement state propose similar cost containment issue exist foreign country company business federal state government pursue direct method reduce cost drug pay company participate state governmentmanage medicaid program certain qualify federal state government program discount rebate provide participate state local government entity rebate medicaid relate state program reduce revenue million million million decrease compare primarily exclusivity loss pravachol low plavix sale shift patient enrollment medicaid medicare medicare result decrease medicaid rebate partially offset corresponding increase company manage health care rebate company participate prime vendor program government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase prime vendor program company participate provide discount outpatient medicine purchase certain public health service entity hospital meet certain criterion company record discount relate prime vendor program million million million governmental cost containment effort extend federally fund special supplemental nutrition program wic state participate wic program sought obtain rebate manufacturer infant formula product program state conduct competitive bidding infant formula contract require use specific infant formula product state wic program physician request noncontract formula wic customer state participate wic program require engage competitive bidding use cost containment measure yield saving equal great saving generate competitive bidding system mead johnson participate program approximately half gross sale subject rebate wic program rebate wic program reduce revenue million million million discussion rebate program item management discussion analysis financial condition result operation result operation environmental regulation company facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require company operation permit subject modification renewal revocation issue authority environment health safety group company monitor operation world provide company overview regulatory requirement oversee implementation company standard compliance company incur operate capital cost matter ongoing basis company expend approximately million million million capital environmental project undertake specifically meet environmental requirement respectively expect spend approximately million company believe table content substantial compliance applicable environmental health safety requirement permit require operation company incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law company current facility operation year time company operator facility generate store dispose substance waste consider hazardous federal state foreign environmental law include comprehensive environmental response compensation liability act cercla result soil groundwater certain facility contaminated company require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently company involve investigation remediation current company facility company identify potentially responsible party prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing company face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site company bear remediation responsibility pursuant contract obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter item financial statementsnote legal proceeding contingency employee company employ approximately people december late company undertake broad range action previously announce threeyear pti multiyear pti company implement comprehensive cost reduction program include workforce reduction area rationalization facility specific productivity goal include reduce total headcount approximately percent position eliminate substantial majority position eliminate company record pretax charge million relate termination benefit relate cost workforce reduction approximately manufacture sell administrative personnel geographic region discussion initiative restructuring activity productivity transformation initiative item financial statementsnote restructure foreign operation company significant operation outside conduct company subsidiary distributor involve business segment company operation pharmaceutical nutritional convatec revenue operation outside billion account company total revenue revenue exceed million france canada spain japan italy mexico germany revenues exceed million france japan canada spain italy mexico revenue exceed million france japan spain canada italy germany single country outside contribute company total revenue geographic breakdown net sale table caption geographic area item financial statementsnote segment information discussion company sale geographic area item management discussion analysis financial condition result operationsgeographic area international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit limitation foreign participation local enterprise restrictive governmental action company international business subject governmentimpose constraint include law price reimbursement use productsdepende direction change relative dollar foreign currency value increase reduce report dollar value company net asset result operation change foreign exchange rate net favorable impact growth rate revenue company predict certainty future change foreign exchange rate effect company attempt mitigate impact operational mean financial instrument discussion item quantitative qualitative disclosure market risk item financial statementsnote financial instrument table content item risk factor factor describe significantly negatively affect company business prospect financial condition operating result credit rating cause trading price company common stock decline additional risk uncertainty presently know company risk company currently consider immaterial impair company operation company face competition pharmaceutical manufacturer include lowerpriced generic product possible company lose market exclusivity product early expect competition manufacturer compete product include lowerpriced generic version company product major challenge united states internationally competition include new product develop competitor low price superior performance feature competitive company current product technological advance patent attain competitor iii result clinical study relate company product competitor product problem licensor supplier distributor business combination company competitor major customer pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity country market exclusivity expire generic version product approve market substantial rapid decline product sale rate decline vary country therapeutic category market exclusivity company product base patent right andor certain regulatory form exclusivity scope company patent right vary country country country include certain european union member state basic patent protection company product exist historically certain country offer right obtain certain type patents andor company licensor file market absent relevant patent protection product datum exclusivity period expire generic version product approve market addition prior expiration datum exclusivity competitor seek regulatory approval submit clinical trial datum obtain marketing approval manufacturer generic product increasingly seek challenge patent expire case launch generic product expiration applicable patent andor final resolution patent litigation length market exclusivity company product impossible predict certainty assurance particular product enjoy market exclusivity period time appear estimate disclose discussion generic version product impact product sale item businesscompetitiongeneric competition information market exclusivity item businessproduct item businessintellectual property product exclusivity patent infringement lawsuit apotex inc apotex corp apotex involve plavix ongoing risk generic competition apotex generic pharmaceutical company previously disclose district court southern district new york district court issue opinion order uphold validity enforceability patent relate plavix rule apotexs generic clopidogrel bisulfate product infringe patent enjoin apotex engage activity infringe patent plavix patent infringement lawsuit ongoing risk company face generic competition apotex generic pharmaceutical company apotex file notice appeal court appeal federal circuit apotex prevail appeal district court decision company face renew generic competition plavix apotex promptly loss market exclusivity plavix andor sustain generic competition material company result operation cash flow material financial condition liquidity possible time reasonably assess outcome appeal apotex district court decision plavix patent litigation timing renew generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical company company record defer tax asset relate foreign tax credit research tax credit charitable contribution carryforward charitable contribution carryforward expire vary amount begin foreign tax credit research tax credit carryforward expire vary amount begin realization foreign tax credit research tax credit charitable contribution carryforward dependent generate sufficient domestic taxable income prior expiration realization assure management believe likely defer tax asset realize foreign tax credit research tax credit charitable contribution carryforward consider realizable reduce near term plavix subject renew additional generic competition event occur company need record additional valuation allowance federal defer tax asset discussion plavix relate matter item financial statementsnote legal proceeding contingency company adversely impact economic factor control incur additional impairment charge investment portfolio december company million principal invest auction rate security ar represent interest collateralize debt obligation support pool residential commercial mortgage credit card insurance securitization structure credit include corporate bond underlie collateral ar hold company consist subprime mortgage estimate market value company ar holding december million reflect million adjustment principal value million ar continue pay interest accord state term base valuation model analysis otherthantemporary impairment factor company record impairment charge million fourth quarter reflect portion ar holding company conclude otherthantemporary decline value addition company record unrealized pretax loss million comprehensive income reduction shareholder equity reflect million adjustment ar holding million marketable security company conclude temporary decline value credit capital market continue deteriorate uncertainty market continue market deteriorate company experience additional rating downgrade investment portfolio include ar company incur additional impairment investment portfolio negatively affect company financial condition cash flow report earning table content company significant operation outside revenue operation outside account company revenue company expose change fluctuation foreign currency exchange rate information company foreign currency exchange exposure item quantitative qualitative disclosure market risk company significant borrowing expose change interest rate december company shortterm borrowing longterm debt billion information company interest rate exposure item quantitative qualitative disclosure market risk company expose economic factor company control company experience difficulty delay manufacture sale product company experience difficulty delay inherent manufacturing sale seizure recall pharmaceutical product force closing manufacture plant failure obtain imposition limitation use loss patent intellectual property right iii failure company vendor supplier comply current good manufacturing practice application regulation quality assurance guideline lead temporary manufacturing shutdown product shortage delay product manufacture construction delay relate construction new facility expansion exist facility include intended support future demand company biologic product manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce biologic physical limitation impact continuous supply company experience difficulty delay development commercialization new product company experience difficulty delay development commercialization new product include inherent risk uncertainty associate product development compound product appear promise development fail reach market expect optimal timeframe fail reach market approve additional indication number reason include efficacy safety concern delay denial necessary regulatory approval difficulty excessive cost manufacture failure enter successfully implement optimal alliance appropriate discovery andor commercialization product maintain consistent scope variety promise latestage product iii failure company product achieve maintain commercial viability legal matter adverse outcome negatively affect company business company currently involve lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition include intellectual property dispute sale marketing practice internationally iii adverse decision litigation include product liability commercial case recall withdrawal pharmaceutical product force closing manufacture plant failure fulfill obligation supply contract government customer result liability product pricing promotion matter vii lawsuit claim assert violation security antitrust federal state pricing law viii environmental health safety matter tax liability assurance increase scope matter additional lawsuit claim proceeding investigation future assurance matter material adverse impact company foreign regulation negatively affect company sale profit margin company subject new government law regulation health care reform initiative state federal level country change food drug administration fda foreign regulatory approval process cause delay approve prevent approval new product iii tax change phase tax benefit heretofore available certain foreign country new law regulation judicial governmental decision affect pricing marketing jurisdiction change intellectual property law matter compulsory license alter protection afford product company face increase pricing pressure abroad manage care organization institutional purchaser government agency program negatively affect company sale profit margin pharmaceutical product subject increase price pressure restriction worldwide include rule practice manage care group institutional governmental purchasers judicial decision governmental law regulation relate medicare medicaid healthcare reform include medicare prescription drug improvement modernization act iii potential impact importation restriction legislative andor regulatory change pharmaceutical reimbursement medicare formularie product pricing general development technology andor industry practice directly indirectly impact reimbursement policy practice party payer table content company rely party meet contractual regulatory obligation company rely vendor partner include alliance pharmaceutical company development commercialization product party meet contractual regulatory obligation relation arrangement company failure party meet obligation andor development significant disagreement factor materially disrupt ongoing commercial relationship prevent optimal alignment partner activity material adverse impact company failure execute company business strategy adversely impact growth profitability strategy company currently implement comprehensive cost reduction program include workforce reduction area rationalization facility company expect incur restructuring charge connection program range billion billion pretax basis year million charge incur fourth quarter approximately million charge expect incur company able fully execute strategic transformation business attain new period sustainable revenue earning growth company continue invest key product pipeline focus address area significant unmet medical need failure realize expect cost saving achieve maintain competitive cost base successfully transition product portfolio materially adversely affect company result operation addition company failure hire retain personnel right expertise experience operation critical business function adversely impact execution business strategy change company structure operation revenue cost efficiency result acquisition divestiture merger alliance restructuring strategic initiative result great expect cost difficulty include need regulatory approval appropriate company increasingly dependent information technology outsource arrangement company increasingly dependent information technology system significant breakdown invasion destruction interruption system negatively impact operation company increase dependence thirdparty provider certain service include information technology system failure service provider meet obligation andor development significant disagreement factor materially disrupt company ongoing relationship provider negatively affect operation table content item unresolved staff comment item property company world headquarter locate park avenue new york lease approximately square foot floor space approximately square foot sublet company manufacture product major worldwide location aggregate floor space approximately million square foot facility own company follow table illustrate geographic location company significant manufacturing facility business segment total company pharmaceutical nutritional convatec united states europe middle east africa western hemisphere pacific total portion facility facility own lease company research administration storage distribution information company facility item businessmanufacture quality assurance item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item submission matter vote security holder matter submit vote security holder fourth quarter year end december table content executive officer registrant list information executive officer company february executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve pleasure board director current position age employment history past year james cornelius chief executive officer chairman board guidant chairman board chief executive officer corporation member management council interim chief executive officer chairman board guidant corporation interim chief executive officer director company chief executive officer director company present chairman board chief executive officer company lamberto andreotti senior vice president president international executive vice president president worldwide medicine group division company worldwide pharmaceutical present executive vice president president worldwide member management council pharmaceutical division company stephen bear present senior vice president human resource corporate staff senior vice president human resource company corporate staff member management council andrew bonfield present chief financial officer corporate staff company executive vice president chief financial officer corporate staff member management council joseph caldarella vice president finance pharmaceutical research institute vice president corporate controller division company corporate staff present vice president corporate controller corporate staff company john celentano president latin america canada worldwide medicines president health care group group division company member management council present president health care group division company anthony hooper president europe middle east africa worldwide president pharmaceuticals medicine group division company member management council present president pharmaceuticals worldwide medicine group division company sandra leung vice president corporate secretary corporate staff senior vice president general counsel company corporate staff vice president corporate secretary acting general member management council counsel corporate staff company present senior vice president general counsel corporate staff company table content elliott sigal phd senior vice president global clinical pharmaceutical executive vice president chief scientific officer development pharmaceutical research institute division president pharmaceutical research development company member management council present chief scientific officer president pharmaceutical research development division company robert zito executive vice president communications new york stock senior vice president corporate business exchange communication chief communication officer present senior vice president corporate affairs corporate staff member management council company table content item market registrant common stock stockholder matter market price bristolmyer squibb common preferred stock trade new york stock exchange nyse trade nyse arca inc pacific exchange inc symbol bmy bmypr december company voluntarily withdraw security list nyse arca inc quarterly summary high low market price present common high low high low quarter second quarter quarter fourth quarter prefer high low high low quarter second quarter quarter fourth quarter second quarter trades companys prefer stock prefer stock pay quarterly dividend share holder common stock number record holder common stock december number record holder base actual number holder register book company date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company vote security principal holder reference proxy statement file march respect vote security principal holder incorporate reference hereof response information require item table content dividend board director company declare follow dividend share pay quarter indicate common prefer quarter second quarter quarter fourth quarter december board director company declare quarterly dividend share common stock company share prefer stock company pay february shareholders record january unregistere sale equity security use proceed follow table summarize surrender company equity security connection stock option restrict stock program month period end december total number approximate dollar total number share purchase value share average price publicly share pay announce plan purchase period purchaseda sharea programsb plan programsb dollar million share datum january february march month end march april june month end june july august september month end september october november december month end december month end december reflect follow transaction month end december surrender company share common stock pay exercise price satisfy tax withholding obligation connection exercise employee stock option surrender company share common stock satisfy tax withholding obligation connection vest restricted stock issue employee june company announce board director authorize purchase billion company common stock month end december share repurchase pursuant program purchase share program expect table content performance graph follow performance graph compare performance bristolmyer squibb period indicate performance standard poor stock index average performance group consist peer corporation lineofbusiness basis corporation make peer company group abbott laboratories astrazeneca plc eli lilly company glaxosmithkline plc johnson johnson merck inc novartis pfizer inc sanofiaventis include performance aventis prior merger sanofi scheringplough corporation wyeth total return index reflect reinveste dividend weight beginningperiod market capitalization report time period measure performance group proxy statement comparison fiveyear cumulative total return bristolmyer squibb index peer group assume invest bristolmyer squibb common stock index peer company group index value december specify year assume dividend reinveste table content item select financial datum fiveyear financial summary amount million share datum income statement datum net sale earn continue operation minority interest income taxis net earning continue operation net earning continue operation common share basic diluted average common share outstanding basic dilute dividend pay common prefer stock dividend declare common share financial position datum december total asset cash cash equivalent marketable security longterm debt stockholder equity company record item affect comparability result discussion item year item management discussion analysis financial condition result operationsexpense item financial statementsnote alliance investment note restructure note acquisition divestiture note discontinue operation asset hold sale note cash cash equivalent marketable security note shortterm borrowing longterm debt note legal proceeding contingency exclude discontinued operation medical imaging year oncology therapeutic network year million weightedaverage share issuable million million respectively interest expense net tax assume conversion convertible debt include diluted earning share calculation antidilutive include impact adoption statement financial accounting standard sfas employer account define benefit pension postretirement plansan amendment fasb statement discussion sfas item financial statementsnote pension postretirement benefit include medical imaging asset classify held sale table content item management discussion analysis financial condition result operation executive summary company bristolmyer squibb company bms company bristolmyer squibb global biopharmaceutical relate health care product company mission extend enhance human life provide high quality pharmaceutical relate health care product company engage discovery development licensing manufacturing marketing distribution sale pharmaceutical relate health care product company reportable segmentspharmaceutical nutritional convatec pharmaceutical segment consist global pharmaceuticalbiotechnology international consumer medicine business account approximately company net sale nutritional segment consist mead johnson nutritionals mead johnson primarily infant formula children nutritional business account approximately company net sale convatec segment consist ostomy wound skin care business account approximately company net sale previously include health care operating segment january company complete sale medical imaging business avista capital partner avista result medical imaging business previously include health care operating segment present company result discontinue operation financial highlight worldwide net sale continue operation increase billion compare plavix clopidogrel bisulfate sale grew primarily reflect adverse impact generic competition august mid strong underlying sale growth key product company pharmaceutical segment include avaproavalide irbesartanirbesartanhydrochlorothiazide reyataz atazanavir sulfate sustiva efavirenz franchise abilify aripiprazole experience double digit sale growth year sale company new specialty biologic medicine baraclude entecavir orencia abatacept sprycel dasatinib continue strong addition company launch ixempra ixabepilone treatment metastatic locally advanced breast cancer overall worldwide sale growth moderate significant decline pravachol pravastatin sodium sale generic competition net earning continue operation billion compare billion result include million charge acquire inprocess research development relate purchase adnexus therapeutics inc adnexus million charge connection company threeyear productivity transformation initiative pti million impairment charge company investment certain auction rate security ar result include million increase reserve price sale litigation settlement million early debt retirement cost additionally company record gain sale product asset property million million respectively december company announce board director board declare percent dividend increase increase dividend increase result quarterly dividend thirtyone cent share company common stock indicative dividend year share subject normal quarterly review board business environment company conduct business primarily pharmaceuticalbiotechnology industry highly competitive subject numerous government regulation competitive factor significantly affect company sale product include product efficacy safety price cost effectiveness marketing effectiveness product label quality control quality assurance manufacturing operation research development new product successfully compete business health care industry company demonstrate product offer medical benefit cost advantage currently company new product introduction compete product market therapeutic category addition potential competition new product competitor introduce future company manufacture brand product price high generic product generic competition company lead challenge globally pharmaceuticalbiotechnology industry majority innovative product commercial value usually realize period product market exclusivity product lose exclusivity long protect patent table content subject new compete product form generic brand exclusivity loss company lose major portion product sale short period time currently generic version biological product approve law law change future absence new legislation food drug administration fda take step allow generic version certain biologic competitor seek approval biological product file safety efficacy datum address challenge biologic manufacturing involve complex process costly traditional pharmaceutical operation internationally health care industry subject governmentimposed regulation authorize price price control continue impact company sale congress state legislature consider number proposal enact law effect major change health care system nationally state level drive budget concern medicaid access reimbursement restriction implement state propose addition medicare prescription drug improvement modernization act provide outpatient prescription drug coverage senior citizen legislation modest favorable impact company result increase number senior drug coverage continue potential negative impact pharmaceutical business result pricing pressure control market outside company operate environment governmentmandate costcontainment program regulatory body group exert downward pressure pricing pricing freedom limited united kingdom instance operation profit control plan germany operation reference price system company face significant delay market access new product year elapse drug approval new medicine available national market growth manage care organization mcos play large role competition surround health care industry mco seek reduce health care expenditure participant make volume purchase enter longterm contract negotiate discount pharmaceutical provider market potential create large pool participant marketing prescription drug mcos important company strategy company compete inclusion mco formulary company generally successful major product include company believe development manage care industry include continued consolidation continue generally downward pressure price pharmaceuticalbiotechnology production process complex highly regulate vary widely product product shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval biologic manufacturing involve complex process traditional pharmaceutical operation biologic important company product portfolio company continue arrangement thirdparty manufacturer substantial investment increase internal capacity produce biologic commercial scale investment build new stateoftheart manufacturing facility production biologic devens massachusetts construction begin company maintain competitive position market strive uphold position dependent success discover develop innovative costeffective product serve unmet medical need recently company competitor announce cost reduction program effort reduce respective cost basis increase productivity competitiveness company announce threeyear pti reduce cost streamline operation rationalize global manufacturing effort productive competitive biopharmaceutical company company subsidiary subject number significant pende lawsuit claim proceeding investigation possible time reasonably assess final outcome investigation litigation additional discussion legal matter item financial statementsnote legal proceeding contingency strategy december company outline multiyear strategy design transform company nextgeneration biopharmaceutical company strategy encompass aspect geographie business yield substantial cost saving cost avoidance increase company financial flexibility advantage attractive market opportunity arise company develop nextgeneration biopharmaceutical company continue invest key growth product include specialty biologic medicine cardiovascular metabolic drug company continue execute ongoing strategy longterm growth scale asset profitable decline mature brand increase focus table content key new growth product include plavix abilify avaproavalide reyataz sustiva franchise erbitux cetuximab orencia baraclude sprycel ixempra company experience series major anticipate exclusivity loss expect significant new exclusivity loss year order support production specialty product pharmaceutical portfolio include biologic company complete land purchase acre site locate new largescale expandable multiproject bulk biologic manufacturing facility deven massachusetts company commit million fund construction facility begin facility project operationally complete company plan submit site regulatory approval commercial production biologic compound anticipate begin addition company expand manati puerto rico facility expansion target startup new stateoftheart facility expand manati puerto rico facility support fill finishing company sterile product biologic compound include orencia company internally discover develop biologic medicine commercial quantity compound currently development compound receive regulatory approval keep strategy company invest billion research development represent growth rate research development dedicated pharmaceutical product include milestone payment inlicense development program billion compare billion consistent company objective maximize value nonpharmaceutical business january company complete sale medical imaging business avista company continue seek opportunity maximize value remain health care group business transition nextgeneration biopharmaceutical company company seek reallocate resource enable strategic acquisition acquisition adnexus october pursue partnership collaborative arrangement worldwide alliance astrazeneca plc astrazeneca discover develop commercialize saxagliptin dapagliflozin separate agreement pfizer inc pfizer research development commercialization pfizer discovery program development commercialization apixaban productivity transformation initiative company undertake broad range action fourth quarter previously announce threeyear pti reduce cost streamline operation rationalize global manufacturing initiative track achieve billion annual cost saving cost avoidance pretax basis central company strategy nimble flexible generation biopharmaceutical enterprise key productivity initiative include reduce general administrative operation simplify standardize outsource appropriate process service rationalize company mature brand portfolio consolidate global manufacturing network eliminate complexity enhance profitability simplify geographic footprint implement efficient gotomarket model specific productivity goal include reduce number brand company mature product portfolio percent reduce number manufacture facility percent end reduce total headcount approximately percent position eliminate substantial majority position eliminate productivity activity entire organization fourth quarter impend closure manufacturing facility include mayaguez puerto rico barceloneta puerto rico cost associate implementation pti estimate billion billion pretax basis million incur approximately million expect incur ultimate timing recording charge predict certainty affect occurrence trigger event expense recognition generally accept accounting principle gaap factor table content new product pipeline development december company medarex inc medarex announce topline datum registrational trial constitute monotherapy program ipilimumab patient metastatic melanoma result study conduct special protocol assessment meet primary endpoint rule good objective response rate percent totality datum registrational program include clear dose response effect observe study good objective response rate study range midsingle digit midteen determine independent radiology review receipt additional datum ongoing clinical trial company plan meet fda discuss regulatory pathway goal submit regulatory filing middle support datum november company pierre fabre medicament pierre fabre announce termination license agreement development vinflunine chemotherapy agent investigation treatment advance metastatic bladder cancer tumor type november abilify approve fda adjunctive addon treatment antidepressant therapy adult major depressive disorder mdd abilify medication approve fda addon treatment mdd fda approve abilify treatment schizophrenia adolescent patient age accept priority review supplemental new drug application snda treatment pediatric patient age bipolar disorder update sprycel label include low recommend start dose daily twice daily start dose patient chronicphase chronic myeloid leukemia resistant intolerant imatinib approve fda november european commission august quarter sprycel receive approval andor reimbursement additional european market include ireland norway sweden greece approve canada new zealand october atripla efavirenz mgemtricitabine mgtenofovir disoproxil fumarate approve canada oncedaily singletablet regimen treatment human immunodeficiency virus infection adult december european commission grant marketing authorization atripla formally approve commercialization country european union norway iceland atripla launch germany austria october company launch ixempra treatment patient metastatic locally advanced breast cancer addition japanese new drug application ixabepilone submit december marketing authorization application ixabepilone review european medicine evaluation agency emea follow submission september october company acquire privatelyheld adnexus developer new therapeutic class biologic call adnectins adnectins proprietary class target biologic base naturally occur protein find human serum october company imclone system incorporate imclone announce fda approve update erbitux product labeling include overall survival datum single agent epidermal growth factor inhibitor egfrexpresse metastatic colorectal cancer mcrc patient failure irinotecan oxaliplatinbase regiment september company imclone announce phase iii study erbitux combination platinumbase chemotherapy conduct merck kgaa meet primary endpoint increase overall survival compare chemotherapy patient advance nonsmall cell lung cancer previously disclose early study conduct imclone company evaluate use erbitux combination different platinumbase therapy meet primary endpoint increase progressionfree survival patient advance nonsmall cell lung cancer key secondary endpoint study statistically significant favor erbituxcontaine arm september fda approve snda single tablet plavix loading dose prove effective broad acute coronary syndrome patient population tablet clopidogrel bisulfate launch december currently emea reviewin august company pfizer finalize collaborative agreement research development commercialization pfizer discovery program include advanced preclinical compound potential application treatment metabolic disorder include obesity diabetes company record upfront charge million accordance term agreement pfizer responsible research earlystage development activity metabolic disorder program company jointly conduct phase iii development commercialization activity company share development commercialization expense profitslosse basis pfizer assume large share expense profitslosse table content august fda accept file review supplemental biologic license application orencia treatment pediatric patient juvenile idiopathic arthritis orencia approve european commission receive approval andor reimbursement european market include germany austria sweden netherlands denmark april fda approve update orencia product label progression structural joint damage important measure treatment rheumatoid arthritis indication strengthen slow inhibit progression structural damage adult patient moderately severely active inadequate response diseasemodifye antirheumatic drug methotrexate tumor necrosis factor antagonist july company imclone amend term agreement codevelopment copromotion erbitux north america amendment company jointly agree expand investment ongoing clinical development plan erbitux development cost threshold value sole responsibility company cost excess threshold share company accord predetermine ratio additional funding company intend explore use erbitux additional tumor type include brain breast bladder gastric lung pancrea prostate company isis pharmaceuticals inc isis enter collaborative agreement discover develop commercialize novel antisense drug target proprotein convertase subtilisin kexin prevention treatment cardiovascular disease company upfront payment million isis agreement provide isis million research funding period year april company pfizer enter worldwide collaboration develop commercialize apixaban anticoagulant discover company study prevention treatment broad range venous arterial thrombotic condition accordance term agreement pfizer upfront payment million million company december respectively pfizer fund development cost effective january go forward company fund company receive additional payment million pfizer base development regulatory milestone company jointly develop clinical marketing strategy apixaban share commercialization expense profitslosse equally global basis february baraclude add american association study liver disease treatment guideline hepatitis firstline treatment option baraclude receive approval andor reimbursement additional european market include italy quarter january company enter worldwide japan codevelopment cocommercialization agreement astrazeneca develop commercialize investigational compound study treatment type diabetes company receive upfront payment million astrazeneca addition company receive milestone payment astrazeneca successful achievement regulatory sale relate stage company agree initial development plan compound majority development cost pay astrazeneca subsequent development cost generally share equally july company decide investigational compound dapagliflozin selective inhibitor sodiumglucose transporter study treatment diabete phase iii testing base result phase clinical trial december company enter collaboration agreement exelixis pharmaceuticals inc exelixis discover develop commercialize novel target therapy treatment cancer agreement effective january accordance term agreement company upfront payment million exelixis january company exercise option develop commercialize compound target therapeutic target pay exelixis million february exelixis eligible receive million additional investigational drug candidate select company option exelixis company share equally development cost commercial profit company responsible development pay development milestone royalty exelixis table content result operation follow discussion company result continue operation exclude result relate medical imaging business previously present component health care operating segment prior divestiture january oncology therapeutic network otn business previously present separate operating segment prior divestiture business segregate continue operation reflect discontinued operation period present discontinued operation company result operation follow change dollar million net sale earning continue operation minority interest income taxis net sale provision income taxis effective tax rate net earning continue operation net sale net sale net sale continue operation increase billion include favorable foreign exchange impact compare net sale increase billion compare international net sale increase billion compare include favorable foreign exchange impact net sale continue operation decrease billion compare net sale decrease billion compare international net sale decrease billion compare composition change net sale follow analysis change total change volume price foreign exchange general company business seasonal information pharmaceutical prescriber demand reference table business segment pharmaceutical section set forth comparison change net sale estimate total prescription growth retail mail order customer certain company key pharmaceutical product new product sell pharmaceutical business company operate reportable segmentspharmaceutical nutritional convatec previously component health care operating segment january company complete sale avista medical imaging business previously present component health care operating segment company complete sale otn previously present separate operating segment result operation medical imaging otn present company result discontinue operation accordance statement financial standard sfas accounting impairment disposal longlive asset accordingly medical image otn result operation prior period reclassify discontinued operation conform current year presentation table content company net sale segment follow net sale change dollar million pharmaceutical net sale nutritional net sale convatec net sale health care group total company recognize revenue net sale adjustment arrive net sale report consolidated statement earning adjustment refer grosstonet sale adjustment describe critical accounting policy reconciliation companys gross sale net sale significant category grosstonet sale adjustment follow year end december dollar millions gross sale grosstonet sale adjustment prime vendor chargeback woman infant child wic rebate manage health care rebate contract discount medicaid rebate cash discount sale return adjustment total grosstonet sale adjustment net sale slight decrease grosstonet sale adjustment compare affect number factor sale return decrease primarily high accrual cardiovascular nonexclusive brand discontinue commercialization tequin gatifloxacin decrease prime vendor chargeback primarily low sale taxol paclitaxel result loss exclusivity partially offset increase manage health care rebate contract discount primarily result high plavix sale reversal reserve relate tricare retail pharmacy refund program partially offset low sale pravachol loss exclusivity additionally increase cash discount primarily high plavix sale volume decrease grosstonet sale adjustment compare affect number factor include change customer mix portfolio shift case product require low rebate change contract status decrease prime vendor chargeback primarily result low plavix net sale volume erosion highlyrebate paraplatin carboplatin taxol paclitaxel generic competition impact discontinue commercialization tequin manage health care rebate contract discount decrease primarily result reversal reserve relate tricare retail pharmacy refund program exclusivity loss pravachol reduce medicaid rebate addition low plavix net sale shift patient enrollment medicaid medicare medicare result decrease medicaid rebate partially offset corresponding increase manage health care rebate decrease cash discount primarily low sale pravachol loss exclusivity low plavix sale volume increase sale return primarily high return trend nonexclusive brand discontinue commercialization tequin table content activity end balance significant category grosstonet sale adjustment follow manage health care woman rebates infant prime vendor child contract medicaid cash sale dollar million chargeback wic rebate discount rebate discount return adjustment total balance january provision relate sale current period provision relate sale prior period return payment impact foreign currency translation discontinue operation balance december provision relate sale current period provision relate sale prior period return payment impact foreign currency translation discontinue operation balance december company record grosstonet sale adjustment relate sale prior period significant item include charge sale return million primarily relate high expect return certain nonexclusive product company record grosstonet sale adjustment relate sale prior period significant item include charge sale return million primarily relate high expect return trend certain nonexclusive product discontinued commercialization tequin credit contract discount million primarily reversal reserve relate tricare retail pharmacy refund program significant revision estimate grosstonet sale adjustment pharmaceutical composition change pharmaceutical sale follow analysis change foreign total change volume price exchange worldwide pharmaceutical sale increase million include favorable foreign exchange impact compare period pharmaceutical sale increase million million primarily increase plavix sale reflect adverse impact generic competition august mid strong underlying sale growth sale growth attribute increase sale abilify sustiva franchise reyataz avaproavalide erbitux sale new product sprycel orencia baraclude ixempra increase partially offset increase generic competition pravachol international pharmaceutical sale increase include favorable foreign exchange impact million million exclude impact foreign exchange decrease sale primarily increase generic competition pravachol taxol paclitaxel partially offset sale growth abilify reyataz plavix avaproavalide new product baraclude sprycel worldwide pharmaceutical sale decrease million pharmaceuticals sale decrease million million primarily low sale plavix result launch generic clopidogrel bisulfate august loss exclusivity pravachol partially offset continued growth abilify erbitux reyataz sustiva franchise avaproavalide sale new product include orencia table content baraclude sprycel international pharmaceutical sale decrease million million primarily decline pravachol taxol paclitaxel sale result increase generic competition europe partially offset increase sale new product include reyataz abilify baraclude key pharmaceutical product sale represent total pharmaceutical sale respectively follow change dollar million cardiovascular plavix avaproavalide pravachol coumadin virology reyataz sustiva franchise total revenue baraclude oncology erbitux taxol paclitaxel sprycel ixempra affective psychiatric disorder abilify total revenue immunoscience orencia pharmaceutical efferalgan change excess sale plavix platelet aggregation inhibitor company alliance sanofi increase include favorable foreign exchange impact million million sale increase million million company estimate adverse effect generic clopidogrel bisulfate launch august range billion billion company estimate negative impact generic clopidogrel bisulfate range million million inventory generic clopidogrel bisulfate distribution channel substantially deplete june estimate total prescription demand clopidogrel bisulfate brand generic increase approximately compare estimate total prescription demand brand plavix increase period sale decrease million million sale decrease million million market exclusivity plavix expect expire major european market composition matter patent plavix subject litigation datum exclusivity plavix expire july key composition matter patent expire majority member country additional information plavix litigation item financial statementsnote legal proceeding contingency sale avaproavalide angiotensin receptor blocker treatment hypertension sanofi alliance increase include favorable foreign exchange impact million million sale increase million million primarily high average net selling price estimate total prescription demand decrease approximately compare international sale increase include favorable foreign exchange impact million million sale increase include favorable foreign exchange impact million million sale increase million million international sale increase include favorable foreign exchange impact million million market exclusivity avaproavalide know aprovelkarvea expect expire include pediatric extension country company market avaproavalide japan sale pravachol hmg coa reductase inhibitor decrease include favorable foreign exchange impact million million increase generic competition key european market estimate total prescription demand decrease approximately compare sale decrease table content million million market exclusivity expiration april result generic competition strength generic competition key european market market exclusivity end exception sweden expiration occur march italy expiration occur january france generic competition authorize company commence july previously disclose company authorize watson pharmaceutical distribute pravastatin sodium tablet sale coumadin oral anticoagulant predominantly patient atrial fibrillation deep venous thrombosispulmonary embolism decrease include favorable foreign exchange impact million million primarily low demand drive continued competition partially offset high average net selling price estimate total prescription demand decrease approximately compare sale increase million million primarily high average net selling price partially offset low demand drive continued competition market exclusivity coumadin expire sale reyataz protease inhibitor treatment hiv increase include favorable foreign exchange impact million million primarily increase demand majority market sale increase million million primarily high demand estimate total prescription demand increase approximately compare international sale increase include favorable foreign exchange impact million million sale increase million million primarily increase demand europe latin america market exclusivity reyataz expect expire country japan data exclusivity expire total revenue sustiva franchise nonnucleoside reverse transcriptase inhibitor treatment hiv increase include favorable foreign exchange impact million million sale increase million million primarily high demand result successful launch atripla july estimate total prescription demand sustiva franchise increase approximately compare international sale increase include favorable foreign exchange impact million million primarily high demand market july company gilead sciences inc gilead launch atripla oncedaily single tablet threedrug regimen hiv intend standalone therapy combination antiretroviral total revenue sustiva franchise include sale sustiva revenue bulk efavirenz include combination therapy atripla company record revenue bulk efavirenz component atripla sale atripla joint venture gilead thirdparty customer sale increase million million high demand launch atripla quarter market exclusivity sustiva expect expire country company market sustiva japan additional information revenue recognition sustiva franchise item financial statementsnote alliance investment sale baraclude oral antiviral agent treatment chronic hepatitis increase million million continued growth market include china japan korea sales increase million million baraclude launch april china february germany july france japan september company composition matter patent expire japan previously disclose uncertainty china exclusivity law uncertainty possible company china receive marketing authorization china health authority sale erbitux sell company exclusively increase million million primarily increase demand usage treatment head neck cancer transition broad distribution model sale increase million million erbitux market company distribution copromotion agreement imclone use patent relate combination therapy cytotoxic treatment expire patent covering monotherapy currently generic version biological product approve law law change future absence new legislation fda take step allow generic version certain biologic competitor seek approval biological product file safety efficacy datum address challenge biologic manufacturing involve complex process costly traditional pharmaceutical operation company right market erbitux north america japan agreement imclone expire september company market erbitux country previously disclose imclone yeda research development company ltd yeda litigation ownership use patent combination therapy cytotoxic treatment relate erbitux september district court grant yeda complete ownership patent pursuant settlement agreement execute imclone sanofi yeda announce december end worldwide litigation relate use patent settlement agreement change imclone worldwide royalty rate erbitux sale commercial agreement imclone company pay royalty imclone sale erbitux impact settlement agreement information pertain legal proceeding involve erbitux item financial statementsnote legal proceeding contingency note alliance investment table content sale taxol paclitaxel anticancer agent sell exclusively nonus market decrease include favorable foreign exchange impact million million primarily increase generic competition europe japan sale decrease include unfavorable foreign exchange impact million million primarily increase generic competition europe generic entry japan quarter market exclusivity protection taxol paclitaxel expire country generic paclitaxel product receive regulatory approval japan enter market sale sprycel oral inhibitor multiple tyrosine kinase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib meslylate increase million million sprycel launch july certain european market begin fourth quarter market exclusivity sprycel expect expire country patent pende grant expire sale ixempra microtubule inhibitor treatment patient metastatic locally advanced breast cancer million ixempra launch october company composition matter patent correspond patent country expire company submit request patent term extension composition matter patent possibly extent term patent correspond patent country eligible patent term restoration possibly extend term patent country total revenue abilify antipsychotic agent treatment schizophrenia acute bipolar mania bipolar disorder increase include favorable foreign exchange impact million million sale increase million million primarily high demand high average net selling price estimate total prescription demand increase approximately compare sale increase million million primarily high demand high average net selling price total revenue abilify primarily consist alliance revenue represent company share net sale country copromote otsuka pharmaceutical ltd otsuka product sell otsuka affiliate distributor otsukas market exclusivity protection abilify expect expire include grant patent term extension information patent litigation relate abilify item financial statementsnote legal proceeding contingency company right copromote abilify european country france germany spain act exclusive distributor product rest composition matter patent force germany france italy netherlands romania sweden switzerland spain denmark original expiration date extend grant supplemental protection certificate country romania denmark datum exclusivity expire company contractual right market abilify expire november puerto rico country company exclusive right market abilify june additional information revenue recognition abilify item financial statementsnote alliance investment sale orencia fusion protein indicate adult patient moderate severe inadequate response currently available treatment methotrexate antitumor necrosis factor therapy increase include favorable foreign exchange impact million million primarily demand substantially sale orencia currently launch february orencia launch europe company submit request patent term extension composition matter patent expire possibly extend term patent note generic version biological product approve law law change future sale efferalgan paracetamol formulation acetaminophen pain relief sell principally europe increase include favorable foreign exchange impact million million primarily severe flu season sale decrease million million primarily change government reimbursement instance basic exclusivity loss date indicate expiration date patent claim active ingredient drug method drug approve indication instance basic exclusivity loss date indicate expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval prior expiration datum exclusivity period submit clinical trial datum obtain marketing approval company assess market exclusivity period product case bycase basis length market exclusivity company product difficult predict certainty complex interaction patent regulatory form exclusivity factor assurance table content particular product enjoy market exclusivity period time company currently anticipate estimate market exclusivitie report business planning purpose intend reflect company legal opinion strength weakness particular patent legal position estimate prescription change datum provide include information retail mail order channel reflect information channel hospital institution longterm care estimate prescription datum base nextgeneration prescription service ngps version provide ims health im supplier market research pharmaceutical industry describe company calculate estimate total prescription change base ngps version datum weightedaverage basis reflect fact mail order prescription include great volume product supply compare retail prescription mail order prescription typically reflect day prescription retail prescription typically reflect day prescription calculation derive multiplying ngps mail order prescription datum factor approximate add ngps retail prescription company believe calculation estimate total prescription change base weightedaverage approach respect retail mail order channel provide superior estimate total prescription demand company use methodology internal demand forecast table content estimate endus demand follow table set forth company key pharmaceutical product sell pharmaceutical business year end december total net sale period change report net sale period iii estimate total prescription change retail mail order channel calculate company base ngps version weightedaverage basis month inventory hand distribution channel prior year prescription datum adjust conform ngps version datum year end december december change change month dollar million total net sale net salesa total prescription hand plavix avaproavalide pravachol coumadin reyataz sustiva franchise total revenue baraclude erbitux sprycel ixemprae abilify total revenue orencia year end december december change change month dollar million total net sale net sale total prescription hand plavix avaproavalide pravachol coumadin reyataz sustiva franchise total revenue baraclude erbitux sprycel ixemprae abilify total revenue orencia table content year end december december total change change month dollar million net sale net sale total prescription hand plavix avaproavalide pravachol coumadin reyataz sustiva franchise total revenue baraclude erbitux sprycel ixemprae abilify total revenue orencia reflect percentage change net sale dollar term include change average selling price wholesaler buy pattern derive multiplying ngps mail order prescription datum factor approximate add ngps retail prescription begin quarter sustiva franchise total revenue include sale sustiva revenue bulk efavirenz include combination therapy atripla change total prescription growth sustiva franchise include brand sustiva atripla prescription unit baraclude launch april erbitux orencia ixempra parenterally administer product prescriptionlevel datum physician write prescription product sprycel launch july ixempra launch october orencia launch february change excess estimate prescription change datum report annual report include information retail mail order channel reflect information channel hospital institution longterm care datum provide im product im recordkeeping process estimate base im sampling procedure subject inherent limitation estimate base sample margin error company continuously seeks improve quality estimate prescription change amount ultimate patientconsumer demand review methodology process calculation estimate review analysis party datum calculation company expect continue review refine methodology process calculation estimate continue review analyze party datum calculation pursuant securities exchange commission sec consent order describe sec consent order company monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel company obligate disclose product level inventory excess month hand expect demand subject minimis exception follow product estimate level inventory distribution channel excess month hand case company pharmaceutical product december case company international pharmaceutical nutritional convatec product december andor september december kenalog approximately month inventory hand wholesaler distribution channel estimate value kenalog inventory wholesaler distribution channel month hand approximately million december increase level inventory hand december volatile demand product fourth quarter result temporary product supply shortage company expect work wholesaler inventory level month hand quarter table content december dafalgan analgesic product sell principally europe approximately month inventory hand direct customer compare approximately month inventory hand september increase level inventory hand primarily private pharmacist purchase dafalgan approximately week seasonality product december monopril cardiovascular product approximately month inventory hand direct customer compare month inventory hand september increase level inventory hand december primarily initial stock new exclusive distributor poland stocking support launch monopril poland december videxvidex antiviral product approximately month inventory hand direct customer compare month inventory hand september increase level inventory hand primarily government purchasing pattern brazil company contractually obligate provide videxvidex brazilian government placement order product government term contract company control inventory level relate order december ostomy business approximately month inventory hand direct customer compare month inventory hand september increase level inventory primarily increase purchase significant wholesaler anticipation price increase product sell exclusively wholesaler distributor company determine month hand estimate information respect inventory level product hand outmovement product provide company large wholesaler account approximately total gross sale pharmaceutical product provide company distributor factor influence company estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum represent recordkeeping process reflect estimate pharmaceutical product sell exclusively wholesaler distributor companys pharmaceutical business outside nutritional convatec business unit world company significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely case direct customer product level inventory ultimate patientconsumer demand outmovement datum exist available company develop variety methodology calculate estimate datum include factor historical sale direct customer thirdparty market research datum relate prescription trend endus demand accordingly company rely variety method estimate direct customer product level inventory calculate month hand business unit factor affect company estimate include generic competition seasonality product direct customer purchase light price increase new product product presentation launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation health care group health care group consist nutritional convatec operating segment nutritional operating segment consist mead johnson nutritional primarily infant formula children nutritional business convatec operating segment consist ostomy wound skin care business follow discussion exclude sale relate medical imaging business discontinue operation previously include component health care segment combine revenue health care group increase million combine revenue health care group increase million million table content nutritional composition change nutritional sale follow analysis change total change volume price foreign exchange key nutritional product line sale represent total nutritional sale respectively follow change dollar million infant formula enfamil toddlerchildren nutritional enfagrow worldwide nutritional sale increase include favorable foreign exchange impact million worldwide nutritional sale million increase include favorable foreign exchange impact million international nutritional sale increase include favorable foreign exchange impact million primarily increase sale toddler children nutritional product enfamil company good sell infant formula international nutritional sale increase include favorable foreign exchange impact million million primarily increase sale children nutritional product nutritional sale million million million respectively increase sale increase sale primarily increase sale enfamil convatec composition change convatec sale follow analysis change total change volume price foreign exchange convatec sale business key product sale year end december follow change dollar million convatec ostomy wound therapeutic worldwide convatec sale increase include favorable foreign exchange impact million ostomy sale increase million include favorable foreign exchange impact sale wound therapeutic product increase include favorable foreign exchange impact million primarily continued growth aquacel franchise worldwide convatec sale increase include favorable foreign exchange impact million million primarily sale flexiseal aquacel international convatec sale increase include favorable foreign exchange impact million primarily continued growth aquacel international convatec sale increase include favorable foreign exchange impact million primarily growth aquacel convatec sale increase million primarily flexiseal continue growth aquacel brand convatec sale increase million primarily flexiseal continue growth aquacel brand table content geographic area general company product available country world large market france canada spain japan italy mexico germany company sale geographic area follow change dollar million united states total europe middle east africa total western hemisphere total pacific total total sale increase primarily increase plavix sale continue growth abilify sustiva franchise erbitux avaproavalide reyataz sale new product baraclude orencia sprycel partially offset increase generic competition pravachol sale decrease primarily result low sale plavix loss exclusivity pravachol april partially offset growth remain pharmaceutical product include recently launch product sale europe middle east africa increase include favorable foreign exchange impact exclude impact foreign exchange decrease sale primarily increase generic competition pravachol taxol paclitaxel partially offset sale growth major european market sprycel reyataz sustiva franchise abilify sale decrease result sale decline pravachol taxol paclitaxel increase generic competition decrease sale partially offset increase sale major european market reyataz avaproavalide sale western hemisphere country increase include favorable foreign exchange impact primarily increase sale plavix canada mexico key nutritional product avaproavalide canada partially offset discontinued commercialization tequin sale increase include favorable foreign exchange impact exclude impact foreign exchange decrease sale primarily decrease sale tequin pharmaceutical product partially offset increase sale avaproavalide canada key nutritional product sale pacific region increase include favorable foreign exchange impact primarily increase sale baraclude china japan korea key nutritional product partially offset decrease sale taxol paclitaxel pravachol increase generic competition sale remain consistent compare table content expense change dollar million cost product sell net sale marketing sell administrative net sale advertising product promotion net sale research development net sale acquire inprocess research development net sale provision restructure net net sale litigation expense net net sale gain sale product asset business net sale equity net income affiliate net sale expense net net sale total expense net net sale change excess cost product sell percentage sale decrease compare margin improvement primarily sale growth high margin product include increase sale plavix cost product sell percentage sale respectively company include million percentage sale certain cost cost product sell reported marketing sell administrative expense prior year result addition reclassification increase primarily unfavorable impact pharmaceutical net sale mix include low sale plavix impairment charge tequin emsam relate asset manufacture facility marketing sell administrative expense increase million compare primarily unfavorable impact foreign exchange high marketing expense partially offset low sale force expense marketing sell administrative expense decrease million million primarily abovementione reclassification low sale force expense result previously announce restructure primary care sale organization effective march low expense pravachol partially offset impact adoption stock option expense marketing sell administrative expense percentage sale compare include decrease reclassification respectively advertising product promotion expenditure increase million compare primarily drive increase spend directto customer advertising plavix abilify orencia investment support launch ixempra high spending new product europe unfavorable impact foreign exchange advertising product promotion expenditure decrease million compare million primarily drive divestiture consumer medicine business low spending mature brand partially offset increase investment new product include orencia sprycel company investment research development million increase investment research development million represent increase million increase reflect company strategy continue investment latestage compound develop pipeline disease area address significant unmet medical need increase partially offset share codevelopment cost alliance partner astrazeneca pfizer research development cost include table content charge million upfront milestone payment exelixis pfizer adnexus isis research development cost include charge million million respectively consist primarily upfront milestone payment exelixis solvay global medarex pierre fabre research development spending dedicated pharmaceutical product pharmaceutical sale compare respectively acquire inprocess research development charge million connection purchase adnexu fourth quarter additional information acquisition item financial statementsnote acquisition divestiture restructure program include pti begin late implement realign streamline operation order increase productivity reduce operating expense rationalize company manufacture network research facility sale marketing organization pti expect generate approximately billion cost reduction cost avoidance additional information restructuring item financial statementsnote restructure additional information pti productivity transformation initiative litigation expense net settlement income insurance recovery million million million million expense relate reserve record propose settlement certain pharmaceutical pricing sale litigation million net expense consist increase reserve million settlement principle certain pricing sale investigation partially offset insurance recovery million unrelated matter million income settlement litigation matter million net expense consist increase reserve million liability primarily relate private litigation governmental investigation partially offset insurance recovery million additional information litigation item financial statementsnote legal proceeding contingency gain sale product asset million million net tax sale bufferin excedrin brand japan certain asset relate dermatology product gain sale product asset million million net tax sale inventory patent intellectual property right relate dovonex gain sale business million million net tax relate sale consumer medicine business relate asset additional information transaction item financial statementsnote acquisition divestiture equity net income affiliate million compare million million respectively equity net income affiliate principally relate company joint venture sanofi investment imclone million increase equity net income affiliate primarily increase net income sanofi joint venture partially offset decrease net income equity investment imclone million increase equity net income affiliate primarily increase net income joint venture sanofi income equity investment imclone compare loss additional information equity net income affiliate item financial statement note alliance investment expense net million million million respectively expense net include net interest expense foreign exchange gain loss income thirdparty contract manufacture royalty income expense debt retirement cost impairment marketable security gain loss disposal property plant equipment gain loss sale marketable security insurance recovery defer income recognize certain litigation matter million increase expense net primarily impairment charge million company investment ar net unfavorability foreign exchange partially offset low net interest expense debt retirement cost incur million increase expense net primarily high debt retirement cost connection repurchase billion note compare repurchase billion note million non recur income result termination muraglitazar collaborative agreement partially offset low net foreign exchange loss additional information item financial statementsnote expense net note cash cash equivalent marketable security note shortterm borrowing longterm debt stockbase compensation expense recognize sfas revise sharebased payment sfas year end december million million respectively expense record cost product sell marketing sell administrative expense research development expense stockbase compensation expense recognize accounting principle board apb year end december million expense record marketing sell administrative expense table content year end december company record expenseincome item affect comparability result period present set forth follow table discussion item item financial statementsnote alliance investment note restructure item note acquisition divestiture note income taxis note cash cash equivalent marketable security note shortterm borrowing longterm debt note legal proceeding contingency gain marketing acquire provision sale cost selling research inprocess litigation product product research restructure expense asset expense year end december sell administrative development development net net business net total dollar million productivity transformation initiative downsize streamline worldwide operation accelerate depreciation asset impairment process standardization implementation cost litigation settlement insurance recovery product liability upfront milestone payment acquire inprocess research development auction rate security impairment downsize streamline worldwide operation accelerate depreciation asset impairment contract termination gain sale property product asset income taxis item change estimate taxis prior year item increasedecrease net earning ontinue peration gain sale cost marketing research provision litigation product product sell restructure expense asset expense year end december sell administrative development net net business net total dollar million litigation matter pharmaceutical pricing sale litigation product liability claim damage commercial litigation insurance recovery debt retirement cost accelerate depreciation asset impairment contract termination upfront milestone payment downsize streamline worldwide operation gain sale product asset income taxis item change estimate taxis prior year item increasedecrease net earning con inuing oper tion table content gain provision sale cost research litigation product product restructure expense asset expense year end december sell development net net business net total dollar million litigation matter private litigation governmental investigation erisa liability matter pharmaceutical pricing sale litigation insurance recovery accelerate depreciation asset impairment debt retirement cost downsize streamline worldwide operation upfront milestone payment loss sale fix asset gain sale equity investment termination muraglitazar agreement gain sale consumer medicine business income taxis item adjustment taxis repatriation foreign earning increasedecrease net earning continue operation earning continue operation minority interest income taxis earning continue operation minority interest income taxis change dollar million pharmaceutical nutritional convatec health care group total segment corporateother total earning continue operation minority interest income taxis increase million million increase primarily drive increase plavix sale strong sale growth key product improve gross margin increase equity net income affiliate partially offset net impact item affect comparability result discuss investment advertising product promotion research development earning continue operation minority interest income taxis decrease million million decrease primarily drive net impact item affect comparability result discuss low net sale pharmaceutical product result low plavix net sale loss exclusivity pravachol increase spending research development partially offset increase equity net income affiliate low advertising promotion expensespharmaceutical earning continue operation minority interest income taxis increase million increase primarily increase plavix sale strong sale growth key product improve gross margin increase equity net income affiliate partially offset acquire inprocess research development charge continue investment research development include upfront milestone payment investment advertising product promotion earning continue operation minority interest income taxis decrease million million primarily low net sale result low plavix sale loss exclusivity pravachol investment research development continue investment key product new product table content nutritional earning continue operation minority interest income taxis increase million primarily growth key product partially offset low gross margin primarily high dairy cost increase investment advertising product promotion establishment allowance doubtful account earning continue operation minority interest income taxis increase million million primarily sale growth children nutritional product partially offset increase investment advertising expense research development program convatec earning continue operation minority interest income taxis increase million primarily increase growth key product improve gross margin partially offset increase investment research development program product promotion earning continue operation minority interest income taxis increase million million primarily drive increase sale corporateother loss continue operation minority interest income taxis decrease million result include gain sale product asset million million respectively additional difference primarily debt retirement cost increase reserve price sale litigation settlement low net interest expense partially offset impairment certain ar property high restructuring charge loss continue operation minority interest income taxis increase million million primarily low gain sale product asset compare gain sale consumer medicine business high debt retirement cost compare million income item result termination muraglitazar collaborative agreement low insurance recovery compare partially offset low litigation charge compare income taxis effective income tax rate earning continue operation minority interest income taxis compare tax rate unfavorably impact impairment company investment certain ar tax benefit non deductible writeoff acquire inprocess research development expense relate acquisition adnexus partially offset tax benefit million quarter favorable resolution certain tax matter internal revenue service irs relate deductibility litigation settlement expense impact foreign tax credit effective tax rate unfavorably impact elimination tax benefit section internal revenue code treatment provision portion certain litigation reserve nondeductible partially offset favorable tax legislation enact related tax treatment certain intercompany transaction company foreign subsidiary implementation tax planning strategy relate utilization certain charitable contribution increase effective tax rate primarily aforementioned section benefit elimination treatment provision portion certain litigation reserve nondeductible tax benefit associate settlement irs examination favorable adjustment taxis special dividend american job creation act partially offset favorable tax legislation enact related tax treatment certain intercompany transaction company foreign subsidiary implementation tax planning strategy relate utilization certain charitable contribution company record significant defer tax asset december relate foreign tax credit carryforward approximately million research tax credit carryforward approximately million charitable contribution carryforward million charitable contribution carryforward expire vary amount begin foreign tax credit research tax credit carryforward expire vary amount begin foreign tax credit research tax credit reduce derecognition fin realization credit charitable contribution carryforward dependent generate sufficient domestic taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action pti increase biologic manufacturing capacity implement tax planning strategy increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit charitable contribution carryforward table content minority interest minority interest net taxis increase million primarily high earning company partnership sanofi territory cover america minority interest net taxis decrease million million primarily low earning company partnership sanofi territory cover america change year reflect negative impact generic clopidogrel bisulfate august mid discontinued operation december company enter definitive agreement avista sale medical imaging business purchase price approximately million cash subject customary postclosing adjustment close transaction complete january result transaction company expect recognize pretax gain approximately million million million million loss net tax quarter subject postclosing adjustment medical imaging previously include health care operating segment company complete sale otn equity partner llc cash proceed million include impact preliminary work capital adjustment company record pretax gain million million net tax present gain sale discontinue operation consolidated statement earning otn previously present separate segment follow summarize financial information relate medical imaging otn business segregate continue operation report discontinue operation date disposition reflect cost certain service provide medical imaging otn cost allocate company medical imaging otn service include legal counsel insurance external audit fee payroll process certain human resource service information technology system support year end december dollar million net sale earningsloss income taxis provision income taxis net earningsloss discontinue operation financial position liquidity capital resource cash cash equivalent marketable security approximately billion december compare billion december company continue maintain sufficient level work capital approximately billion december decrease billion december future period company expect cash generate operation exist cash cash equivalent marketable security borrowing capital market sufficient cover cash need work capital capital expenditure company expect include substantial investment facility increase maintain company capacity provide biologic commercial scale milestone payment dividend pay cash cash equivalent marketable security conversion workingcapital item borrowing expect fund near term operation outside december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide cash cash equivalent december primarily consist bank deposit time deposit money market fund cash equivalent primarily highly liquid investment original maturity month time purchase record cost approximate fair value company maintain cash cash equivalent balance dollar foreign currency subject currency rate risk january company convert substantial portion cash equivalent money market fund treasury bill similar investmentsmarketable security december consist dollardenominated float rate security frs primarily aaaaaa rate frs longterm debt security coupon reset periodically benchmark interest rate underlie asset company frs consist primarily investment grade corporate bond loan carry value frs reduce million million million december reflect change fair market value company assess decline fair market value temporary record pretax million reduction million net tax shareholder equity accumulate comprehensive income oci table content previously disclose september company sanofi post million million bond district court southern district new york district court collateral support preliminary injunction issue august collateral report marketable security company consolidate balance sheet december result outcome plavix patent litigation note june district court order release million bond release issuer bond liability connection bond company obligations collateral arrangement respect bond effectively terminate addition december company million principal invest ar ar hold company private placement security longterm nominal maturity interest rate reset dutch auction month monthly auction historically provide liquid market security company investment ar represent interest collateralize debt obligation support pool residential commercial mortgage credit card insurance securitization structure credit include corporate bond underlie collateral ar hold company consist subprime mortgage consistent company investment policy guideline ar investment hold company aaaaaa credit rating time purchase liquidity issue experience global credit capital market ar hold company december experience multiple fail auction security submit sale exceed purchase order addition fourth quarter million principal invest ar hold company downgrade place credit watch security retain aaa rating december estimate market value company ar holding december million reflect million adjustment principal value million ar continue pay interest accord state term base valuation model analysis otherthantemporary impairment factor company record pretax impairment charge million fourth quarter reflect portion ar holding company conclude otherthantemporary decline value addition company record unrealized loss million pretax net tax accumulate oci reduction shareholder equity reflect adjustment ars holding company conclude temporary decline value million impairment charge material impact company liquidity financial flexibility historically give liquidity create auction ar present current asset marketable security give fail auction company ars illiquid successful auction accordingly entire remain ar reclassify marketable security noncurrent asset credit capital market continue deteriorate uncertainty credit capital market continue market deteriorate company experience additional rating downgrade investment portfolio include ar company incur additional impairment investment portfolio negatively affect company financial condition cash flow report earning company believe base company current cash cash equivalent marketable security balance billion december expect operating cash flow current lack liquidity credit capital market material impact company liquidity cash flow financial flexibility ability fund operation include dividend february company complete sale leaseback administrative facility paris france approximately million company expect record gain majority defer reduce future lease rental cost lease period december company complete sale leaseback administrative facility new jersey million result pretax gain transaction million million defer reduce future lease rental cost lease period range year shortterm borrowing end billion million respectively company maintain cash balance shortterm investment excess shortterm borrowing million yen note million yen note million note associate unamortized discount interest rate swap valuation billion float rate convertible debenture putcall reclassify longterm debt shortterm borrowing longterm debt billion december compare billion december billion reduction primarily reclassification shortterm borrowing note september repayment remain billion balance float rate bank term facility fourth quarter company restructure longterm debt retire outstanding billion principal note cash tender offer subsequent redemption issue million aggregate principal note million aggregate principal note billion aggregate principal note company incur aggregate pretax expense approximately million table content connection early redemption note termination relate interest rate swap include writeoff relate unamortized discount issuance cost defer loss interest rate lock addition company repay billion billion float rate bank term facility december company replace prior billion revolve credit facility new billion fiveyear revolve credit facility syndicate lender extendable anniversary date consent lender facility contain customary term condition substantially similar prior facility include financial covenant ratio consolidated debt consolidated capital exceed end quarter company compliance covenant inception facility borrowing outstanding revolve credit facility december second quarter company repurchase outstanding billion aggregate principal note incur aggregate pretax loss approximately million connection early redemption note termination relate interest rate swap majority company debt fix rate company enter fixed float interest rate swap billion billion billion december longterm debt pretax interest expense net interest swap gain million million million respectively decrease interest expense primarily effect debt restructure increase interest expense primarily high interest rate moodys investor service moodys longterm shortterm credit rating company currently prime respectively moodys long term credit rating remain stable outlook standard poor longterm shortterm credit rating company currently respectively second quarter revise longterm credit rating outlook stable negative fitch rating fitch longterm shortterm credit rating company currently respectively quarter fitch revise longterm credit rating outlook stable negative work capital year end december follow december dollar million work capital decrease work capital billion december december impact decrease marketable security reduction carrying value float rate security certain ar fair market value subsequent reclassification remain value ar noncurrent asset increase shortterm borrowing longterm debt reclassification note increase accrue royalty result increase plavix sale increase receivable primarily increase plavix sale reclassification medical imaging asset liability hold sale reclassification certain tax contingency current foreign income taxis payable noncurrent adoption fin january follow discussion companys cash flow activity include discontinue operation company cash flow activity year end december follow year end december dollar million cash flow provide byused operating activity invest activity financing activity net cash provide operating activity billion billion million increase compare attributable high net earning million high net change adjustment net earning million high net change operate asset liability million table content net positive change adjustment net earning compare million mainly include million negative cash flow variance low litigation settlement expense million positive cash flow variance result impairment charge asset writeoff mainly reduction carrying value ar fair value impend closure manufacture facility positive cash flow variance acquire inprocess research development relate acquisition adnexu million negative cash flow variance defer income tax benefit adjustment include defer tax benefit restructuring company international operation upfront cash receipt alliance partner resolution audit issue irs partially offset litigation payment adjustment include net defer tax charge payment litigation settlement offset defer tax benefit additional litigation accrual accrual additional foreign tax credit defer tax benefit equitybase compensation million positive cash flow variance high provision restructure connection pti net positive change operate asset liability compare million mainly include million positive cash flow variance account payable accrue expense primarily increase accrue royalty result increase plavix sale high purchase raw material significant paydown payable early result low payment invoice december reduction accrue rebate return quarter primarily result low sale volume million negative cash flow variance receivables primarily increase plavix sale low collection result low pravachol sale million positive cash flow variance defer income liability mainly upfront cash receipt alliance partner million negative cash flow variance inventory primarily increase inventory anticipation new product launch strategic build exist product reduction inventory result pravachol exclusivity loss million negative cash flow variance income taxis payable primarily relate payment settle tax issue irs audit net cash investing activity million net cash provide investing activity million million negative cash flow variance primarily attributable million negative cash flow variance acquisition adnexu million negative cash flow variance proceed disposal property connection sale leaseback transaction million positive cash flow variance license milestone payment imclone somerset pharmaceuticals inc net cash financing activity million million million positive cash flow variance mainly attributable million positive cash flow variance mainly high cash proceed exercise stock option compare net cash provide operating activity billion billion million increase compare mainly attributable significant change adjustment net earning million net change operate asset liability million offset low net earning million significant positive change adjustment net earning compare million mainly include million positive cash flow variance defer income tax benefit low level increase defer tax benefit compare increase defer tax benefit associate research development foreign tax credit increase litigation reserve increase defer tax benefit associate reversal tax liability relate repatriation special dividend ajca million positive cash flow variance low gain sale product asset compare sale business million positive cash flow variance deferred income recognize related termination muraglitazar collaborative agreement table content net positive change operate asset liability compare million mainly include million negative cash flow variance receivables increase cash flow drive increase receivable alliance partner partially offset low trade receivable volume increase cash flow drive collection foreign withholding taxis alliance partner million positive cash flow variance inventory primarily increase inventory result growth new product anticipation new product launch reduction inventory result pravachol exclusivity loss million negative cash flow variance litigation primarily settlement payment million dpa vanlev litigation partially offset unrelated insurance recovery million million positive cash flow variance income taxis payable primarily relate payment settlement examination irs year repatriation special dividend ajca net cash provide investing activity million compare net cash provide million million negative cash flow variance primarily attributable million negative cash flow variance mainly sale marketable security million negative cash flow variance low proceed sale product asset compare sale consumer medicine otn business million negative cash flow variance milestone payment primarily relate imclone million positive cash flow variance proceed disposal property connection sale leaseback transaction net cash financing activity million compare million million positive cash flow variance mainly attributable million positive cash flow variance repayment shortterm borrowing negative cash flow variance retirement longterm debt company repay debt million retire note million company retire note million cash provide operation borrowing primarily past year pay dividend approximately billion company invest approximately billion past year capital expansion improve plant efficiency maintain superior research facility past year company repurchase common stock share repurchase program authorize company purchase common stock time time open market private transaction market condition permit program intend reduce increase share outstanding option exercise obtain share general corporate purpose dividend declare common share december company declare quarterly dividend common share indicate dividend year share dividend decision quarterly basis company board director companys financial condition liquidity affect obligation milestone onetime payment outcome pende litigation investigation include challenge plavix patent andor potential renew additional generic competition plavix additional impairment investment portfolio information item financial statementsnote alliance investment note cash cash equivalent marketable security note shortterm borrowing longterm debt note legal proceeding contingency table content contractual obligation payment period company contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt operating lease purchase obligation standby letter creditperformance guarantee uncertain tax position pension liability total current portion longterm debt obligation include shortterm borrowing company consolidated balance sheet december balance approximate outstanding nominal longterm debt value contractual obligation table exclude interest payment obligation company convertible debenture include payment contain feature uncertainty relate timing reversal uncertain tax position shortterm uncertain tax benefit provide table longterm amount exclude table total million addition company commit potential future milestone payment party inlicense development program payment agreement generally payable achievement certain developmental regulatory andor commercial milestone specific timing predict achievement milestone probable reasonably estimable contingency record company consolidate balance sheet discussion contractual obligation item financial statementsnote shortterm borrowing longterm debt note financial instrument note lease note pension postretirement benefit plan sec consent order previously disclose august company enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit company quarterly report form period end september term consent company agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice company agree consent certain measure implement include establish formal review certification process annual quarterly report file sec establish business risk disclosure group retain outside consultant comprehensively study help reengineer company account financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand ensure company budget process give appropriate weight input come come adequately document process company establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basisthe company maintain imas pharmaceutical wholesaler account nearly total gross sale pharmaceutical product current term ima company large wholesaler customer provide company weekly information respect month hand productlevel inventory outmovement product wholesaler currently account approximately total gross sale pharmaceutical product inventory information receive wholesaler company internal information estimate month hand product level inventory wholesaler company estimate month hand product inventory level pharmaceutical businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast company pharmaceutical business outside nutritional convatec business unit world company significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly company rely variety method estimate month hand product level inventory business unit table content company believe abovedescribe procedure provide reasonable basis ensure compliance consent previously disclose june company enter dpa attorney office district new jersey resolve investigation usao company relate wholesaler inventory accounting matter cover company settlement sec pursuant dpa usao file criminal complaint company allege conspiracy commit security fraud agree defer prosecution company dismiss complaint year company satisfied requirement dpa copy dpa file exhibit form file company june incorporate reference hereto exhibit fiscal year end december term dpa company agree retain monitor monitor define power responsibility dpa include oversee company compliance term dpa consent settlement derivative action federal security class action power responsibility monitor end april monitor file final report usao june june dpa expire complaint dismiss company ongoing obligation dpa recently issue accounting standard december meeting financial accounting standard board fasb ratify consensus reach emerge issue task force eitf issue account collaborative arrangement relate development commercialization intellectual property eitf conclude collaborative arrangement participant actively involve expose significant risk reward depend ultimate commercial success endeavor revenue cost incur party connection collaborative arrangement present gross net base criterion eitf report revenue gross principal versus net agent accounting literature payment collaborator evaluate present base nature arrangement term nature entitys business payment scope accounting literature nature purpose collaborative arrangement disclose accounting policy classification amount significant financial statement amount relate arrangement activity arrangement conduct separate legal entity account accounting literature require disclosure eitf apply entire collaborative agreement issue effective fiscal year begin december apply retrospectively period present collaborative arrangement exist effective date company currently process evaluate impact adopt pronouncement december fasb issue sfas business combination replace sfas business combination require acquirer recognize asset acquire liability assume noncontrolle interest acquiree acquisition date measure fair value date limit exception statement require acquirer business combination achieve stage recognize identifiable asset liability noncontrolle interest acquiree amount fair value sfas make amendment authoritative literature intend provide additional guidance confirm guidance literature provide statement statement apply business combination acquisition date fiscal year begin december company currently process evaluate impact adopt pronouncement december fasb issue sfas noncontrolle interest consolidate financial statementsan amendment arb sfas establish accounting reporting standard require ownership interest subsidiary hold party parent clearly identify label present consolidated statement financial position equity separate parent equity statement require consolidate net income attributable parent noncontrolle interest clearly identify present face consolidate statement income change parent ownership interest parent retain control financial interest subsidiary account consistently subsidiary deconsolidate retain noncontrolle equity investment subsidiary initially measure fair value gain loss deconsolidation subsidiary measure fair value noncontrolle equity investment statement require entity provide sufficient disclosure clearly identify distinguish interest parent interest noncontrolle owner statement effective fiscal year begin december company currently process evaluate impact adopt pronouncement june eitf reach consensus issue account nonrefundable advance payment good service receive future research development activity nonrefundable advance payment good service render future research development activity defer capitalize amount recognize expense relate good deliver service perform good service long expect provide issue effective fiscal year begin december early application permit pronouncement expect material effect company consolidate financial statement table content february fasb issue sfas fair value option financial asset financial liabilitiesincluding amendment fasb statement permit entity measure certain financial asset financial liability fair value objective sfas improve financial reporting allow entity mitigate volatility report earning cause measurement relate asset liability different attribute apply complex hedge accounting provision sfas entity elect fair value option instrument report unrealize gain loss earning subsequent reporting date fair value option election irrevocable new election date occur sfas establishe presentation disclosure requirement help financial statement user understand effect entitys election earning eliminate disclosure requirement accounting standard asset liability measure fair value display face balance sheet statement effective fiscal year begin november company elect early adoption pronouncement permit adoption accounting pronouncement expect material effect company consolidate financial statement september fasb issue statement sfas employer account define benefit pension postretirement plansan amendment fasb statement pronouncement require employer recognize overfunde underfunded status define benefit postretirement plan multiemployer plan asset liability statement financial position recognize change fund status year change occur comprehensive income business entity pronouncement require employer measure fund status plan date yearend statement financial position limited exception pronouncement require prior period restate reflect impact sfas company adopt sfas fiscal year end december adoption accounting pronouncement result million reduction accumulate oci stockholder equity million reduction total asset million increase total liability adoption sfas impact company result operation cash flow september fasb issue sfas fair value measurement pronouncement define fair value establishe framework measure fair value expand disclosure fair value measurement statement effective fiscal year begin november november fasb agree oneyear deferral implementation sfas nonfinancial asset liabilitie adoption accounting pronouncement expect material effect company consolidate financial statement financial asset liability asset liability carry fair value company currently process evaluate impact adopt pronouncement nonfinancial asset liability september sec issue staff accounting bulletin sab consider effect prior year misstatement quantify misstatement current year financial statement express staff view process quantify financial statement misstatement bulletin effective interim period fiscal year end november sab require company utilize dual approach assess quantitative effect financial statement misstatement dual approach include income statement focus balance sheet focus assessment adoption bulletin effect company consolidate financial statement july fasb issue fasb interpretation fin accounting uncertainty income taxis interpretation fasb statement case company effective january fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas accounting income taxis fin require tax position evaluate recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return difference tax position take tax return amount recognize financial statement record adjustment income taxis payable receivable adjustment defer taxis fin require expand disclosure end reporting period include tabular reconciliation unrecognized tax benefit company adopt fin january result adoption accounting pronouncement company recognize million previously unrecognized tax benefit account increase opening balance retain earning fasb issue fasb staff position fsp fin definition settlement fasb interpretation effective retroactively january fsp fin provide guidance determine tax position effectively settle purpose recognize previously unrecognized tax benefit adoption fsp fin effect company consolidate financial statement march fasb issue sfas accounting service financial asset amendment fasb statement pronouncement relate account separately recognize service asset servicing liability statement effective fiscal year begin september adoption accounting pronouncement material effect company consolidate financial statement table content february fasb issue sfas account certain hybrid financial instrument amendment fasb statement pronouncement primarily resolve certain issue address implementation sfas accounting derivative instrument hedge activity concern beneficial interest securitize financial asset statement effective financial instrument acquire issue subject remeasurement event occur begin fiscal year adoption account pronouncement material effect company consolidate financial statement fasb issue sfas accounting change error correctionsa replacement apb opinion fasb statement pronouncement apply voluntary change account principle revise requirement accounting reporting change accounting principle sfas require retrospective application prior period financial statement voluntary change accounting principle impracticable pronouncement require change method depreciation amortization depletion longlive nonfinancial asset account change accounting estimate affect change accounting principle sfas effective accounting change correction error fiscal year begin december statement change transition provision exist accounting pronouncement include transition phase effective date sfas adoption account pronouncement material effect company consolidate financial statement march fasb issue fin accounting conditional asset retirement obligationsan interpretation fasb statement fin clarifie entity record liability conditional asset retirement obligation fair value obligation reasonably estimate asset retirement obligation cover fin entity legal obligation perform asset retirement activity time method settling obligation conditional future event control entity fin clarifie entity sufficient information reasonably estimate fair value asset retirement obligation interpretation effective later end fiscal year end december company adopt provision fin fiscal year end december adoption accounting pronouncement material effect company consolidate financial statement december fasb issue sfas revise sharebased payment sfas require measurement recognition compensation expense stockbase payment award employee director base estimate fair value sfas supersede company previous accounting apb accounting stock issue employee period begin january march sec issue sab sharebased payment relate sfas company apply provision sab adoption sfas company adopt sfas modify prospective transition method require application accounting standard january elect alternative method provide fsp transition election relate accounting tax effect sharebase payment award determine company pool excess tax benefit company consolidate financial statement year end december reflect impact sfas accordance modify prospective transition method company consolidate financial statement prior period restate reflect include impact sfas stockbase compensation expense recognize sfas year end december million million net tax share corresponding record additional paidin capital stockholder equity additionally million relate performance award reclassify liability stockholder equity connection adoption sfas critical accounting policy company prepare financial statement conformity accounting principle generally accept preparation financial statement conformity gaap require use estimate assumption affect report amount asset liability include disclosure contingent asset contingent liability date financial statement report amount revenue expense report period company critical accounting policy important company financial condition result operation require difficult subjective complex judgment management application result need estimate effect matter inherently uncertain uncertainty factor surround estimate judgment preparation consolidated financial statement actual result vary estimate company believe follow discussion represent critical accounting policy management discuss company critical accounting policy audit committee board director table content revenue recognition company recognize revenue accordance sab revenue recognition financial statement amend sab revenue recognition company accounting policy revenue recognition substantial impact report result rely certain estimate require difficult subjective complex judgment management company recognize revenue net grosstonet sale adjustment discuss involve significant estimate judgment title substantially risk reward ownership transfer customer generally occur date shipment case new product product introduction extension exist line product company determine product similar therapeutic category company determine new product dissimilar characteristic exist product company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return discussion revenue recognition item financial statementsnote accounting policiesrevenue recognition sale rebate return accrual grosstonet sale adjustment company follow significant category grosstonet sale adjustment prime vendor chargeback wic rebate manage health care rebate contract discount medicaid rebate cash discount sale return adjustment involve significant estimate judgment require company use information external source company account grosstonet sale adjustment accordance eitf issue accounting consideration give vendor customer include reseller vendor product sfas revenue recognition right return exist applicable net sale section reconciliation company gross sale net sale significant category grosstonet sale adjustment prime vendor chargeback company business participate prime vendor program government entity significant department defense department veteran affair party pricing product extend wholesaler list price participate entity entity purchase product wholesaler low prime vendor price wholesaler charge difference acquisition cost low prime vendor price company company account prime vendor chargeback reduce account receivable equal company estimate chargeback claim attributable sale company determines estimate prime vendor chargeback primarily base historical experience prime vendor chargeback current contract price prime vendor program company consider prime vendor payment level inventory distribution channel company claim processing time lag adjust reduction account receivable periodically quarter reflect actual experience wic rebate company nutritional business participate competitive bidding basis nutrition program sponsor state tribal government commonwealth puerto rico territory wic program company reimburse entity difference wholesaler list price contract price eligible product company account wic rebate establish accrual equal company estimate wic rebate claim attributable sale company determines estimate wic rebate accrual primarily base historical experience wic rebate current contract price wic program company consider level inventory distribution channel new wic contract terminate wic contract change exist wic contract wic participation adjust accrual periodically quarter reflect actual experience manage health care rebate contract discount company offer rebate discount manage health care organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit addition commercial plan globally contract counterpartie hospital group purchasing organization company account manage health care rebate contract discount establish accrual equal company estimate manage health care rebate contract discount attributable sale company determine table content estimate manage health care rebate contract discount accrual primarily base historical experience rebate discount current contract price company consider sale performance product subject manage health care rebate contract discount level inventory distribution channel adjust accrual periodically quarter reflect actual experience medicaid rebate company business participate state governmentmanage medicaid program certain qualify federal state government program discount rebate provide participate state local government entity discount rebate provide program include company medicaid rebate accrual consider medicaid rebate purpose discussion company account medicaid rebate establish accrual equal company estimate medicaid rebate claim attributable sale company determines estimate medicaid rebate accrual primarily base historical experience medicaid rebate expansion prospective basis participation nonmandatory aspect qualify federal state government program legal interpretation applicable law relate medicaid qualify federal state government program new information change medicaid program regulation guideline impact rebate company consider outstanding medicaid claims medicaid payment level inventory distribution channel adjust accrual periodically quarter reflect actual experience cash discount certain country company offer cash discount approximate sale price incentive prompt payment company account cash discount reduce account receivable discount company consider payment performance adjust accrual reflect actual experience sale return company account sale return accordance sfas revenue recognition right return exist establish accrual equal company estimate sale record related product expect return provision sale return million million million respectively gross sale year return establish product company determine estimate sale return accrual primarily base historical experience sale return consider factor impact sale return factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product company consider factor adjust accrual periodically quarter reflect actual experience company consider level inventory distribution channel determine believe adjustment sale return accrual appropriate company adjust sale return accrual base historical experience company return good policy shelf life company product life cycle product level inventory distribution channel company consider introduction generic product factor impact sale return calculation base historical experience company return good policy event product recall product discontinuance company consider reason impact action adjust sale return accrual appropriate taking account historical experience estimate level inventory distribution channel product discontinuance estimate continue demand sale return accrual new product estimate primarily base historical sale return experience similar product line product similar therapeutic category limit circumstance new product extension exist line product company historical experience product similar therapeutic category company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return company consider shelf life new product determine believe adjustment sale return accrual appropriate shelf life connection new product tend short shelf life establish product company develop optimal manufacturing process new product lengthen shelf life addition high launch quantity manufacture advance launch date ensure sufficient supply exist satisfy market demand case company assess reduce shelf life estimate level inventory distribution channel project demand determine believe adjustment sale return accrual appropriate table content adjustment addition grosstonet sale adjustment describe company make grosstonet sale adjustment example company offer sale discount significantly nonus business offer consumer coupon rebate significantly nutritional pharmaceutical business addition number country outside include major european country company provide rebate government entity company generally account grosstonet adjustment establish accrual equal company estimate adjustment attributable sale company generally determine estimate accrual grosstonet sale adjustment primarily base historical experience performance commitment government entity relevant factor include estimate level inventory distribution channel adjust accrual periodically quarter reflect actual experience use information external source company use information external source estimate grosstonet sale adjustment company estimate inventory wholesaler defer revenue consign inventory base project prescription demandbase sale product historical inventory experience company analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum companys internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital company receive information im supplier market research pharmaceutical industry use project prescription demandbase sale pharmaceutical product prior quarter company historically report estimate total prescription growth estimate therapeutic category share base data ims national prescription audit npa im legacy national projection methodology ims available subscription basis report datum base simple unweighted sum project prescription retail mail order channel quarter company begin disclose npa prescription growth therapeutic category share datum base version im new revise ngps projection methodology consistency ngps version datum current comparative time period properly account trend break new projection methodology coincident change report ims datum ngps version basis company begin report retail mail prescription growth category share weight retailequivalent basis account significantly large size average mail order prescription compare size average retail prescription retail equivalization calculation apply mail order volume share report product time period ims refined improve ngps projection methodology fully roll ngps version npa subscriber result newly revise volume estimate historic time period quarter company new im standard ngps version projection methodology apply ngps version datum report prescription growth market share period present annual report company continue practice combine retail mail prescription volume retail equivalent basis company use methodology internal demand forecast company use information external source identify prescription trend patient demand average selling price company estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date company receive thirdparty information retirement benefit company pension plan postretirement benefit plan account actuarial valuation require sfas employer account pension sfas employer account postretirement benefit pension company consider accounting retirement plan critical management require significant subjective judgment number actuarial assumption include discount rate salary growth longterm return plan asset retirement turnover health care cost trend rate mortality rate depend assumption estimate pension postretirement benefit expense vary range outcome material effect report earning addition assumption materially affect project benefit obligation future cash funding company adopt sfas employer account define benefit pension postretirement plansan amendment fasb statement fiscal year end december adoption accounting pronouncement result million reduction accumulate comprehensive income stockholder equity million reduction total asset million increase total liability adoption sfas impact company result operation cash flow table content plan description company certain subsidiary define benefit pension plan define contribution plan termination indemnity plan regular time employee principal define benefit pension plan bristolmyers squibb retirement income plan principal define contribution plan bristolmyer squibb saving investment program approximately total company define benefit pension plan asset liability hold plan asset plan hold single trust common asset allocation specify reference section total company plan plan international plan benefit company define benefit pension plan base primarily year credit service participant compensation asset company define benefit plan consist primarily equity fixedincome security december fair market value plan asset company define benefit plan increase million million december plan asset allocate equity security compare end fix income security compare end private equity investment compare end bristolmyer squibb common stock represent asset plan end company provide comprehensive medical group life benefit substantially retiree elect participate company comprehensive medical group life plan asset allocation postretirement plan identical asset allocation describe define benefit pension plan accrual account significant assumption consistent requirement sfas company account pension benefit accrual method recognize pension expense payment benefit retiree accrual method accounting pension benefit necessarily require actuarial assumption concern future event determine timing benefit payment company key assumption calculate cost pension benefit discount rate rate compensation increase expect longterm rate return plan asset company consultation actuary evaluate key actuarial assumption assumption calculate cost pension benefit retirement turnover mortality rate base expectation actual experience appropriate determine assumption december year calculate liability information date pension expense follow year depend assumption pension expense vary range outcome material effect report earning addition assumption materially affect project benefit obligation future cash fund actual result give year differ estimate economic factor determine discount rate company use yield high quality corporate bond coincide cash flow plan estimate payout citigroup median yield curve determine discount rate plan assume rate compensation increase company determine future pension obligation reflect estimate change actual future compensation level general price level productivity seniority factor net pension expense company define benefit pension plan include earning minority interest income taxis million compare million plan pension expense determine assumed discount rate assume rate compensation increase present value benefit obligation december plan determine assumed discount rate assume rate compensation increase assume discount rate determine plan pension expense reduce expense increase approximately million assumed rate compensation increase determine plan pension expense reduce expense decrease approximately million assumed discount rate determine accumulate benefit obligation december reduce accumulate benefit obligation increase million plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million table content actual rate return earn plan asset year follow year return year return december company increase assumed discount rate plan maintain assume rate compensation increase compensation assume increase scale different rate different age rate disclose december single rate age produce present value benefit obligation company maintain expect rate return plan asset company expect net pension expense define benefit pension plan include earning minority interest income taxis approximately million low million reflect primarily increase discount rate company assume discount rate expect longterm rate return plan asset calculate cost pension benefit cost postretirement benefit plan case discount rate december rate respectively pension benefit versus respectively postretirement benefit reflect short duration postretirement liability december respectively health care cost retiree population assume increase trend expect increase year actual cost higher assume likely significant upward pressure company expense retiree health care effect medicare prescription drug improvement modernization act reflect net periodic postretirement benefit cost reduction million accumulate postretirement benefit obligation january reduction million recognition actuarial gain loss sfas require recognition actuarial gain loss component stockholder equity accumulate comprehensive income sfas provide delayed recognition year prior amount arise change estimate plan benefit obligation change assume discount rate difference actual expect return plan asset assumption change net actuarial gain loss determine base marketrelated value plan asset differ fair market value calculate value recognize change fair value systematic rational manner year amortize pension income expense year extent unrecognize net actuarial loss gain exceed great project benefit obligation marketrelated value plan asset begin year net gain loss recognize pension income expense prospectively period approximate average remain service period active employee expect receive benefit plan approximately year extent offset loss gain subsequent year unrecognized net actuarial loss reflect large steady reduction weightedaverage discount rate year offset future unrecognized gain high discount rate higher expect return plan asset amortization unrecognized loss expect increase pension expense million progressively low amount follow year plan funding company fund policy define benefit plan contribute amount provide current service fund past service liability company contribute million million define benefit plan respectively discussion retirement benefit item financial statementsnote pension postretirement benefit plan table content acquire inprocess research development fair value inprocess research development acquire business combination determine base present value research project project cash flow income approach utilize consistent guidance practice aid issue american institute certify public accountant asset acquire business combination research development activity focus software electronic device pharmaceutical industry future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weightedaverage cost capital acquire inprocess research development expense incurred underlying product receive regulatory approval future alternative use addition cost nonrefundable relate acquisition licensing product receive regulatory approval market alternative future use charge earning incur discussion acquire inprocess research development item financial statementsnote accounting policiesacquire inprocess research development impairment longlive asset accordance sfas accounting impairment disposal longlive asset company periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow company report asset dispose low carrying value estimate net realizable value accordance sfas goodwill intangible asset goodwill tested annually impairment twostep process step identify potential impairment second step measure impairment loss goodwill deem impaired carrying reporting unit goodwill exceed estimate fair value sfas require indefinitelive intangible asset test impairment onestep process consist comparison fair value carry value intangible asset intangible asset deem impaired net book value exceed estimate fair value intangible asset evaluate impairment accordance sfas describe estimate future cash flow base reasonable supportable assumption projection require management judgment change key assumption company business prospect change market condition result impairment charge discussion impairment longlive asset item financial statementsnote accounting policiesimpairment longlive asset goodwill intangible asset equity investment company review equity investment impairment base determination decline market value investment company carry value temporary making determination company consider apb opinion equity method accounting investment common stock relate interpretation set forth factor evaluate determine loss value recognize include company ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment company investment imclone subject accounting discussion company investment imclone item financial statementsnote alliance investment discussion equity investment item financial statementsnote accounting policiesinvestment note alliance investment table content marketable security company marketable security december consist dollar denominate frs primarily aaaaaa rate frs long long term debt security coupon reset periodically benchmark interest rate underlie asset company frs consist primarily investment grade corporate bond loan company account marketable security accordance sfas account certain investment debt equity security classifie available sale addition december company principal invest ar ar hold company private placement security longterm nominal maturity interest rate reset dutch auction month monthly auction historically provide liquid market security company investment ar represent interest collateralize debt obligation support pool residential commercial mortgage credit card insurance securitization structure credit include corporate bond underlie collateral ar hold company consist subprime mortgage lack availability observable market quote company investment portfolio marketable security ar company utilize valuation model include base expect cash flow stream collateral value include assessment counterparty credit quality default risk underlie security discount rate overall capital market liquidity valuation company investment portfolio subject uncertainty difficult predict factor impact company valuation include change credit rating security underlie asset support security rate default underlie asset underlie collateral value discount rate counterparty risk ongoing strength quality market credit liquidity credit capital market continue deteriorate uncertainty market continue market deteriorate company experience additional rating downgrade investment portfolio include ar company incur additional impairment investment portfolio negatively affect company financial condition cash flow report earning discussion marketable security item financial statementsnote cash cash equivalent marketable security restructuring streamline operation rationalize manufacture facility company periodically record restructuring charge result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place actual result vary estimate adjustment million million million record respectively reflect change estimate restructure action take prior period discussion restructure item financial statementsnote accounting policiesrestructuring note restructure item contingency normal course business company subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency item financial statementsnote accounting policiescontingencie note legal proceeding contingency income taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis company asset liability adjust change tax rate tax law change enact valuation allowance record reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment december company net defer tax asset million million respectively net valuation allowance million million respectively table content company record significant defer tax asset december relate foreign tax credit carryforward approximately million research tax credit carryforward approximately million charitable contribution carryfoward million charitable contribution carryforward expire vary amount begin foreign tax credit research tax credit carryforward expire vary amount begin foreign tax credit research credit reduce derecognition fin realization credit charitable contribution carryforward dependent generate sufficient domestic taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action pti increase biologic manufacturing capacity implement tax planning strategy increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit charitable contribution carryforward company conduct business country world subject tax numerous jurisdiction result business activity company file significant number tax return subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report company require year resolve company establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know company adopt fin january result adoption accounting pronouncement company recognize million previously unrecognized tax benefit account increase opening balance retain earning previously report adoption fin company total uncertain tax benefit january net deferred income tax benefit exclude interest penalty million addition company derecognize adoption million unrecognized tax benefit tax rate impact settle gross unrecognized tax benefit january million total unrecognized tax benefit december exclude amount record reduction defer tax asset exclude interest penalty decrease million reduction primarily tax benefit recognize favorable resolution uncertain tax position partially offset additional uncertain tax benefit accrue additional information unrecognized tax benefit item financial statementsnote income taxis december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide discussion income taxis item financial statementsnote accounting policiesincome taxis note income taxis stockbase compensation expense company adopt sfas sharebase payment require measurement recognition compensation expense stockbase payment award employee director base estimate fair value company use modify prospective transition method require application accounting standard january elect alternative method provide fsp determine company pool excess tax benefit company consolidate financial statement year end december reflect impact sfas accordance modify prospective transition method company consolidate financial statement prior period restate reflect include impact sfas stockbase compensation expense recognize sfas year end december million million respectively million million net tax respectively share respectively correspond record additional paidin capital stockholder equity comparatively pro forma basis stockbase compensation expense million million net tax recognize year end december apb additionally million relate performance award reclassify liability stockholder equity connection adoption sfas rthe company estimate fair value stockbase payment award date grant optionprice model value portion award ultimately expect vest recognize expense requisite service period companys consolidate statement earning prior adoption sfas company account stockbased award employee director intrinsic value method relate stock option accordance apb table content allow sfas accounting stockbase compensation intrinsic value method stockbase compensation expense recognize company consolidate statement earning exercise price company stock option grant employee director equal fair market value underlie stock date grant stockbase compensation expense recognize period base value portion stockbase payment award ultimately expect vest period stockbase compensation expense recognize company consolidate statement earning year end december include compensation expense stockbase payment award grant prior vested january base grant date fair value estimate accordance pro forma provision sfas compensation expense stockbase payment award grant subsequent january base grant date fair value estimate accordance provision sfas conjunction adoption sfas company change method attribute value stockbase compensation expense accelerate multipleoption approach straightline single option method compensation expense stockbase payment award grant prior continue recognize accelerated multipleoption approach compensation expense stockbase payment award service condition grant subsequent january recognize straightline singleoption method stockbase payment award grant subsequent january service market condition recognize accelerated multipleoption approach require sfas prior company apply apb opinion recognize compensation expense stock option grant plan exercise price option date grant equal fair market value date grant restrict stock company recognize compensation expense straightline basis period restriction expire fair value option grant estimate common share common share common share respectively date grant blackschole optionprice model assumption blackschole optionprice model follows expect volatility riskfree interest rate dividend yield expect life yrs yrs yrs company determine fair value certain stockbase payment award date grant optionprice model model affect company stock price assumption number highly complex subjective variable variable include limited company expect stock price volatility term award actual project employee stock option exercise behavior respect accounting treatment retirement eligibility provision employee stockbase compensation award company historically follow nominal vest period approach adoption sfas company follow nonsubstantive vest period approach recognize compensation cost oneyear period award grant retirementeligible employee period grant date date retirement eligibility achieve year vest period impact apply nonsubstantive vest period approach material company consolidate financial statement stockbase compensation expense recognize consolidated statement earning year end december base award ultimately expect vest reduce estimate forfeiture company estimate forfeiture time grant revise necessary subsequent period actual forfeiture differ estimate company pro forma information require sfas period prior company account forfeiture occurredspecial note forwardlooke statement annual report write oral statement company make time time contain certain forwardlooking statement meaning section security act section securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base table content current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing company goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year company include important factor cautionary statement include annual report particularly item risk factor company believe cause actual result differ materially forwardlooke statement company believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date company undertake obligation release publicly revision forwardlooke statement result new information future event table content item quantitative qualitative disclosure market risk company expose market risk change currency exchange rate interest rate deterioration credit capital market reduce risk company enter certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument manage consolidated basis efficiently net exposure advantage natural offset derivative financial instrument speculative purpose gain loss hedge transaction offset gain loss underlying exposure hedge ineffective portion hedge report earning occur company primary net foreign currency translation exposure euro canadian dollar japanese yen mexican peso chinese renminbi company utilize foreign currency contract hedge anticipate transaction primarily intercompany transaction certain foreign currency designate derivative instrument foreign currency cash flow hedge appropriate table summarize company outstanding foreign exchange forward contract december fair value foreign exchange forward contract base yearend currency rate fair value foreign exchange forward contract view relation fair value underlie hedged transaction overall reduction exposure adverse fluctuation foreign currency exchange rate weight average strike fair value dollar million currency rate price notional assetliability maturity foreign exchange forwards cash flow hedge australian dollar british pound canadian dollar euro japanese yen mexican peso polish zloty swedish krona swiss franc total cash flow hedge nonqualifye hedge australian dollar british pound canadian dollar euro japanese yen polish zloty turkish lira total nonqualifying hedge total contract nonqualifye hedge hedge qualify hedge accounting treatment prescribe sfas accounting derivative instrument hedging activity december company hold foreign exchange option contract buy sell japanese yen total notional fair market value buy contract million million respectively fully offset total notional fair market value sell contract million million respectively december company hold foreign exchange forward contract maturity date notional amount fair value express table dollar million year maturity notional fair value december fair value company foreign exchange forward contract net liability million million record noncurrent asset million record current liability company estimate appreciation depreciation underlie currency hedge level dollar december variable hold constant decrease million increase million respectively fair value foreign exchange forward contract hold december table content company obligate settle foreign exchange forward contract base specify contract rate december balance defer loss foreign exchange forward contract include accumulate comprehensive income oci pretax basis million million net tax expect reclassify earning month december fair value company foreign exchange forward contract net liability million million record noncurrent asset million record current liability year end december impact hedge ineffectiveness earning significant additionally year end december impact discontinue hedge pretax loss million pretax loss million pretax gain million respectively furthermore company use foreign exchange forward contract offset exposure certain asset liability earning denominate foreign currency foreign exchange forward contract designate hedge change fair value derivative recognize earning occur notional fair value amount foreign exchange forward contract december describe table foreign exchange forward contract type outstanding december impact foreign exchange forward contract designate hedge pretax gain million amount recognize earning relate foreign exchange forward contract qualify hedge accounting treatment significant addition foreign exchange hedge contract note company utilize forward contract hedge foreign currencydenominate monetary asset liability primary objective forward contract protect dollar value foreign currencydenominate monetary asset liability effect volatility foreign exchange rate occur prior receipt settlement dollar foreign currency denominate monetary asset liability primarily denominate euro forward contract designate hedge mark market expense net notional fair value amount purchase foreign exchange forward contract material december million million asset respectively december notional fair value amount sell foreign exchange forward contract december million million liability respectively december company use nonus dollar borrowing primarily million note million note hedge foreign currency exposure company net investment certain foreign affiliate nonus dollar borrowing designate hedge net investment effective portion foreign exchange gain loss hedge record foreign currency translation component accumulate oci december million million loss respectively record foreign currency translation component accumulate oci company use derivative instrument interest rate risk management strategy derivative instrument comprise principally fix float rate interest rate swap subject fairvalue hedge accounting treatment november connection funding retirement fix rate debt company execute fix float interest rate swap convert billion billion billion inception company newly issue fix rate debt pay variable rate debt total notional outstanding interest rate swap billion billion billion december billion billion billion december accordance sfas accounting derivative instrument hedging activity company recognize net increase interest expense million million respectively net reduction interest expense million impact interest rate swap table content sfas require revaluation fair value swap contract underlie debt hedge swap contract underlie debt revalue result increase noncurrent asset million current liability million reduction longterm debt million december increase noncurrent asset million current liability million reduction longterm debt million december swap contract generally hold maturity intend create appropriate balance fix float rate debt company swap contract qualify fair value hedge terminate prior maturity date report carry value underlie debt amortize earning remain life debt swap contract qualify cash flow hedge terminate report accumulate oci amortize earning remain life debt follow table summarize interest rate swap outstanding december earning impact terminate interest rate swap contract interest rate swap outstanding notional underlie variable rate year fair interest rate contract debt receive transaction maturity value dollar million swap associate note month libor note month libor million note month eur euribor million note month eur euribor note month libor note month libor earning impact terminate interest rate swap contract notional total pretax pretax incomeexpense recognize year underlie defer termination debt gainloss interest rate contract dollar million interest rate swap lock associate note note swap associate note note note note underlying note extinguish underlying note extinguish underlying note extinguish december company hold interest rate swap contract notional value billion billion billion fair value net liability million estimate increase decrease basis point shortterm longterm interest rate material impact company consolidate financial position result operation cash flow company million million longterm debt outstanding december respectively additional information item financial statementsnote shortterm borrowing longterm debt note financial instrumentsthe company marketable security december consist dollar denominate float rate security frs primarily aaaaaa rate frs long longterm debt security coupon reset periodically benchmark interest rate underlie asset company frs consist primarily investment grade corporate bond loan company account marketable security accordance sfas account certain investment debt equity security classifie available sale carrying value frs reduced million table content million million december reflect change fair market value company assess decline fair market value temporary record pretax million reduction million net tax shareholder equity accumulate oci addition december company million principal invest auction rate security ar ar hold company private placement security longterm nominal maturity interest rate reset dutch auction month monthly auction historically provide liquid market security company investment ar represent interest collateralize debt obligation support pool residential commercial mortgage credit card insurance securitization structure credit include corporate bond underlie collateral ar hold company consist subprime mortgage consistent company investment policy guideline ar investment hold company aaaaaa credit rating time purchase liquidity issue experience global credit capital market ar hold company december experience multiple fail auction security submit sale exceed purchase order addition fourth quarter million principal invest ar hold company downgrade place credit watch security retain aaa rating december estimate market value company ar holding december million reflect million adjustment principal value million ar continue pay interest accord state term base thirdparty valuation model analysis thantemporary impairment factor company record pretax impairment charge million fourth quarter reflect portion ar holding company conclude otherthantemporary decline value addition company record unrealized loss million pre tax net tax accumulate oci reduction shareholder equity reflect adjustment ars holding company conclude temporary decline value million impairment charge material impact company liquidity financial flexibility lack availability observable market quote company investment portfolio marketable security ar company utilize valuation model include base expect cash flow stream collateral value include assessment counterparty credit quality default risk underlie security discount rate overall capital market liquidity valuation company investment portfolio subject uncertainty difficult predict factor impact company valuation include change credit rating security underlie asset support security rate default underlie asset underlie collateral value discount rate counterparty risk ongoing strength quality market credit liquidity credit capital market continue deteriorate uncertainty market continue market deteriorate company experience additional rating downgrade investment portfolio include ar company incur additional impairment investment portfolio negatively affect company financial condition cash flow report earning marketable security december consist dollardenominated ar frs principal value ars frs million million respectively company carry value ar frs december principal value approximate fair value table content bristolmyer squibb company consolidate statement earning dollar share million share datum item financial statement supplementary datum year end december earning net sale cost product sell marketing sell administrative advertising product promotion research development acquire inprocess research development provision restructure net litigation expense net gain sale product asset business equity net income affiliate expense net total expense net earning continue operation minority interest income taxis provision income taxis minority interest net taxis net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning earning common share basic net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning common share dilute net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning common share average common share outstanding basic dilute dividend declare common share accompany note integral financial statement table content bristolmyers squibb company consolidate statement comprehensive income retain earning dollar millions year end december comprehensive income net earning comprehensive incomeloss foreign currency translation tax effect net tax liability defer gainslosse derivative qualify hedge net tax benefit net tax liability minimum pension liability adjustment net tax liability net tax benefit defer gain pension postretirement benefit net tax liability defer gainslosse available sale security net tax benefit net tax liability net tax benefit total comprehensive income comprehensive income retain earning retain earning january cumulative effect adoption fin net earning cash dividend declare retain earning december accompany note integral financial statement table content bristolmyers squibb company consolidated balance sheet dollar million share datum december asset current asset cash cash equivalent marketable security receivables net allowance inventory net deferred income taxis net valuation allowance prepaid expense asset hold sale total current asset property plant equipment net goodwill intangible asset net deferred income taxis net valuation allowance asset total asset liability current liability shortterm borrowing account payable accrue expense defer income accrue rebate return foreign income taxis payable dividend payable accrue litigation liability liabilitie relate asset hold sale total current liability pension liability postretirement liability defer income foreign income taxis payable liability longterm debt total liability commitment contingency note stockholder equity prefer stock convertible series authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock restrict stock accumulate comprehensive loss retain earning cost treasury stock million common share million total stockholder equity total liability stockholder equity accompany note integral financial statement table content bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization defer income tax benefit litigation settlement expense net recovery stockbase compensation expense provision restructure gain sale product asset business defer income recognize acquire inprocess research development impairment charge asset writeoff loss disposal property plant equipment investment company defer expense extinguishment longterm debt underover distribution earning affiliate unfunded pension expense change operate asset liability receivables inventory prepaid expense asset litigation settlement payment net insurance recovery account payable accrue expense product liability foreign income taxis payable deferred income liability net cash provide operating activity cash flow invest activity proceed marketable security purchase marketable security addition property plant equipment capitalize software proceed disposal property plant equipment investment company proceed sale product asset business proceed sale leaseback property milestone payment purchase adnexus therapeutic net cash acquire purchase investment net cash inprovide investing activity cash flow financing activity shortterm repaymentsborrowing longterm borrowing longterm debt repayment charge extinguishment longterm debt issuance common stock stock plan excess tax benefit sharebase payment arrangement dividend pay net cash financing activity effect exchange rate cash cash equivalent decrease cash cash equivalent cash cash equivalent begin period cash cash equivalent end period consolidate statement cash flow include activity medical imaging business accompany note integral financial statement table content note accounting policy basis consolidation consolidate financial statement prepare conformity united states generally accept accounting principle gaap include account bristolmyer squibb company bms company bristolmyers squibb control majorityowned subsidiary intercompany balance transaction eliminate certain prior year amount reclassify conform current year presentation use estimate preparation financial statement require use estimate assumption base complex judgment consider reasonable affect report amount asset liability disclosure contingent asset contingent liability date financial statement report amount revenue expense report period significant assumption employ estimate determine value intangible asset restructuring charge accrual sale rebate return accrual legal contingency tax asset tax liability stockbase compensation cost retirement postretirement benefit include actuarial assumption financial instrument observable market quote estimate apply revenue recognition policy actual result differ estimate result revenue recognition company recognize revenue accordance staff accounting bulletin sab revenue recognition financial statement amend sab revenue recognition title substantially risk reward ownership transfer customer generally revenue recognize time shipment case certain sale nutritional convatec segment certain nonus business pharmaceutical segment revenue recognize date receipt purchaser accordance statement financial accounting standard sfas revenue recognition right return exist revenue reduce time recognition reflect expect return estimate base historical experience business trend additionally accordance emerge issue task force eitf issue account consideration give vendor customer include reseller vendor product provision time revenue recognition discount rebate estimate sale allowance base historical experience update change fact circumstance appropriate provision record reduction revenue case new product product introduction extension exist line product company determine product similar therapeutic category company determine new product dissimilar characteristic exist product company reliably estimate expect return new product company defer recognition revenue right return long exist company develop sufficient historical experience estimate sale return sale rebate return accrual medicaid rebate accrual million million december respectively woman infant child wic rebate accrual million million december respectively sale return accrual million million december respectively manage health care rebate contractual discount accrual million million december respectively rebate accrual establish period relate revenue recognize result reduction sale establishment liability include accrue liability accrual record base estimate proportion record revenue result rebate return prime vendor chargeback accrual establish similar manner record reduction account receivable million million december respectivelyincome taxis provision income taxis determine asset liability approach accounting income taxis approach defer taxis represent future tax consequence expect occur report amount asset liability recover pay provision income taxis represent income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis company asset liability adjust change tax rate tax law change enact valuation allowance record reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment december company net defer tax asset million million respectively net valuation allowance million million respectively table content note accounting policy continue company record significant defer tax asset december relate foreign tax credit carryforward approximately million research tax credit carryforward approximately million charitable contribution carryforward million charitable contribution carryforward expire vary amount begin foreign tax credit research tax credit carryforward expire vary amount begin foreign tax credit research credit reduce derecognition financial accounting standard board fasb interpretation fin accounting uncertainty income taxis interpretation fasb statement realization credit charitable contribution carryforward dependent generate sufficient domestic taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action productivity transformation initiative pti increase biologic manufacturing capacity implement tax planning strategy increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit charitable contribution carryforward company conduct business country world subject tax numerous jurisdiction result business activity company file significant number tax return subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report company require year resolve company establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation note income taxis july fasb issue fin case company effective january fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas accounting income taxis fin require tax position evaluate recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return difference tax position take tax return amount recognize financial statement record adjustment income taxis payable receivable adjustment defer taxis fin require expand disclosure end reporting period include tabular reconciliation unrecognized tax benefit company adopt fin january result adoption accounting pronouncement company recognize million previously unrecognized tax benefit account increase opening balance retain earning fasb issue fasb staff position fsp fin definition settlement fasb interpretation effective retroactively january fsp fin provide guidance determine tax position effectively settle purpose recognize previously unrecognized tax benefit adoption fsp fin effect company consolidate financial statement previously report adoption fin company total uncertain tax benefit january net deferred income tax benefit exclude interest penalty million addition company derecognize adoption million unrecognized tax benefit tax rate impact settle gross unrecognized tax benefit january million december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide cash cash equivalent cash cash equivalent primarily consist bank deposit time deposit money market fund cash equivalent primarily highly liquid investment original maturity month time purchase record cost approximate fair value company maintain cash cash equivalent balance dollar foreign currency subject currency rate risk marketable security company account marketable security accordance sfas account certain investment debt equity security company determine appropriate classification marketable security availableforsale time purchase december company investment marketable security report fair value fair value determine base observable market quote valuation model assessment table content note accounting policy continue counterparty credit worthiness credit default risk underlie security overall capital market liquidity decline fair value consider temporary charge earning consider temporary report component accumulate comprehensive income oci stockholders equity company use average cost method determine cost basis computing realize gain loss sale available forsale security realize gain loss include income expense inventory valuation inventory generally state average cost excess market capital asset depreciation expenditure addition renewal improvement capitalize cost depreciation generally compute straightline method base estimate useful life relate asset estimate useful life major class depreciable asset year building year machinery equipment fixture company periodically evaluate current event circumstance indicate carry value depreciable asset recoverable impairment longlive asset company periodically evaluate current fact circumstance indicate carry value depreciable asset hold recoverable circumstance determine exist estimate undiscounted future cash flow produce longlived asset appropriate grouping asset compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique include discount value estimate future cash flow company report asset dispose low carrying value estimate net realizable value capitalize software certain cost obtain internal use software significant system project capitalize amortize estimate useful life software range year cost obtain software project significant expense incur capitalize software net accumulate amortization include intangible asset million million december respectively amortization expense million million million year end december respectively investment company account lessowne company ability exercise significant influence equity method accounting cost method company share net income loss equity investment include equity net income affiliate consolidate statement earning loss recognize income expense decline market value deem temporary company review equity investment impairment base determination decline market value investment company carry value temporary making determination company consider accounting principle board apb opinion equity method accounting investment common stock relate interpretation set forth factor evaluate determine loss value recognize include company ability hold investment market price market price fluctuation investment publicly trade share inability investee sustain earning capacity justify carry investment goodwill intangible asset accordance sfas goodwill intangible asset goodwill test impairment annually twostep process step identify potential impairment second step measure impairment loss goodwill deem impaired carrying reporting unit goodwill exceed estimate fair value company complete annual goodwill impairment assessment quarter monitor potential impairment remain quarter indicate impairment goodwillother intangible asset consist patent trademark technology license capitalize software amortize straightline basis useful life range year intangible asset capitalize software deem impair net carry value exceed estimate fair value capitalize software evaluate impairment describe impairment longlive asset table content note accounting policy continue restructure streamline operation rationalize manufacture facility company periodically record restructuring charge result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place actual result vary estimate product liability accrual product liability include associate legal cost record undiscounted basis probable liability incur liability reasonably estimate base exist information accrual adjust periodically assessment effort progress additional information available receivables relate insurance thirdparty recovery product liability record undiscounted basis probable recovery realize classified reduction litigation charge consolidate statement earning contingency normal course business company subject loss contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability tax matter accordance sfas accounting contingency company record accrual loss contingency probable liability incur loss reasonably estimate company accordance sfas recognize gain contingency realize discussion contingency note income taxis note legal proceeding contingency derivative financial instrument derivative financial instrument company principally management interest rate foreign currency exposure company hold issue derivative financial instrument speculative purpose company record derivative instrument balance sheet fair value change derivative fair value recognize earning specific hedge criterion meet derivative designate fair value hedge change fair value derivative hedge item attributable hedge risk recognize consolidated statement earning derivative designate cash flow hedge effective portion change fair value derivative record oci subsequently recognize consolidated statement earning hedge item affect earning cash flow classify consistent underlying hedged item purchase foreign currency option entire change fair value include measurement hedge effectiveness cash flow hedge ineffective portion change fair value cash flow hedge recognize charge credit earning company designate assign derivative hedge forecast transaction specific asset specific liability hedge asset liability sell extinguish forecast transaction hedge long expect occur company immediately recognize gain loss designate hedge financial instrument consolidate statement earning shipping handling cost company typically charge customer shipping handling cost ship handling cost include marketing sell administrative expense million million million advertising cost advertising cost expense incur advertising expense million million million respectively table content note accounting policy continue research development research development cost expense incur company time time enter strategic alliance party company right develop manufacture market andor sell pharmaceutical product right own party result alliance company obligate payment alliance partner connection research development contingent achievement certain predetermine criterion milestone achieve prior regulatory approval product payment expense research development milestone payment connection regulatory approval include nonus regulatory approval additional indication capitalize amortize cost product sell remain useful life asset capitalize milestone payment test recoverability periodically event change circumstance indicate carrying amount recoverable company record research development net reimbursement connection collaboration agreement acquire inprocess research development fair value inprocess research development acquire business combination determine base present value research project project cash flow income approach utilize consistent guidance practice aid issue american institute certify public accountant asset acquire business combination research development activity focus software electronic device pharmaceutical industry future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underlie patent determine fair value research project expect revenue adjust technical risk completion result cash flow discount rate approximating company weightedaverage cost capital acquire inprocess research development expense incurred underlying product receive regulatory approval future alternative use addition cost nonrefundable relate acquisition licensing product receive regulatory approval market alternative future use charge earning incur earning share basic earning common share compute weightedaverage number share outstanding year dilute earning common share compute weightedaverage number share outstanding year plus incremental share outstanding assume exercise dilutive stock option restrict stock convertible instrument foreign currency translation statement earning company foreign subsidiary translate dollar average exchange rate net asset company foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation adjustment account include accumulate oci recently issue accounting standard december meeting fasb ratify consensus reach eitf issue accounting collaborative arrangement relate development commercialization intellectual property eitf conclude collaborative arrangement participant actively involve expose significant risk reward depend ultimate commercial success endeavor revenue cost incur party connection collaborative arrangement present gross net base criterion eitf report revenue gross principal versus net agent accounting literature payment collaborator evaluate present base nature arrangement term nature entitys business payment scope accounting literature nature purpose collaborative arrangement disclose accounting policy classification amount significant financial statement amount relate arrangement activity arrangement conduct separate legal entity account accounting literature require disclosure eitf apply entire collaborative agreement issue effective fiscal year begin december apply retrospectively period present collaborative arrangement exist effective date company currently process evaluate impact adopt pronouncementin december fasb issue sfas business combination replace sfas business combination require acquirer recognize asset acquire liability assume noncontrolle interest acquiree acquisition date measure fair value date limit exception statement require table content note accounting policy continue acquirer business combination achieve stage recognize identifiable asset liability noncontrolle interest acquiree amount fair value sfas make amendment authoritative literature intend provide additional guidance confirm guidance literature provide statement statement apply business combination acquisition date december company currently process evaluate impact adopt pronouncement december fasb issue sfas noncontrolle interest consolidate financial statementsan amendment arb sfas establish accounting reporting standard require ownership interest subsidiary hold party parent clearly identify label present consolidated statement financial position equity separate parent equity statement require consolidate net income attributable parent noncontrolle interest clearly identify present face consolidate statement income change parent ownership interest parent retain control financial interest subsidiary account consistently subsidiary deconsolidate retain noncontrolle equity investment subsidiary initially measure fair value gain loss deconsolidation subsidiary measure fair value noncontrolle equity investment statement require entity provide sufficient disclosure clearly identify distinguish interest parent interest noncontrolle owner statement effective fiscal year begin december company currently process evaluate impact adopt pronouncement june eitf reach consensus issue account nonrefundable advance payment good service receive future research development activity nonrefundable advance payment good service render future research development activity defer capitalize amount recognize expense relate good deliver service perform good service long expect provide issue effective fiscal year begin december early application permit pronouncement expect material effect company consolidate financial statement february fasb issue sfas fair value option financial asset financial liabilitiesincluding amendment fasb statement permit entity measure certain financial asset financial liability fair value objective sfas improve financial reporting allow entity mitigate volatility report earning cause measurement relate asset liability different attribute apply complex hedge accounting provision sfas entity elect fair value option instrument report unrealize gain loss earning subsequent reporting date fair value option election irrevocable new election date occur sfas establishe presentation disclosure requirement help financial statement user understand effect entitys election earning eliminate disclosure requirement accounting standard asset liability measure fair value display face balance sheet statement effective fiscal year begin november company elect early adoption pronouncement permit adoption accounting pronouncement expect material effect company consolidate financial statement september fasb issue statement sfas employer account define benefit pension postretirement plansan amendment fasb statement pronouncement require employer recognize overfunde underfunded status define benefit postretirement plan multiemployer plan asset liability statement financial position recognize change fund status year change occur comprehensive income business entity pronouncement require employer measure fund status plan date yearend statement financial position limited exception pronouncement require prior period restate reflect impact sfas company adopt sfas fiscal year end december adoption accounting pronouncement result million reduction accumulate oci stockholder equity million reduction total asset million increase total liability adoption sfas impact company result operation cash flow september fasb issue sfas fair value measurement pronouncement define fair value establishe framework measure fair value expand disclosure fair value measurement statement effective fiscal year begin november november fasb agree oneyear deferral implementation sfas nonfinancial asset liabilitie adoption accounting pronouncement expect material effect company consolidate financial statement financial asset liability asset liability carry fair value company currently process evaluate impact adopt pronouncement nonfinancial asset liability table content note accounting policy continue september securities exchange commission sec issue sab consider effect prior year misstatement quantify misstatement current year financial statement express staff view process quantify financial statement misstatement bulletin effective interim period fiscal year end november sab require company utilize dual approach assess quantitative effect financial statement misstatement dual approach include income statement focus balance sheet focus assessment adoption bulletin effect company consolidate financial statement july fasb issue fasb interpretation fin accounting uncertainty income taxis interpretation fasb statement case company effective january fin clarifie accounting uncertainty income taxis recognize enterprise financial statement accordance sfas accounting income taxis fin require tax position evaluate recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return difference tax position take tax return amount recognize financial statement record adjustment income taxis payable receivable adjustment defer taxis fin require expand disclosure end reporting period include tabular reconciliation unrecognized tax benefit company adopt fin january result adoption accounting pronouncement company recognize million previously unrecognized tax benefit account increase opening balance retain earning fasb issue fsp fin definition settlement fasb interpretation effective retroactively january fsp fin provide guidance determine tax position effectively settle purpose recognize previously unrecognized tax benefit adoption fsp fin effect company consolidate financial statement march fasb issue sfas accounting service financial asset amendment fasb statement pronouncement relate account separately recognize service asset servicing liability statement effective fiscal year begin september adoption accounting pronouncement material effect company consolidate financial statement february fasb issue sfas account certain hybrid financial instrument amendment fasb statement pronouncement primarily resolve certain issue address implementation sfas accounting derivative instrument hedge activity concern beneficial interest securitize financial asset statement effective financial instrument acquire issue subject remeasurement event occur begin fiscal year adoption account pronouncement material effect company consolidate financial statement fasb issue sfas accounting change error correctionsa replacement apb opinion fasb statement pronouncement apply voluntary change account principle revise requirement accounting reporting change accounting principle sfas require retrospective application prior period financial statement voluntary change accounting principle impracticable pronouncement require change method depreciation amortization depletion longlive nonfinancial asset account change accounting estimate effect change accounting principle sfas effective accounting change correction error fiscal year begin december statement change transition provision exist accounting pronouncement include transition phase effective date sfas adoption account pronouncement material effect company consolidate financial statement march fasb issue fin accounting conditional asset retirement obligationsan interpretation fasb statement fin clarifie entity record liability conditional asset retirement obligation fair value obligation reasonably estimate asset retirement obligation cover fin entity legal obligation perform asset retirement activity time method settling obligation conditional future event control entity fin clarifie entity sufficient information reasonably estimate fair value asset retirement obligation interpretation effective later end fiscal year end december company adopt provision fin fiscal year end december adoption accounting pronouncement material effect company consolidate financial statementsin december fasb issue sfas revise sharebased payment sfas require measurement recognition compensation expense stockbase payment award employee director base estimate fair value sfas supersede company previous accounting apb accounting stock issue employee period begin january march sec issue sab sharebase table content note accounting policy continue payment relate sfas company apply provision sab adoption sfas company adopt sfas modify prospective transition method require application accounting standard january elect alternative method provide fsp transition election relate accounting tax effect sharebase payment award determine company pool excess tax benefit company consolidate financial statement year end december reflect impact sfas accordance modify prospective transition method company consolidate financial statement prior period restate reflect include impact sfas stockbase compensation expense recognize sfas year end december million million net tax share corresponding record additional paidin capital stockholder equity additionally million relate performance award reclassify liability stockholder equity connection adoption sfas note alliance investment sanofiaventis company agreement sanofiaventis sanofi codevelopment cocommercialization avaproavalide irbesartan angiotensin receptor antagonist indicate treatment hypertension diabetic nephropathy plavix clopidogrel platelet aggregation inhibitor worldwide alliance operate framework geographic territory america principally canada puerto rico latin american countries australia europe asia accordingly territory partnership form manage central expense market research development royalty supply finish product individual country general country level agreement copromote partnership form party sell brand comarket party operate sell brand independently place agreement expire later respect plavix respect avaproavalide americas australia europe asia expiration patent exclusivity right applicable territory company act operating partner territory cover americas australia own majority control interest territory sanofis ownership interest territory company consolidate country partnership result territory record sanofis share result minority interest net taxis million million million company record sale territory comarkete country territory cover europe asia million million million cash flow operating activity partnership territory cover americas australia record operating activity company consolidate statement cash flow distribution partnership profit sanofi sanofis fund ongoing partnership operation occur routine basis record operating activity company consolidated statement cash flow sanofi act operating partner territory cover europe asia own majority financial control interest territory company ownership interest partnership territory company account investment partnership entity territory equity method record share result equity net income affiliate consolidate statement earning company share net income partnership entity tax million million million company routinely receive distribution profit provide fund ongoing operation partnership territory cover europe asia transactions record operating activity company consolidate statement cash flow company sanofi company form alliance copromotion irbesartan company contribute irbesartan distribution right sanofi pay company total million year end december company account transaction sale interest license million defer amortized income expect useful life license approximately year formation irbesartan copromotion alliance company recognize income million million million respectively unamortize portion defer income record liability section consolidate balance sheet million million december respectively table content note alliance investment continue follow summarize financial information company equity investment partnership sanofi territory cover europe asia dollar millions revenue gross profit net income current asset current liability otsuka company worldwide commercialization agreement otsuka pharmaceutical ltd otsuka codevelop copromote otsuka abilify aripiprazole treatment schizophrenia relate psychiatric disorder japan china taiwan north korea south korea philippines thailand indonesia pakistan egypt product currently copromote otsuka united kingdom germany france spain germany spain product invoice thirdparty customer company behalf otsuka company record alliance revenue contractual share thirdparty net sale record expense relate product company recognize alliance revenue abilify ship risk reward ownership transfer thirdparty customer france italy company presently exclusive distributor product company record net sale relate cost product sell expense company exclusive right sell abilify country europe americas number countries asia country company record net sale relate cost product sell term agreement company purchase product otsuka perform finish manufacture sale company otsuka thirdparty customer agreement expire november entire european union agreement expire june country company exclusive right sell abilify agreement expire later anniversary commercial sale country expiration applicable patent country company record total revenue abilify million million million total milestone payment otsuka agreement december million million expense acquire inprocess research development remain million capitalize intangible asset amortize cost product sell remain life agreement range year company amortize cost product sell million unamortized capitalize payment balance million million december respectively imclone company commercialization agreement expire september imclone system incorporate imclone biopharmaceutical company focus develop targeted cancer treatment codevelopment copromotion erbitux food drug administration fda approve biologics license application erbitux use combination irinotecan treatment patient epidermal growth factor receptor egfrexpresse metastatic colorectal cancer mcrc refractory irinotecanbase chemotherapy use single agent treatment patient egfrexpresse mcrc intolerant irinotecanbase chemotherapy march fda approve erbitux use treatment squamous cell carcinoma head neck combination radiation monotherapy company pay million milestone payment imclone fda approval agreement imclone receive distribution fee base flat rate net sale north america october company imclone amend codevelopment agreement merck kgaa provide cocommercialization erbitux japan expire imclone ability terminate agreement determine commercially unreasonable continue erbitux market japan application submit japanese pharmaceutical medical device agency use erbitux treat patient advance colorectal cancer company account million total approval milestone pay license acquisition amortize payment cost product sell remain term agreement end company amortize cost product sell million million million respectively unamortized portion approval payment record intangible asset million million december respectively table content note alliance investment continue company account investment imclone equity method record share result equity net income affiliate consolidate statement earning company record investment market value holding imclone common stock million approximately million december respectively million approximately million december respectively company hold million share imclone stock represent approximately imclone share outstanding december share basis carry value imclone investment closing market price imclone share december respectively compare respectively december company determine equity share imclone net income loss eliminate imclone result milestone revenue imclone recognize million preapproval milestone payment company company record million preapproval milestone payment equity investment expense remain million acquire inprocess research development period milestone revenue recognize imclone excess million eliminate company determine equity share imclone result share imclone result operation company record net income million net income million net loss million company record net sale erbitux million million million gilead company gilead sciences inc gilead enter joint venture develop commercialize fixeddose combination company sustiva efavirenz gileads truvada emtricitabine tenofovir disoproxil fumarate july fda grant approval atripla efavirenz emtricitabine tenofovir disoproxil fumarate treatment human immunodeficiency virus infection adult september company amend agreement commercialize atripla canada atripla approve health canada october european commission december commercialization country norway iceland gilead record atripla revenue consolidate result joint venture operating result company record revenue bulk efavirenz component atripla sale product joint venture gilead thirdparty customer company revenue efavirenz component determine apply percentage atripla revenue approximate revenue sustiva brand company record efavirenz revenue million million respectively relate atripla sale company account participation joint venture equity method accounting record share joint venture result equity net income affiliate consolidate statement earning company record equity loss joint venture gilead million million million astrazeneca january company enter worldwide japan codevelopment cocommercialization agreement astrazeneca plc astrazeneca codevelopment cocommercialization saxagliptin dppiv inhibitor saxagliptin agreement codevelopment cocommercialization dapagliflozin sodiumglucose contransporter sglt inhibitor sglt agreement compound study treatment diabete discover company term agreement company receive astrazeneca upfront payment million january defer recognize useful life product income company amortize income million upfront payment unamortized portion upfront payment million december milestone payment expect receive company successful achievement development regulatory event salesrelated milestone saxagliptin agreement company receive million development regulatory milestone meet additional million salesbased milestone meet sglt agreement company receive million development regulatory milestone meet additional million salesbased milestone meet agreement company astrazeneca share development commercialization cost majority development cost initial development plan pay astrazeneca additional development cost generally share equally company record development cost relate saxagliptin dapagliflozin net astrazenecas share research development expense agreement company jointly develop clinical marketing strategy share commercialization expense profitslosse equally global basis exclude japan company manufacture productspfizer april company pfizer inc pfizer enter worldwide codevelopment cocommercialization agreement apixaban anticoagulant discover company study prevention treatment broad range venous arterial thrombotic condition accordance term agreement pfizer upfront payment table content note alliance investment continue million company defer recognize life agreement income december company pfizer agree include japan worldwide agreement connection japan agreement pfizer additional upfront payment million december defer recognize useful life product income company amortize income million upfront payment unamortized portion upfront payment million december pfizer fund development cost effective january go forward company fund company record apixaban development cost net pfizer share research development expense company receive additional payment million pfizer base development regulatory milestone company jointly develop clinical marketing strategy share commercialization expense profitslosse equally global basis manufacture product arrangement note restructure activity december company announce threeyear plan fundamentally change way run business meet challenge change business environment advantage diverse opportunity marketplace company transform nextgeneration biopharmaceutical company previously announce pti company aim achieve culture continuous improvement enhance efficiency effectiveness competitiveness substantially improve cost base company record pretax charge million relate termination benefit relate cost workforce reduction approximately manufacture sell administrative personnel geographic region charge offset million adjustment reflect change estimate restructure action take prior period follow table present detail charge segment type company expect substantially complete activity end termination dollar million benefit exit cost total pharmaceutical nutritional convatec corporateother subtotal change estimate provision restructure net activity company record pretax charge million relate termination benefit relate cost workforce reduction approximately sell operate administrative personnel primarily north america europe asia latin america charge decrease million adjustment reflect change estimate restructure action take prior period follow table present detail charge segment type company expect substantially complete activity termination benefit exit cost total dollar million pharmaceutical nutritional convatec subtotal change estimate provision restructure net table content note restructure continue activity company record pretax charge million relate termination benefit relate cost workforce reduction approximately sell administrative personnel primarily north america latin america europe africa asia charge include restructure cardiovascularmetabolic primary care sale organization charge offset million adjustment reflect change estimate restructure action take prior period follow table present detail charge segment type company substantially complete restructuring activity termination dollar million benefit exit cost total pharmaceutical nutritional convatec subtotal change estimate provision restructure net restructuring charge spend liability associate prior current action follow employee termination exit cost dollar million liability liability total balance january charge spend change estimate balance december charge spend change estimate balance december charge spend change estimate balance december addition charge company record million million million accelerate depreciation fix asset impairment charge primarily relate rationalization manufacture network respectively charge primarily record cost product sell consolidated statement operation primarily relate pharmaceutical segment note acquisition divestiture october company complete acquisition adnexus therapeutics inc adnexus developer new therapeutic class biologic call adnectins net purchase price million addition event certain future development regulatory milestone achieve company obligate term agreement pay stockholder adnexus additional million net purchase price acquisition preliminarily allocate tangible identifiable intangible asset acquire liability assume base estimate fair value acquisition date million million allocate acquire inprocess research development immediately expense million assign identifiable intangible asset predominantly relate exist process technology future discovery excess purchase price associate transaction cost estimate fair value net asset acquire record goodwill acquisition account purchase method accordingly result operation include accompany consolidated financial statement date acquisition pro forma supplemental financial information include impact business combination material july company complete sale bufferin excedrin brand japan asia exclude china taiwan certain oceanic country lion corporation japan million cash result transaction company recognize pretax gain million million net tax quarter january company complete sale inventory trademark patent intellectual property right relate dovonex treatment psoriasis warner chilcott company inc million cash addition company receive royalty base net sale dovonex end result transaction company recognize pretax gain million million net tax quarter table content note acquisition divestiture continue quarter company complete sale canadian consumer medicine consumer medicine business relate asset novartis novartis term agreement novartis acquire trademark patent intellectual property right consumer medicine million cash include impact work capital adjustment million attributable postclose supply arrangement company novartis relate asset include right consumer medicine brand latin america europe middle east africa result operation consumer medicine include company consolidated statement earning date disposal result transaction company record pretax gain million million net tax quarter note discontinue operation asset hold sale december company enter definitive agreement avista capital partner avista sale medical imaging business purchase price approximately million cash subject customary postclosing adjustment close transaction complete january company expect recognize pretax gain approximately million million million million loss net tax quarter subject postclosing adjustment result medical imaging business previously include health care operating segment include incomeloss discontinue operation net tax period present net asset associate medical imaging business total approximately million asset total million reclassify asset hold sale december period time company continue generate cash flow report income statement activity incomeloss discontinue operation net tax associate medical imaging business activity rise cash flow income statement activity transitional nature generally result agreement ensure facilitate orderly transfer business operation agreement include service accounting customer service distribution manufacturing activity expect material company result operation cash flow agreement extend period generally month majority range month follow asset liability segregate classified asset hold sale liability relate asset hold sale appropriate consolidated balance sheet december asset liability relate medical imaging business describe total million asset total million balance december reclassify amount present adjusted exclude cash intercompany receivables payable business hold sale company exclude divestiture addition goodwill december million exclude follow summary net asset hold sale consider determine gain sale dollar million december asset receivables net allowance inventory net asset property plant equipment net intangible asset net total asset hold sale liability account payable accrue liability total liability relate asset hold sale net asset hold sale company complete sale oncology therapeutic network otn equity partner llc cash proceed million include impact preliminary work capital adjustment company record pretax gain million million net tax present gain sale discontinue operation consolidated statement earning otn previously present separate segment table content note discontinue operation asset hold sale continue follow summarize financial information relate medical imaging otn business segregate continue operation report discontinue operation date disposition reflect cost certain service provide medical imaging otn company cost allocate company medical imaging otn service include legal counsel insurance external audit fee payroll process certain human resource service information technology system support year end december dollar million net sale earning income tax provision income taxis net earning discontinue operation consolidated statement cash flow include medical image otn business date disposition company use centralized approach cash management financing operation accordingly debt allocate business table content note earning share numerator basic earning share net earning available common stockholder numerator diluted earning share net earning available common stockholder interest expense add assume conversion convertible debt common stock denominator basic earning share weightedaverage number common stock outstanding period denominator diluted earning share weightedaverage share outstanding adjusted effect dilutive stock option assume conversion convertible debt common stock computation basic diluted earning common share follow year end december amount million share datum basic net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning basic earning share average common share outstanding basic net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning common share dilute net earning continue operation interest expense conversion convertible debt net taxis net earning continue operation diluted earning common share calculation discontinue operation earning net taxis gain disposal net taxis net earning dilute earning share average common share outstanding conversion convertible debt incremental share outstanding assume exerciseveste dilutive stock optionsrestricte stock average common share outstanding diluted net earning continue operation discontinue operation earning net taxis gain disposal net taxis net earning common share weightedaverage share issuable exercise stock option include diluted earning share calculation antidilutive million million million respectively million weightedaverage share issuable million million respectively interest expense net tax assume conversion convertible debt include diluted earning share calculation antidilutive table content note expense net component expense net follow year end december dollar million interest expense interest income foreign exchange transaction loss net expense net interest expense increase net interest swap loss million interest expense increase net interest swap loss million interest expense reduce net interest swap gain million net include income thirdparty contract manufacture royalty income expense debt retirement cost impairment marketable security gain loss disposal property plant equipment gain loss sale marketable security insurance recovery defer income recognize certain litigation matter item financial statementsnote financial instrument additional discussion terminate swap contract note income taxis component earning loss continue operation minority interest income taxis follow year end december dollar million nonus amount categorize base location tax authority provisionbenefit income taxis attributable continue operation consist year end december dollar millions current nonus defer nonus table content note income taxis continue effective tax rate company provision income taxis different compute apply statutory federal income tax rate earning continue operation minority interest income taxis result follow earning minority interest income taxis dollar million earning continue operation minority interest income tax statutory rate foreign tax effect operation ireland puerto rico switzerland state local taxis net valuation allowance federal foreign contingent tax matter dividend repatriation ajca federal research tax credit acquire inprocess research development expense impairment auction rate security federal foreign valuation allowance foreign effective income tax rate earning continue operation minority interest income taxis compare tax rate unfavorably impact impairment company investment certain auction rate security ar tax benefit nondeductible writeoff acquire inprocess research development expense relate acquisition adnexus partially offset tax benefit million quarter favorable resolution certain tax matter internal revenue service irs relate deductibility litigation settlement expense impact foreign tax credit effective tax rate unfavorably impact elimination tax benefit section internal revenue code treatment provision portion certain litigation reserve nondeductible partially offset favorable tax legislation enact related tax treatment certain intercompany transaction company foreign subsidiary implementation tax planning strategy relate utilization certain charitable contribution increase effective tax rate primarily aforementioned section benefit elimination treatment provision portion certain litigation reserve nondeductible tax benefit associate settlement irs examination favorable adjustment taxis special dividend american job creation act partially offset favorable tax legislation enact related tax treatment certain intercompany transaction company foreign subsidiary implementation tax planning strategy relate utilization certain charitable contribution table content note income taxis continue defer taxis valuation allowance component current noncurrent defer income tax asset liability follow december dollar millions acquire inprocess research development intercompany profit inventory item federal foreign tax credit carryforward defer income federal research development tax credit carryforward federal charitable contribution carryforward state net operating loss carryforward foreign net operating loss carryforward foreign defer tax asset pension postretirement benefit depreciation share base compensation repatriation foreign earning legal settlement net valuation allowance defer tax asset net recognize deferred income taxis current deferred income taxis noncurrent foreign income taxis payable liability noncurrent total company record significant defer tax asset december relate foreign tax credit carryforward approximately million research tax credit carryforward approximately million charitable contribution carryforward million charitable contribution carryforward expire vary amount begin foreign tax credit research tax credit carryforward expire vary amount begin foreign tax credit research tax credit reduce derecognition fin realization credit charitable contribution carryforward dependent generate sufficient domestic taxable income prior expiration realization assure management believe likely defer tax asset realize company anticipate increase level domestic profitability time undertaking action pti increase biologic manufacturing capacity implement tax planning strategy increase domestic profitability likely cause company effective tax rate increase enhance company ability utilize foreign tax credit research tax credit charitable contribution carryforward company record defer tax asset relate foreign net operating loss carryforward million december increase million compare million december primarily international reorganization company foreign affiliate operate loss carryforward relate international reorganization fully offset establishment valuation allowance million reflect company view loss carryfoward expect realize valuation allowance million december relate million state defer tax asset million foreign net operating loss tax credit carryforward million state net operating loss tax credit carryforward company believe likely realize million state defer tax asset relate adnexus acquisition offset goodwill income taxis pay year million million million respectivelyin october company file refund claim irs year carry foreign tax credit recover taxis pay principal refund claim approximately million fourth quarter company accrue interest income refund claim approximately million net federal benefit reflect provision income taxis table content note income taxis continue current tax benefit realize exercise stock option credit capital excess par value stock amount million million million respectively december company approximately billion undistributed earning foreign subsidiary taxis provide company invest expect invest undistributed earning permanently offshore future earning repatriate company determine earning remit foreseeable future additional tax provision require complexity tax law assumption practicable estimate amount income taxis provide company conduct business country world subject tax numerous jurisdiction result business activity company file significant number tax return subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report company require year resolve company establish liability possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation company adopt provision fin january result recognition million previously unrecognized tax benefit account increase opening balance retain earning reconciliation company change uncertain tax position january december follow unrecognized unrecognized unrecognized income tax benefit federal state income tax benefit defer include interest penalty foreign include income tax net deferred income dollar million tax benefit interest penalty interest penalty benefit tax benefit total uncertain tax position recognize impact effective tax rate january add tax attributable defer tax item january balance gross uncertain tax position january gross addition tax position relate current year gross reduction tax position relate current year gross addition tax position relate prior year gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance gross uncertain tax position december tax attributable defer tax item december total uncertain tax position recognize impact effective tax rate december uncertain tax benefit december record company defer tax asset extent uncertainty directly relate asset record current noncurrent income tax payablea previously report adoption fin company total uncertain tax benefit january net deferred income tax benefit exclude interest penalty million addition company derecognize adoption million unrecognized tax benefit tax rate impact settle gross unrecognized tax benefit january million table content note income taxis continue include balance unrecognized tax benefit million uncertain tax position january million december ultimate deductibility highly certain uncertainty time deductibility impact defer tax accounting interest penaltie applicable disallowance short deductibility period affect annual effective tax rate accelerate payment cash tax authority utilization tax attribute early period amount unrecognized tax benefit recognize impact effective tax rate million january million december company classify interest penalty relate unrecognized tax benefit income tax expense amount reflect separately reconciliation total interest penalty relate uncertain tax position recognize statement earning million interest million penalty total interest penalty relate uncertain tax position recognize balance sheet december million interest million penalty company currently examination number tax authority include major tax jurisdiction list table propose adjustment tax issue transfer price certain tax credit deductibility certain expense company estimate reasonably possible balance unrecognized tax benefit december decrease range approximately million million month result anticipate effective settlement certain tax audits jurisdiction list settlement involve payment additional taxis adjustment certain defer taxis andor recognition tax benefit company anticipate reasonably possible new issue raise tax authority require increase balance unrecognized tax benefit estimate increase company believe adequately provide open tax year tax jurisdiction fin company file income tax return federal jurisdiction state foreign jurisdiction exception company subject federal state local nonus income tax examination tax authority follow summary major tax jurisdiction tax authority assert additional taxis company base tax year currently audit subsequent year likely audit canada france germany italy mexico table content note cash cash equivalent marketable security cash cash equivalent december primarily consist bank deposit time deposit money market fund cash equivalent primarily highly liquid investment original maturity month time purchase record cost approximate fair value company maintain cash cash equivalent balance dollar foreign currency subject currency rate risk marketable security december consist dollardenominated float rate security frs primarily aaaaaa rate frs longterm debt security coupon reset periodically benchmark interest rate underlie asset company frs consist primarily investment grade corporate bond loan company account marketable security accordance sfas account certain investment debt equity security classifie available sale carrying value frs reduce million million million december reflect change fair market value company assess decline fair market value temporary record pretax million reduction million net tax shareholder equity accumulate oci addition december company million principal invest ar ar hold company private placement security longterm nominal maturity interest rate reset dutch auction month monthly auction historically provide liquid market security company investment ar represent interest collateralize debt obligation support pool residential commercial mortgage credit card insurance securitization structure credit include corporate bond underlie collateral ar hold company consist subprime mortgage consistent company investment policy guideline ar investment hold company aaaaaa credit rating time purchase liquidity issue experience global credit capital market ar hold company december experience multiple fail auction security submit sale exceed purchase order addition fourth quarter million principal invest ar hold company downgrade place credit watch security retain aaa rating december estimate market value company ar holding december million reflect million adjustment principal value million ar continue pay interest accord state term base valuation model analysis otherthantemporary impairment factor company record pretax impairment charge million fourth quarter reflect portion ar holding company conclude otherthantemporary decline value addition company record unrealized loss million pretax net tax accumulate oci reduction shareholder equity reflect adjustment ars holding company conclude temporary decline value million impairment charge material impact company liquidity financial flexibility ar classify prior period current asset marketable security give fail auction company ars illiquid successful auction accordingly entire remain ar reclassify marketable security noncurrent asset marketable security december consist dollardenominated ar frs principal value ars frs million million respectively company carry value ar frs december principal value approximate fair value follow table summarize company available sale debt security december december unrealize loss accumulate december cost fair value carry value oci dollar million shortterm float rate security total shortterm longterm available sale auction rate securitiesa total longterm company record pretax otherthantemporary impairment charge million earning december relate security table content note cash cash equivalent marketable security continue unrealized loss december cost fair value carry value accumulate oci dollar million shortterm auction rate security float rate security total shortterm contractual maturity carry value availableforsale debt security december follow dollar million year year year year total available sale debt security float rate security auction rate security total debt security company purchase billion billion billion debt security respectively sell billion billion billion debt security respectively purchase sale value debt security approximate principal value security note receivables major category receivables follow december dollar million trade receivables miscellaneous receivable allowance receivables net miscellaneous receivable include million million respectively receivables alliance partner miscellaneous receivables include million income tax refund claim additional information company alliance partner note alliance investment note inventory major category inventory follow december dollar million finish good work process raw packaging material inventory net table content note property plant equipment major category property plant equipment follow december dollar million land building machinery equipment fixture construction progress accumulate depreciation property plant equipment net capitalize interest million million million year end december respectively include category property plant equipment show note goodwill change carry goodwill year end december follow pharmaceutical nutritional convatec discontinued dollar million segment segment segment operation total balance january adjustment reduction sale business purchase price allocation adjustment balance december adjustment purchase price adjustment balance december goodwill million record pharmaceutical segment result acquisition adnexus medical imaging goodwill million report discontinue operation write pretax gain disposal discussion acquisition note acquisition divestiture note intangible asset december intangible asset consist follow december dollar million patentstrademark accumulate amortization patentstrademark net license accumulate amortization license net technology accumulate amortization technology net capitalize software accumulate amortization capitalize software net total intangible asset net table content note intangible asset continue include decrease patentstrademark technology million reclassification medical imaging asset hold sale amortization expense intangible asset year end december million million million respectively include million million million amortization expense relate medical imaging discontinue operation year end december respectively expect amortization expense relate current net carrying intangible asset follow year end december dollar million later year note shortterm borrowing longterm debt shortterm borrowing end billion million respectively longterm debt billion december compare billion december company reclassify longterm debt shortterm borrowing million yen note million yen note million note associate unamortized discount interest rate swap valuation billion float rate convertible debenture putcall september company repay billion remain balance fiveyear tranche float rate bank term facility fourth quarter company restructure longterm debt retire outstanding billion note cash tender offer subsequent redemption issue million million inception aggregate principal note million million inception aggregate principal note billion aggregate principal note result million pretax expense comprise item discuss premium pay debt tender million million respectively addition company recognize earning million unamortized discount debt issuance cost associate debt incur pretax loss million relate termination remain billion notional fixedtofloate interest rate swap agreement recognize earning pretax unamortized portion million aforementione loss incur termination million notional fixedtofloate interest rate swap occur june furthermore november company recognize earning accumulate oci pretax unamortized portion million million net tax loss incur settlement interest rate lock contract manage exposure change interest rate anticipate issuance longterm fix rate debt december company replace prior billion revolve credit facility new billion fiveyear revolve credit facility syndicate lender extendable anniversary date consent lender facility contain customary term condition substantially similar prior facility include financial covenant ratio consolidated debt consolidated capital exceed end quarter company compliance covenant inception new facility borrowing outstanding revolve credit facility december company unused shortterm line credit available trade finance facility foreign bank million million december respectively table content note shortterm borrowing longterm debt continue component longterm debt follow december dollar million float rate bank term facility note float rate convertible debenture euro note euro note note note debenture debenture debenture yen note industrial revenue bond yen note yen note variable rate industrial revenue bond company outstanding billion convertible debenture pay interest quarterly annual rate equal threemonth libor reset quarterly minus yield zero final maturity september debenture callable par time september issuer holder redeem debenture par september fundamental change ownership company occur bond initial conversion price conversion rate share adjustable depend average closing price applicable period maximum conversion rate share company enter fixed float interest rate swap billion dollar value december longterm debt conjunction new issuance billion note billion note billion inception company execute fix float interest rate swap convert new fix rate debt pay variable rate debt year end december company realize net increase interest expense million million respectively result higher float rate obtain swap agreement november connection early retirement outstanding billion note company terminate remain billion notional fix float interest rate swap agreement incur pretax loss million april connection early redemption billion note company terminate billion notional fixedtofloate interest rate swap agreement incur pretax loss million june company terminate million notional fixedtofloate interest rate swap agreement relate billion note incur pretax loss million loss amortize interest expense million million recognize respectively remain loss million million loss incur unwind billion swap fully recognize september company terminate million notional fixedtofloate interest rate swap agreement relate million debenture pretax gain million gain recognize interest expense remain life debenture approximately million pretax recognize cash payment interest include payment interest rate swap million million million respectively company cash receipt interest rate swap million million million respectively exclude cash payment interest payment period later dollar million total year longterm debt obligation include shortterm borrowing company consolidated balance sheet december balance approximate outstanding nominal longterm debt value company convertible debenture include payment contain feature describe table content note shortterm borrowing longterm debt continue december company provide total million financial guarantee form standby letter credit performance bond standby letter credit insurance company support thirdparty liability program performance bond issue support range ongoing operating activity include sale company product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority company outstanding financial guarantee expire year expect fund note stockholder equity change common share treasury stock capital excess par value stock restrict stock follow cost capital excess common share treasury treasury par value restrict dollar share million issue share stock stock stock balance january issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock balance december issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock balance december issue pursuant stock plan option amortization restrict stock lapse forfeiture restrict stock balance december share company prefer stock convertible share common stock callable company option reduction number issue share prefer stock conversion share common stock dividend declare common share accumulate balance relate component oci net taxis follow defer charge minimum pension accumulate foreign defer pension currency incomeloss liability postretirement available comprehensive dollar million translation effective hedge adjustment benefit sale security incomeloss balance january comprehensive incomeloss balance december comprehensive incomeloss adjustment adoption sfas balance december comprehensive incomeloss balance december table content note employee stock benefit plan employee stock plan stockholder approve company stock award incentive plan plan plan replace stock incentive plan plan expire plan provide million new share common stock reserve delivery participant plus share remain available new grant plan share recapture outstanding award plan number share actually deliver participant connection award restriction lapse count number share reserve share tender prior year pay purchase price option number share previously utilize satisfy withholding tax obligation exercise continue available reserve december million share common stock reserve issuance pursuant stock plan option conversion prefer stock million million share available grant active plan december respectively adjust combination plan company plan plan executive officer key employee grant option purchase company common stock market price date option grant option generally exercisable installment year fourth anniversary grant date maximum term year generally company issue share stock option exercise treasury stock additionally plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price plan plan provide grant common stock key employee subject restriction continuous employment restriction generally expire fouryear period date grant compensation expense recognize restrict period quarter company begin grant restrict stock unit instead restrict stock plan plan incorporate company longterm performance awards award deliver form target number performance share threeyear cycle awards annual goal set beginning performance period base earning share sale maximum performance result maximum payout goal award set threeyear period base cumulative earning share cumulative sale ultimate payout modify company total stockholder return versus company proxy peer group maximum performance measure result maximum payout target threshold target meet performance period payment plan teamshare stock option plan terminate january fulltime employee exclude key executive grant option purchase company common stock market price date option grant company authorize million share issuance plan individual grant generally exercisable evenly fourth fifth anniversary grant date maximum term year option million share exercise plan december company result operation year end december reflect impact sfas include impact expense stock option company elect alternative method provide fsp determine company pool excess tax benefit result operation year end december restate reflect impact expense stock option prepare accordance apb follow table summarize stockbase compensation expense net tax relate employee stock option restrict stock longterm performance award year end december year end december dollar million cost product sell marketing sell administrative research development total stockbase compensation expense defer tax benefit stockbase compensation net tax table content note employee stock benefit plan continue table reflect pro forma net income dilute net income share year end december year end december dollar million share datum net earning report total stockbase employee compensation expense include report net earning net relate tax effect total stockbase employee compensation expense determine fair valuebase method awards net relate tax effect pro forma basic earning share report pro forma diluted earning share report pro forma stock option summary option activity follow share common weightedaverage stock issue exercise price share million plan share balance january grant exercise expire forfeit balance december grant exercise expire forfeit balance december grant exercise expire forfeit balance december table content note employee stock benefit plan continue information relate stock option grant exercise plan plan summarize follow year end december amount million share datum available stock option award stock option grant weightedaverage grantdate fair value share total intrinsic value stock option exercise cash proceed exercise stock option december million total unrecognized compensation cost relate stock option expect recognize weightedaverage period year follow table summarize information concern company stock compensation plan currently outstanding exercisable option number security remain available future number security issue weightedaverage exercise issuance equity exercise outstanding price outstanding compensation plan exclude share million option right option right security reflect column plan category equity compensation plan approve security holder equity compensation plan approve security holder share plan long issue follow table summarize significant range outstanding exercisable option december amount million share datum option outstanding option exercisable weighted weight average weighted average weight remain average aggregate remain average aggregate contractual exercise intrinsic contractual exercise intrinsic number life price value number life price value range exercise price outstanding year share million exercisable year share million vest expect vest aggregate intrinsic value precede table represent total pretax intrinsic value base company close stock price december receive option holder option holder exercise option date total number inthe money option exercisable december million december million outstanding option exercisable weight average exercise price table content note employee stock benefit plan continue fair value employee stock option grant estimate date grant prior january estimate weightedaverage estimate option value grant blackschole option pricing model follow assumption expect volatility riskfree interest rate dividend yield expect life yrs yrs yrs company derive expect volatility assumption require blackschole model calculate year historical volatility weighting equally derive imply volatility consistent sfas sab prior company historical stock price volatility accordance sfas purpose pro forma information selection blend historical imply volatility approach base company assessment calculation expect volatility representative future stock price trend historical volatility riskfree interest rate assumption base treasury yield curve effect time grant dividend yield assumption base company history expectation dividend payout expect life employee stock option represent weightedaverage period stock option expect remain outstanding derive output latticebinomial model expect life employee stock option impact underlying assumption calibration company model latticebinomial model assume employee exercise behavior function option remain vested life extent option inthemoney latticebinomial model estimate probability exercise function variable base entire history exercise cancellation past option grant company prior company optionprice model indirectly estimate expect life stock option expect life expect volatility stock option base historical economic datum trend future forfeiture employee stock option account incur basis stockbase compensation expense recognize consolidated statement earning month end december base award ultimately expect vest reduce estimate forfeiture sfas require forfeiture estimate time grant revise necessary subsequent period actual forfeiture differ estimate forfeiture estimate base historical experience company pro forma information require sfas period prior company account forfeiture occur company acquire adnexus october acquisition agreement company assume million share adnexu incentive stock option isos replace million share company isos convert option retain original vest schedule include vest commencement date expiration date blackschole model determine expect term individual isos valuation result weightedaverage expect term year weightedaverage fair value october table content note employee stock benefit plan continue restrict stock award restrict stock unit fair value nonveste share company common stock determine base average trading price company common stock grant date restrict share activity follow weightedaverage share thousand number share grantdate fair value nonveste share january grant vested forfeited nonveste share december grant vested forfeited nonveste share december grant vested forfeited nonveste share december expect vest december million million respectively total unrecognized compensation cost relate nonveste restrict stock restrict stock unit cost expect recognize weightedaverage period year balance december year balance december total cost nonveste share share unit grant recognize compensation expense month end december million million million respectively total fair value share share unit vest month end december million million million respectively performance award prior adoption sfas compensation expense relate performance award determine base market price company stock time award apply expect number share contingently issuable amortize threeyear performance cycle adoption sfas fair value performance award estimate date grant monte carlo simulation model market condition monte carlo simulation model utilize multiple input variable determine probability satisfy market condition stipulate award grant calculate fair market value longterm performance award performance award award contain market condition fair value base closing trading price company common stock grant date valuation model award follow assumption weightedaverage expect riskfree grant year grant date expect volatility dividend yield interest rate weightedaverage expect volatility base threeyear historical volatility level company common stock expect dividend yield base historical dividend payment riskfree interest rate reflect yield fiveyear zero coupon treasury bond base performance share contractual term fair value performance award amortize performance period award table content note employee stock benefit plan continue information relate performance award plan plan summarize follow share thousand performance cycle weightedaverage performance share outstanding grant date measurement date share grant grant date fair value december december annually annually total outstanding december million million respectively total unrecognized compensation cost relate performance share plan expect recognize weightedaverage period year year respectively accuracy fair value estimate company determination fair value stockbase payment award date grant optionprice model affect company stock price assumption number highly complex subjective variable variable include limited company expect stock price volatility term award actual project employee stock option exercise behavior optionprice model develop use estimate value trade option vest hedge restriction fully transferable company employee stock option certain characteristic significantly different trade option change subjective assumption materially affect estimate value management opinion exist valuation model provide accurate measure fair value company employee stock option fair value employee stock option determine accordance sfas sab optionprice model value indicative fair value observe willing buyerwilling seller market transaction company adopt sfas require measurement recognition compensation expense stockbase payment award employee director base estimate fair value sfas supersede company previous accounting apb period begin january march sec issue sab relate sfas company apply provision sab adoption sfas company adopt sfas modify prospective transition method require application accounting standard january elect alternative method provide fsp determine company pool excess tax benefit company consolidate financial statement year end december reflect impact sfas accordance modify prospective transition method company consolidate financial statement prior period restate reflect include impact sfas stockbase compensation expense recognize sfas year end december million million respectively million million net tax respectively share share respectively correspond record additional paidin capital stockholder equity additionally million relate performance award reclassify liability stockholder equity connection adoption sfas table content note financial instrument company expose market risk change currency exchange rate interest rate reduce risk company enter certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument manage consolidated basis efficiently net exposure advantage natural offset derivative financial instrument speculative purpose company primary net foreign currency translation exposure euro canadian dollar japanese yen mexican peso chinese renminbi company utilize foreign currency contract hedge anticipate transaction primarily intercompany transaction certain foreign currency designate derivative instrument foreign currency cash flow hedge appropriate notional amount company foreign exchange derivative contract december million million respectively derivative majority qualify hedge future anticipate cash flow effective portion change fair value temporarily defer accumulate oci recognize earning hedge item affect earning table summarize company outstanding foreign exchange forward contract december fair value foreign exchange forward contract base yearend currency rate fair value foreign exchange forward contract view relation fair value underlie hedged transaction overall reduction exposure adverse fluctuation foreign currency exchange rate weightedaverage fair value dollar million currency rate strike price notional assetliability maturity foreign exchange forwards cash flow hedge australian dollar british pound canadian dollar euro japanese yen mexican peso polish zloty swedish krona swiss franc total cash flow hedge nonqualifye hedge australian dollar british pound canadian dollar euro japanese yen polish zloty turkish lira total nonqualifying hedge total contract nonqualifye hedge hedge qualify hedge accounting treatment prescribe sfas accounting derivative instrument hedging activity december company hold foreign exchange option contract buy sell japanese yen total notional fair market value buy contract million million respectively fully offset total notional fair market value sell contract million million respectively company reclassify pretax defer loss million million million respectively accumulate oci earning majority classify cost product sell december balance defer loss foreign exchange forward contract include accumulate oci pretax basis million million net tax expect reclassify earning month table content note financial instrument continue sfas require company perform periodic assessment hedge effectiveness assessment determine derivative designate qualifying hedge continue highly effective offset change cash flow hedge item ineffective portion fair value long defer accumulate oci include current period earning year end december impact hedge ineffectiveness earning significant additionally year end december impact discontinue hedge pretax loss million pretax loss million respectively furthermore company use foreign exchange forward contract offset exposure certain currency asset liability earning denominate certain foreign currency foreign exchange forward contract designate hedge change fair value derivative recognize earning income net occur notional fair value amount foreign exchange forward contract december describe table foreign exchange forward contract type outstanding december impact foreign exchange forward contract designate hedge pretax gain million amount recognize earning relate type foreign exchange forward contract qualify hedge accounting treatment significant fair value forward contract net liability million december million record noncurrent asset million record current liability fair value forward contract net liability million december million record noncurrent asset million record current liability fair value foreign exchange contract base yearend currency rate blackschole model case option contract addition foreign exchange hedge contract note company utilize forward contract hedge foreign currencydenominate monetary asset liability primary objective forward contract protect dollar value foreign currencydenominate monetary asset liability effect volatility foreign exchange rate occur prior receipt settlement dollar foreign currency denominate monetary asset liability primarily denominate euro forward contract designate hedge mark market expense net notional fair value purchase foreign exchange forward contract material december million million asset respectively december notional fair value amount sell foreign exchange forward contract december million million liability respectively december company use nonus dollar borrowing primarily million note million note hedge foreign currency exposure company net investment certain foreign affiliate nonus dollar borrowing designate hedge net investment effective portion foreign exchange gain loss hedge record foreign currency translation component accumulate oci december million million loss respectively record foreign currency translation component accumulate oci company unhedged exposure net foreign currencydenominate asset liability approximately billion billion december respectively primarily mexico japan china australia canada company use derivative instrument interest rate risk management strategy derivative instrument comprise principally fix float rate interest rate swap subject fairvalue hedge accounting treatment november connection funding retirement fix rate debt company execute fix float interest rate swap convert billion billion billion inception company newlyissue fix rate debt pay variable rate debt total notional amount outstanding interest rate swap billion billion billion december billion billion billion december accordance sfas accounting derivative instrument hedging activity company recognize net increase interest expense million million respectively net reduction interest expense million impact interest rate swap swap contract underlie debt hedge record fair value result increase noncurrent asset million current liability million reduction longterm debt million december increase noncurrent asset million current liability million reduction longterm debt million december swap contract generally hold maturity intend create appropriate balance fix float rate debt company swap contract qualify fair value hedge terminate prior maturity date report carry value underlie debt amortize earning remain life debt swap contract qualify cash flow hedge terminate report accumulate oci amortize earning remain life debt follow table summarize interest rate swap outstanding december earning impact terminate interest rate swap contract table content note financial instrument continue interest rate swap outstanding notional underlie variable rate year fair interest rate contract debt receive transaction maturity value dollar million swap associate note month libor note month libor million note month eur euribor million note month eur euribor note month libor note month libor earning impact terminate interest rate swap contract notional pretax incomeexpense total pretax recognize year underlie defer termination debt gainloss interest rate contract dollar million interest rate swap lock associate note note swap associate note note note note underlying note extinguish underlying note extinguish underlying note extinguish carry company financial instrument include cash cash equivalent account receivable account payable approximate fair value december discussion cash cash equivalent marketable security note cash cash equivalent marketable security longterm debt difference fair value carry value material note segment information company organize reportable segmentspharmaceutical nutritional convatec pharmaceutical segment comprise global pharmaceutical international consumer medicine business nutritional segment consist mead johnson primarily infant formula business children nutritional business convatec segment consist ostomy wound skin care business december company enter definitive agreement avista sale medical imaging business closing transaction complete january result medical imaging business previously include health care operating segment include income discontinue operation net tax period net asset associate medical imaging business total approximately million asset total million reclassify asset hold sale december include corporateother company complete sale otn equity partner llc result otn previously present separate operating segment include income discontinue operation net tax year end december result medical imaging business otn include table quarter company complete sale consumer medicine business include pharmaceutical operating segment additional information sale consumer medicine note acquisition divestiture table content note segment information continue company product sell principally wholesale retail trade nationally internationally certain product sell drug manufacturer hospital clinic government agency medical profession wholesaler account approximately respectively company total net sale sale wholesaler account approximately respectively company total net sale wholesaler account respectively company total net sale sale concentrate pharmaceutical segment earning continue operation net sale minority interest income taxis yearend asset dollar million pharmaceutical nutritional convatec health care group total segment corporateother total net sale company key product follow sale product dollar million pharmaceutical plavix avaproavalide pravachol coumadin reyataz sustiva franchise total revenue baraclude erbitux taxol paclitaxel sprycel ixempra abilify total revenue pharmaceutical total pharmaceutical nutritional enfamil enfagrow nutritional total nutritional convatec ostomy wound therapeutic convatec total convatec total corporateother consist principally interest income interest expense certain administrative expense allocation business segment certain corporate program litigation expense impairment auction rate security debt retirement cost gain sale business product asset defer income recognize collaboration agreement restructuring charge corporateother asset include cash cash equivalent marketable security asset discontinue operation certain asset table content note segment information continue capital expenditure depreciation dollar million pharmaceutical nutritional convatec health care group total segment corporateothera total corporateother amount include activity medical imaging business include capital expenditure million million million respectively depreciation expense million million million respectively geographic area net sale yearend asset dollar millions united states europe middle east africa western hemisphere pacific total table content note lease minimum rental commitment noncancelable operating lease primarily real estate motor vehicle effect december follow year end december dollar million later year total minimum payment total minimum sublease rental net minimum rental commitment operate lease rental expense net sublease rental income million million million million million million december company complete sale leaseback administrative facility new jersey million result pretax gain transaction million million defer reduce future lease rental cost lease period range year note pension postretirement benefit plan company certain subsidiary define benefit pension plan define contribution plan termination indemnity plan regular time employee principal pension plan bristolmyers squibb retirement income plan funding policy contribute amount provide current service fund past service liability plan benefit base primarily participant year credit service compensation plan asset consist principally equity fixedincome security company provide comprehensive medical group life benefit substantially retiree elect participate comprehensive medical group life plan medical plan contributory contribution adjust periodically vary date retirement original retire company life insurance plan noncontributory plan asset consist principally equity fixedincome security similar plan exist employee certain country outside net periodic benefit cost company define benefit pension postretirement benefit plan include follow component pension benefit benefitsa dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service costbenefit amortization loss amortization transitional obligation net periodic benefit cost curtailment settlement total net periodic benefit cost company recognize impact medicare prescription drug improvement modernization act accordance fsp accounting disclosure requirement relate medicare prescription drug improvement modernization act record million respectively reduction net periodic benefit cost table content note pension postretirement benefit plan continue net actuarial loss prior service costbenefit amortize accumulate oci net periodic benefit cost million million respectively pension benefit million benefit million respectively benefit estimate net actuarial loss prior service cost amortize accumulate oci net periodic benefit cost dollar million pension benefit benefit amortization net actuarial loss amortization prior service costbenefit change benefit obligation plan asset fund status amount recognize balance sheet year end december company define benefit postretirement benefit plan follow pension benefit benefitsb dollar million benefit obligation begin year service costbenefit earn year interest cost project benefit obligation plan participant contribution curtailment settlement actuarial lossesgain plan amendment retiree drug subsidy receive benefit pay special termination benefit exchange rate gainslosse benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution plan participant contribution settlement retiree drug subsidy receive benefit pay exchange rate lossesgain fair value plan asset end year fund status amount recognize balance sheet consist asset accrue expenses pension postretirement liability accrue benefit cost net recognize amount recognize accumulate comprehensive loss net actuarial loss net obligation adoption prior service cost company recognize impact medicare prescription drug improvement modernization act accordance fsp record million million respectively reduction accumulate postretirement benefit obligation plan underfunde accrue benefit obligation exceed accrue benefit liability december additional minimum liability establish increase accrue benefit liability value underfunde accrue benefit obligation additional minimum liability total million december prior adoption sfa unfunded benefit equalization plan international plan liability reverse accumulate oci adoption sfas table content note pension postretirement benefit plan continue accumulate benefit obligation define benefit pension plan million million december respectively information relate company pension plan december follow december dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset attributable primarily unfunded benefit equalization plan plan international market unfunde benefit equalization plan provide pension benefit employee compensation irs limit fund taxadvantage manner additional information pertaining company pension postretirement plan follow pension benefit benefit dollar million decreaseincrease minimum liability include impact foreign currency fluctuation include comprehensive income weightedaverage assumption determine benefit obligation december follow pension benefit benefit discount rate rate compensation increase weightedaverage actuarial assumption determine net periodic benefit cost year end december follow pension benefit benefit discount rate expect longterm return plan asset rate compensation increase december company expect longterm rate return pension plan asset target asset allocation public equity international private equity fix income approximate apply expect return public equity private equity fix income target allocation actual historical return relevant annualize return period end december year year year pension plan asset represent approximately total company pension plan asset december disclose total company expect return asset pension plan impact international pension plan typically employ aggressive asset allocation expect return disclose benefit relevant asset invest manner pension plan asset international plan asset table content note pension postretirement benefit plan continue assume health care cost trend rate december follow health care cost trend rate assume year rate cost trend rate assume decline ultimate trend rate year rate reach ultimate trend rate assume health care cost trend rate effect amount report health care plan onepercentagepoint change assume health care cost trend rate follow effect percentage percentage dollar million point increase point decrease effect total service interest cost effect postretirement benefit obligation company asset allocation pension postretirement benefit december follow pension benefit benefit public equity security debt security include cash private equity total company investment strategy emphasize equity order achieve high expect return long run low expense low require cash contribution pension plan target asset allocation public equity international private equity fix income maintain cash flow cash contribution benefit payment rebalance target necessary investment diversify major asset category equity passively manage investment actively manage investment strategy international pension plan typically similar asset allocation usually conservative bristolmyer squibb company common stock represent plan asset december asset postretirement benefit commingle pension plan asset investment strategy identical describe pension plan contribution minimum contribution require company cash contribution pension plan million million million respectively company plan cash contribution pension plan contribution pension plan company taxdeductible contribution account retiree medical benefit equal portion pension normal cost contribution international pension plan million million million respectively contribution international plan expect range million million table content note pension postretirement benefit plan continue estimate future benefit payment follow benefit payment mainly pension plan reflect expect future service appropriate expect pay benefit dollar million pension benefit gross medicare subsidy net year adoption sfas company adopt sfas fiscal year end december result million reduction accumulate oci stockholder equity million reduction total asset million increase total liability impact adoption summarize follow sfas adjustment dollar million presfas pretax tax net postsfas current asset defer income taxis noncurrent asset defer income taxis prepay pension asset current liability accrue expense foreign income taxis payable noncurrent liability liabilitie stockholders equity accumulate comprehensive loss saving plan principal define contribution plan bristolmyer squibb saving investment program company contribution base employee contribution level company match company contribution plan million million million termination indemnity plan company operate certain jurisdiction primarily europe require record statutory termination obligation obligation assess accordance eitf issue determination vest benefit obligation define benefit pension plan total pension liability record obligation million december million december table content note legal proceeding contingency lawsuit claim proceeding investigation pende involve company certain subsidiary accordance sfas accounting contingency company record accrual contingency probable liability incur loss reasonably estimate matter involve antitrust security patent infringement pricing sale marketing practice environmental health safety matter consumer fraud employment matter product liability insurance coverage significant matter describe assurance increase scope pende matter future lawsuit claim proceeding investigation material intellectual property plavix litigation plavix currently company large product rank net sale net sale plavix approximately billion year end december billion year end december billion year end december net sale plavix billion billion billion plavix patent subject number challenge include litigation apotex inc apotex corp apotex describe significant market product possible reasonably estimate impact lawsuit company loss market exclusivity plavix sustain generic competition material company sale plavix result operation cash flow material company financial condition liquidity company product partner sanofi company intend vigorously pursue enforcement patent right plavix plavix litigation united states patent infringement litigation apotex relate matter previously disclose company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute district court southern district new york district court entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership apotex suit base patent patent composition matter patent disclose claim thing hydrogen sulfate salt clopidogrel medicine available company plavix plaintiff infringement position base apotexs filing abbreviate new drug application anda fda seek approval sell generic clopidogrel bisulfate prior expiration composition matter patent apotex allege patent invalid andor unenforceable previously disclose march company sanofi announce execute propose settlement agreement march agreement apotex settle pende patent infringement lawsuit response concern express federal trade commission ftc state attorney general party modify march agreement modify agreement july company announce modify agreement fail receive require antitrust clearance state attorney general august apotex launch generic version clopidogrel bisulfate august district court issue preliminary injunction order apotex halt sale generic clopidogrel bisulfate recall product customer june district court issue opinion order uphold validity enforceability patent maintain main patent protection plavix november district court rule apotexs generic clopidogrel bisulfate product infringe patent permanently enjoin apotex engage activity infringe patent include market generic product patent expire damage set later time apotexs appeal district court decision pende court appeal federal circuit hearing schedule march district court stay certain antitrust counterclaim bring apotex pende outcome appeal activity relate damage phase litigation continue previously disclose company territory partnership alliance sanofi plaintiff additional pende patent infringement lawsuit reddys laboratories inc reddys laboratories ltd reddys teva pharmaceuticals usa inc teva cobalt pharmaceuticals inc cobalt relate patent trial date action reddys set january reddys receive final approval anda january court enter order require reddys company business day notice intent launch patent infringement action teva cobalt stay pende resolution apotex litigation party action agree bind outcome litigation apotex teva cobalt appeal outcome litigation table content note legal proceeding contingency continue consequently july district court enter judgment cobalt teva permanently enjoin cobalt teva engage activity infringe patent patent expire cobalt teva file appeal reddys teva cobalt file anda fda exclusivity period statutory stay periods hatchwaxman act expire accordingly final approval fda provide company authorization distribute generic clopidogrel bisulfate product subject legal remedy company apply include injunctive relief damage previously disclose march company serve civil investigative demand ftc request document information relate propose settlement addition previously disclose april company receive subpoena new york state attorney general office antitrust bureau document relate propose settlement company cooperate fully investigation possible time reasonably assess outcome investigation impact company previously disclose company territory partnership alliance sanofi plaintiff pende patent infringement lawsuit institute district court district new jersey entitle sanofisynthelabo sanofisynthelabo inc bristolmyers squibb sanofi pharmaceutical hold partnership watson pharmaceuticals inc watson laboratories inc watson suit file october base patent patent disclose claim particular crystalline polymorph form hydrogen sulfate salt clopidogrel market plavix case discovery phase december court permit watson pursue declaratory judgment counterclaim respect patent january court approve party stipulation stay case pende outcome trial apotex matter april pharmastar file request inter part reexamination patent patent trademark office grant request july patent currently reexamination possible time reasonably assess outcome appeal apotex district court decision plavix patent litigation timing renew generic competition plavix apotex additional generic competition plavix thirdparty generic pharmaceutical company apotex prevail appeal patent litigation company expect face renew generic competition plavix apotex promptly loss market exclusivity plavix andor sustain generic competition material company sale plavix result operation cash flow material company financial condition liquidity additionally possible time reasonably assess damage recover company apotexs ability pay damage event company prevail apotexs appeal district court decision antitrust litigation shareholder derivative action security litigation discussion certain litigation relate plavix plavix litigation international plavix canada apotex inc previously disclose sanofisynthelabo sanofisynthelabo canada inc institute prohibition action federal court canada apotex inc minister health response notice allegation noa apotex direct canadian patent patent cover clopidogrel bisulfate apotexs noa indicate file abbreviate new drug submission ands clopidogrel bisulfate tablet seek approval notice compliance and expiration patent schedule august apotexs noa allege patent invalid infringe march canadian federal court ottawa reject apotexs challenge canadian plavix patent hold asserted claim novel obvious infringe grant sanofis application order prohibition minister health apotex order prohibition preclude approval apotexs ands patent expire federal court decision reverse appeal apotex file appeal canadian federal court appeal hear december december federal court appeal dismiss apotexs appeal uphold federal court issuance order prohibition february apotex file leave appeal decision supreme court canada july supreme court canada grant apotex leave appeal decision canadian federal court appeal biotecanada canadian generic pharmaceutical association canadas researchbase pharmaceutical company grant leave intervene oral hearing schedule april previously disclose april apotex file lawsuit canada ontario superior court justice entitle apotex inc apotex corp sanofiaventis sanofisynthelabo inc bristolmyers squibb company bristolmyers squibb sanofi pharmaceutical hold partnership seek payment million plus interest relate breakup propose settlement agreement defendant file motion dismiss ground forum non convenien subject matter jurisdiction motion grant january table content note legal proceeding contingency continue plavix canada cobalt previously disclose sanofi sanofisynthelabo canada institute prohibition action federal court canada cobalt minister health response noa cobalt direct patent canadian patent patent cobalt noa indicate file ands clopidogrel bisulfate tablet seek notice compliance and expiration patent cobalt allege patent invalid patent invalid infringe case stay pende outcome apotex appeal plavix korea previously disclose june korean intellectual property tribunal kipt invalidate claim sanofis korean patent include claim direct clopidogrel pharmaceutically acceptable salt clopidogrel bisulfate sanofi appeal january patent court affirm kipt decision company sanofi consider option include appeal sanofi commence infringement action generic pharmaceutical company launch generic clopidogrel bisulfate product korea possible time reasonably assess outcome lawsuit impact company plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate tablets australia august genrx file application federal court australia seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september australian court grant sanofis injunction schedule trial date april intellectual property litigation abilify previously disclose otsuka file patent infringement action teva barr pharmaceuticals inc barr sandoz inc sandoz synthon laboratories inc synthon sun pharmaceuticals sun apotex relate patent cover aripiprazole expire october aripiprazole comarketed company otsuka abilify lawsuit currently pende district court district new jersey possible time reasonably assess outcome lawsuit impact company erbitux yeda litigation october yeda research development company ltd yeda file suit imclone aventis pharmaceuticals inc federal court claim individual associate yeda name inventor patent patent cover therapeutic combination egfrspecific monoclonal antibody antineoplastic agent chemotherapeutic agent use treatment cancer september follow trial court issue opinion order hold researcher yeda sole inventor subject matter patent give complete ownership patent yeda imclone appeal imclone file declaratory judgment action district court complaint allege yeda researcher remain sole inventor patent patent invalid commercial agreement imclone company pay royalty imclone sale erbitux impact court decision pursuant settlement agreement execute imclone sanofi yeda announce december end worldwide litigation relate patent yeda sanofi grant imclone worldwide license patent party agree yeda sole owner patent yeda sanofi coowner patent foreign counterpart settlement agreement change imclone worldwide royalty rate erbitux sale commercial agreement imclone company pay royalty imclone sale erbitux impact settlement agreement table content note legal proceeding contingency continue yeda right license patent yeda license patent party result product competition erbitux occur early assess extent competitive impact occur quantify impact yeda license patent amgen inc amgen amgen receive fda approval market egfr product competes erbitux abbott laboratory previously disclose february abbott laboratories abbott file suit imclone district court district massachusetts allege imclone manufacture sale erbitux infringe patent patent seek damage allege infringement pursuant settlement sublicense agreement execute imclone repligen corporation repligen announce september repligen grant imclone royaltyfree irrevocable worldwide sublicense future use patent technology include patent own abbott license repligen agreement abbott repligen company commercial agreement imclone include provision pursuant certain financial consequence company result settlement sublicense agreement responsibility imclone settlement sublicense agreement end lawsuit possible time assess outcome lawsuit potential impact company orencia january repligen regent university michigan file complaint company district court eastern district texas marshall division orencia launch february complaint allege company thenanticipate sale orencia infringe patent repligen amend complaint include ongoing future sale orencia courtordere mediation schedule march trial schedule commence april august zymogenetics inc file complaint company district court district delaware complaint allege company manufacture sale orencia infringe patent nos trial expect commence pravachol december lek lek slovenian generic company whollyowne novartis file suit company watson district court eastern district texas marshall texas leks complaint allege company sale pravachol watson sale authorize generic pravachol infringe patent lek patent patent nos issue issue july company file answer complaint june company believe strong defense suit intend defend vigorously trial schedule commence august possible time reasonably assess outcome lawsuit impact company general commercial litigation clayworth litigation previously disclose company number pharmaceutical manufacturer name defendant action file california state superior court oakland james clayworth bristolmyers squibb company allege defendant conspire fix price pharmaceutical agree charge drug charge outside particularly canada assert claim california cartwright act unfair competition law plaintiff sought treble monetary damage injunctive relief relief december court grant company manufacturer motion summary judgment base passon defense judgment enter favor defendant january notice appeal respect judgment file remain pende possible time reasonably assess outcome lawsuit impact company event plaintiff successful appeal table content note legal proceeding contingency continue rxusa wholesale litigation previously disclose july complaint file drug wholesaler rxusa wholesale inc district court eastern district new york company drug manufacturer drug wholesaler officer defendant mckesson wholesale distribution industry trade group rxusa wholesale inc alcon labs inc complaint allege violation federal new york antitrust law law plaintiff claim defendant allegedly engage anticompetitive act result exclusion plaintiff relevant market seek million damage trebling relief company manufacturer defendant file motion dismiss case november motion remain pende court possible time reasonably estimate outcome lawsuit impact company antitrust litigation previously disclose lawsuit comprise individual suit purport class action file company district court southern district ohio western division plaintiff include pharmacy chain individually assignee certain wholesaler health welfare benefit plansfund individual resident state lawsuit allege thing purport settlement apotex patent infringement litigation violate sherman act relate law plaintiff seek thing permanent injunctive relief bar apotex settlement andor monetary damage class action file behalf direct purchaser consolidate caption plavix direct purchaser antitrust litigation class action file behalf indirect purchaser consolidate caption plavix indirect purchaser antitrust litigation amend complaint file october defendant file consolidated motion dismiss december possible time reasonably assess outcome lawsuit impact company shareholder derivative action july certain member board director current officer company name derivative action file new york state supreme court john frank peter dolan donald beebout peter dolan derivative action file federal district court steven sampson james robinson iii complaints allege breach fiduciary duty allegedly fail disclose material information relate effort settle plavix patent infringement litigation apotex plaintiff seek monetary damage behalf company contribution indemnification decision file december state court grant motion dismiss complaint frank beebout relate certain member board director dismiss complaint officer company file motion dismiss federal district court action sampson pende security litigation bristolmyers squibb security litigation previously disclose june july putative class action complaint minneapolis firefighter relief assoc bristolmyers squibb jean lai bristolmyers squibb company file district southern district new york company company chief executive officer peter dolan current chief financial officer andrew bonfield complaints allege violation security law allegedly fail disclose material information relate effort settle plavix patent infringement litigation apotex september court dismiss lai case prejudice change caption case bristolmyer squibb security litigation appoint ontario teacher pension plan board lead plaintiff october ontario teachers pension plan board file amend complaint make similar allegation early file complaint long name andrew bonfield defendant motion dismiss file company intend defend vigorously litigation possible time reasonably assess outcome lawsuit potential impact company table content note legal proceeding contingency continue price sale promotional practice litigation investigation previously disclose company number defendant defendant number private civil matter relate pricing practice addition company number pharmaceutical manufacturer receive subpoenas document request government agency seek record relate pricing sale marketing practice good price report september company department justice doj office attorney district massachusetts finalize previously disclose agreement principle settle investigation involve company drug pricing sale marketing activity settlement agreement provide civil resolution resolve matter actively investigate discuss doj attorney district massachusetts number year include matter relate price certain product sell year ago subsidiary reimburse governmental health care program financial relationship subsidiary certain customer entitie certain consulting program promotion abilify unapproved indication calculation certain medicaid rebate serzone nefazodone hydrochloride price certain company product reimburse governmental health care program criminal charge company respect matter pursuant agreement company agree pay million plus interest resolve federal state claim result total approximately million settlement date company pay federal portion global settlement approximately million plus interest state portion global settlement approximately million plus interest disburse state approve settlement assurance state approve settlement connection settlement company enter fiveyear corporate integrity agreement office inspector general department health human service settlement cover matter outline doj attorney district massachusetts states indicate pursue matter outside scope settlement event matter result assertion civil andor criminal claim previously disclose result agreement principle company record aggregate reserve million plus interest matter payment federal portion global settlement remain reserve december million plus interest certain state choose participate reserve reflect eventual loss possible time reasonably assess outcome additional matter doj office attorney district massachusetts pursue potential impact company litigation previously disclose company number pharmaceutical manufacturer defendant private class action suit bring attorney general numerous state new york counties city new york action plaintiff allege defendant cause average wholesale price awps product inflate injure government program entity person reimburse prescription drug base awps state attorney general suit pende federal state court country case alabama state court schedule proceed trial february set class action suit arizona attorney general suit file new york counties city new york consolidate district court district massachusetts awp mdl court awp mdl certify class person entity pay reimburse seven company physicianadministere drug june nonjury trial awp mdl court find company liable violation massachusetts consumer protection law respect certain oncology drug certain year award damage thousand class private thirdparty payor instruct party apply court opinion determine damage class medigap insurer august court find damage thousand class company appeal june decision court appeal circuit previously disclose june company settle principle claim class medicare beneficiary nationwide million plus half cost class notice maximum payment million party finalize term settlement hearing schedule preliminary approval class settlement company record reserve million matter accordance gaap reserve reflect company estimate probable loss respect matter assume settlement finalize settlement finalize reserve reflect eventual loss possible time reasonably assess outcome litigation matter describe potential impact company table content note legal proceeding contingency continue product liability litigation company party product liability lawsuit addition lawsuit company face unfiled claim involve product time company believe ongoing matter potential unfiled claim aware potential result material effect company financial result operation environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include comprehensive environmental response compensation liability act cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency epa counterpart state agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable december company estimate share total future cost site approximately million record liability represent sum good estimate simple estimate reasonably estimate minimal probable range cost take account potential recovery party currently expect puerto rico air emission civil litigation previously disclose company defendant class action suit file superior court puerto rico relate air emission governmentowne operate wastewater treatment facility court certify class august august party execute global settlement agreement resolve claim litigation hearing approve settlement hold october term settlement certain measure include capital improvement implement wastewater treatment facility minimize potential future odor emission company share payment plaintiff approximately thousand november court enter final judgment approve settlement conclude company involvement litigation company payment share cost capital improvement finalize early passaic river remediation natural resource damage claim previously disclose september new jersey department environmental protection njdep issue administrative enforcement directive require company company perform assessment natural resource damage implement unspecified interim remedial measure restore condition low passaic river lpr directive name company release nearby bulk chemical reprocess facility operate predecessor mckesson corp subsequently epa issue notice letter numerous party company request performance remedial investigationfeasibility study rif condition lpr consent agreement epa group party commit pay roughly half million estimate rif epa time epa substantially increase estimate scope cost rif result epa agree allow group perform remain rif task group estimate total cost complete rif relate task exceed million group negotiate amend consent agreement epa conduct remain rif work effective deal company mckesson buy remain rif task separately company agree pay approximately thousand rif task previously fund mckesson work cooperatively go forward addition mid epa announce plan seek implementation earlyaction remedial measure address highlycontaminate portion lpr rif complete epa indicate expect select action early group federal natural resource trustee agency propose private party group enter agreement assess natural resource damage lpr group expect discuss proposal trustee near future extent liability company face relate requirement determine table content note legal proceeding contingency continue north brunswick township board education previously disclose october company contact counsel represent north brunswick board education boe site waste material squibb son disposed fill material contain industrial waste heavy metal excess residential standard discover expansion project north brunswick township high school number neighbor residential property adjacent public park area january njdep send company information request letter possible waste disposal site company respond march boe township current owner school property park conduct jointly finance soil remediation work ground water investigation work work plan approve njdep ask company contribute cost financial constraint late boe ask company contribute fund interim basis assure uninterrupted performance necessary site work company continues actively monitor cleanup project include cost date school board township assert claim company instead company local entity negotiate agreement attempt resolve matter mediation central component anticipate agreement provision company interim funding help defray cleanup cost agreement execute party company transmit initial interim funding payment january party recently commence work prepare mediation expect conclude mid od regulatory compliance previously disclose epa investigate industrial commercial facility use refrigeration equipment contain ozone deplete substance od enforce compliance regulation govern prevention service repair leak od requirement company perform voluntary corporatewide audit facility puerto rico use odscontaine refrigeration equipment company submit audit report epa november identify potential violation od requirement facility addition matter cover company audit report letter epa epa previously send company whollyowne subsidiary mead johnson request information compliance od requirement facility evansville indiana company respond request june result identify potential violation evansville facility company currently discussion epa resolve potential violation discover audit identify result epa request information evansville facility epa determine evansville facility facility violation applicable od requirement company subject penalty andor require convert replace refrigeration equipment use nonod approve substitute mact compliancepuerto rico facilities barceloneta humacao previously disclose march company commence voluntary environmental audit barceloneta humacao puerto rico facility determine compliance epa regulation maximum achievable control technology requirement emission hazardous air pollutant pharmaceutical production pharmaceutical mact company submit epa audit report humacao facility june barceloneta facility july disclose potential violation pharmaceutical mact requirement facility company epa currently discussion resolution matter wage hour litigation previously disclose putative class action complaint file company sale representative kin fung bristolmyers squibb company case number file june superior court state california county alameda plaintiff allege company violate california wage hour law thing pay overtime compensation putative class similarly situate sale employee plaintiff file amend complaint september add cause action penalty california labor code private attorney general act california labor code allow plaintiff collect civil penalty violation provision california labor code collect labor workforce development agency california labor code oneyear statute limitation allow recovery penalty outstanding violation pay period interpret require penalty employee pay period january court dismiss kin fung matter entirety fung assertion wish participate plaintiff matter beth amendola bristolmyers squibb company docket file june district court plaintiff allege company violate federal fair labor standard act thing pay overtime compensation putative class similarly situate sale employee party currently engage preliminary discovery amendola matter table content note legal proceeding contingency continue company intends vigorously defend lawsuit matter early stage litigation possible time reasonably assess outcome litigation matter describe expect outcome material company result operation cash flow material financial condition liquidity proceeding sec germany investigation previously disclose october sec notify company conduct informal inquiry activity certain company german pharmaceutical subsidiary employee andor agent october sec inform company inquiry formal secs inquiry encompass matter currently investigation german prosecutor munich germany company understand inquiry investigation concern potential violation foreign corrupt practice act german law respectively company cooperate sec german authority company establish accrual represent minimum expect probable loss respect investigation german prosecutor possible time reasonably assess outcome investigation impact company bari italy investigation previously disclose january company notify prosecutor bari region italy bari prosecutor company investigation result activitie employee region investigation involve number doctor pharmacist pharmaceutical company sale representative main allegation party engage plan defraud national health service company lack appropriate compliance control andor process procedure control activity sale representative february company bari prosecutor reach agreement principle settle matter agreement require final approval civil court final hearing matter occur company pay administrative fine material company convatec italy investigation italian competition authority investigate complaint lodge hospital ferrara region italy relate allegation medical device company include convatec boycott tender ferrara tender convatec respond allegation early year convatec receive statement objection italian competition authority authority allege medical device company include convatec act concert manner regard ferrara tender tender pricing discussion region act way prevent competition italy hearing matter hold july august competition authority issue decision find medical device company infringe italian antitrust law participate ferrara tender impose fine convatec convatec division bms italy fine impose bms italy fine base convatec market share turnover company fine amount small convatec appeal decision administrative court hearing appeal expect early mid decision likely issue soon note subsequent event december company enter definitive agreement avista sale medical imaging business purchase price approximately million cash subject customary postclosing adjustment close transaction complete january company expect recognize pretax gain approximately million million million million loss net tax quarter subject post closing adjustment february company complete sale leaseback administrative facility paris france approximately million company expect record gain majority defer reduce future lease rental cost lease period table content note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year net sale gross margin net earningsloss continue operation net earning discontinue operation net net earningsloss earning common share basic net earningsloss continue operation net earning discontinue operation net net earningsloss common share dilute net earningsloss continue operation net earning discontinue operation net net earningsloss common share dividend declare common share cash cash equivalent marketable security net sale gross margin net earningsloss continue operation net earning discontinue operation net net earningsloss earning common share basic net earningsloss continue operation net earning discontinue operation net net earningsloss common share dilute net earningsloss continue operation net earning discontinue operation net net earningsloss common share dividend declare common share cash cash equivalent marketable security earning share quarter add amount year period compute discrete basis common equivalent share exclude computation dilute earning share effect antidilutive follow million second fourth quarter quarter quarter quarter year month end december result net loss basic diluted loss share equal million weightedaverage share issuable million million interest expense net tax conversion convertible debt include diluted earning share calculation antidilutive table content note select quarterly financial datum unaudite continued company record follow item affect comparability result second fourth dollar million quarter quarter quarter quarter year productivity transformation initiative downsize streamline worldwide operation accelerate depreciation asset impairment process standardization implementation cost litigation settlement insurance recovery product liability upfront milestone payment acquire inprocess research development auction rate security impairment downsize streamline worldwide operation accelerate depreciation asset impairment contract termination gain sale property product asset income taxis item change estimate taxis prior year item increasedecrease net earning continue operation second fourth quarter quarter quarter quarter year litigation matter pharmaceutical pricing sale litigation product liability claim damage commercial litigation insurance recovery debt retirement cost accelerate depreciation asset impairment contract termination upfront milestone payment downsize streamline worldwide operation gain sale product asset income taxis item minority interest net taxis change estimate taxis prior year item increasedecrease net earning continue operation financial information reflect medical imaging business discontinue operation note discontinued operation asset hold sale table content report independent register public accounting firm board director stockholder bristolmyers squibb company audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income retain earning cash flow year end audits include financial statement schedule year end december list index item financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audits consolidate financial statement company year end december effect retrospective adjustment discontinue operation bristolmyer squibb medical imaging business discuss note consolidated financial statement audit auditor report date march express unqualified opinion statement conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion consolidate financial statement present fairly material respect financial position company december result operation cash flow year end conformity accounting principle generally accept united states america opinion financial statement schedule year end december consider relation basic consolidated financial statement take present fairly material respect information set forth audit retrospective adjustment consolidate financial statement operation discontinue discuss note consolidated financial statement procedure include obtain company underlie accounting analysis prepare management retrospective adjustment discontinue operation compare retrospectively adjust amount consolidated financial statement analysis compare previously report amount previously issue consolidated financial statement year testing mathematical accuracy accounting analysis compare adjustment retrospectively adjust consolidated financial statement discontinue operation company support documentation opinion retrospective adjustment appropriate properly apply engage audit review apply procedure consolidate financial statement company respect retrospective adjustment accordingly express opinion form assurance consolidated financial statement take discuss note consolidated financial statement company adopt financial accounting standard board interpretation fin accounting uncertainty income taxis interpretation fasb statement effective january statement financial accounting standard sfas sharebase payment effective january sfas employer account define benefit pension postretirement plan amendment fasb statement effective december audit accordance standard public company accounting oversight board united states company internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting deloitte touche llp deloitte touche llp parsippany new jersey february table content report independent register public accounting firm board director stockholder bristolmyers squibb company opinion consolidate statement earning comprehensive income retain earning cash flow year end december effect adjustment retrospectively reflect discontinue operation describe note present fairly material respect result operation cash flow bristolmyer squibb company subsidiary year end december conformity accounting principle generally accept united states america consolidated financial statement effect adjustment discuss note present addition opinion financial statement schedule year end december effect adjustment retrospectively reflect discontinue operation describe note financial statement schedule present fairly material respect information set forth read conjunction relate consolidated financial statement refer financial statement schedule year end december effect adjustment discuss note financial statement schedule present financial statement financial statement schedule responsibility company management responsibility express opinion financial statement financial statement schedule base audit conduct audit effect adjustment describe statement accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audit provide reasonable basis opinion engage audit review apply procedure adjustment retrospectively reflect discontinue operation describe note financial statement note financial statement schedule accordingly express opinion form assurance adjustment appropriate properly apply adjustment audit auditor pricewaterhousecooper llp pricewaterhousecooper llp philadelphia march table content item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report form issue report effectiveness company internal control financial reporting december include change internal control financial reporting change companys internal control financial reporting quarter end december materially affect reasonably likely materially affect company internal control financial reporting item information table content report independent register public accounting firm board director stockholder bristolmyers squibb company audit internal control financial reporting bristolmyer squibb company subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design supervision company principal executive principal financial officer person perform similar function effect company board director management personnel provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting include possibility collusion improper management override control material misstatement error fraud prevented detect timely basis projection evaluation effectiveness internal control financial reporting future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission audit accordance standard public company accounting oversight board united states consolidated financial statement financial statement schedule year end december company report date february express unqualified opinion financial statement financial statement schedule include explanatory paragraph company adoption financial accounting standard board interpretation fin accounting uncertainty income taxis interpretation fasb statement effective january deloitte touche llp deloitte touche llp parsippany new jersey february table content iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item information require item respect executive officer registrant include reliance general instruction instruction item regulation item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item table content item